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MOLECULAR IDENTIFICATION OF NOVEL GENES
ASSOCIATED WITH ATHEROSCLEROSIS
STEPHEN R. ARCHACKI
ABSTRACT
Despite the identification of the risk factors which lead to CAD, we hypothesize
there are novel genes to be identified that cause dysfunctional mechanisms leading to
disease. For these discoveries, we utilized the genechip also referred to as a microarray.
We did expression profiling of coronary arteries from human patients with and
without disease and identified 56 genes. The association of 49 genes with CAD appears
to be novel, and they included genes: ICAM-2, PIM-2, ECGF1, fusin, B cell activator
(BL34, GOS8), Rho GTPase activating protein-4, retinoic acid receptor responder, ß2arrestin, membrane aminopeptidase, cathepsins K and H, MIR-7, TNF-α-induced protein
2 (B94), and flavocytochrome 558.
It is well-known that IMAs are resistant to the development of atherosclerosis,
whereas the coronary arteries are athero-prone. The contrasting properties of these
arteries provides an innovative strategy to identify the gene(s) that may play important
roles in the development of CAD.
We found 29 genes with a significant difference in their expression levels
between IMA and the coronary artery which included the TES gene encoding Testin.
Using assays relevant to atherosclerosis, we showed that the knockdown of TES
expression by siRNA promoted oxLDL-mediated monocyte adhesion to endothelial cells
(EC), EC migration, and the transendothelial migration of monocytes, while the overexpression of TES in ECs blunted these processes. These results define a new molecular
determinant (TES) for CAD and establish a novel role for TES.
We also investigated the gene expression of the ECs harvested from IMA and Cor
to further distinguish these arteries’ differential sensitivities to the develop
atherosclerosis. The most statistically significant gene identified was the adenosine A2B
receptor (A2B). Consequently, A2B was selected for follow-up functional studies to
define its role(s) in ECs and how it may promote a resistance to atherosclerosis. We
showed that the over-expression of the A2B receptor blunted processes relevant to the
atherosclerosis.
In sum, expression profiling offered us the opportunity to identify novel genes that
may be related to atherosclerosis. The identification of genes associated with this disease
may lead to more aggressive interventions to halt the disease process of atherosclerosis
by understanding the underlying genetic processes.
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CHAPTER 1
INTRODUCTION
1.1 The Development of Atherosclerosis.
The heart is one of the most important organs in the entire human body. It is
really nothing more than a pump and composed of four muscular chambers and beats an
average of 70 times per minute. The coronary arteries are the heart’s own system to
deliver oxygen-rich blood to itself. There are two main coronary arteries (the left and the
right), and they are the first branches off of the aorta. They are called the coronary
arteries because they encircle the heart in the manner of a crown. In fact, the word
"coronary" comes from the Latin "corona" and Greek "koron" meaning crown.
Based on the American Heart Association 2010 Statistical Update, the death rate
from CAD was 262.5 per 100,000. Specifically, the rates are 306.6 per 100,000 for white
males, 422.8 per 100,000 for black males, 215.5 per 100,000 for white females, and 298.2
per 100,000 for black females. Interestingly, 1 death occurs every 38 seconds. The
expense of CAD management and intervention on the U.S. health care system is immense
with direct and indirect costs totaling approximately $111.8 billion for 2002 (1).
The coronary artery consists of 3 layers, the (1) intima, (2) media, and (3)
adventitia. The intima is an inner monolayer of endothelial cells (ECs) lining the lumen
1

and is bound by the internal elastic lamina, a fenestrated sheet of elastin fibers. The
media consists of the thin subendothelial space in between these two areas contains thin
elastin and collagen fibers along with smooth muscle cells (SMCs). And, the adventitia
consists of the outer covering of the area consisting of collagen, connective tissue, and
fibroblasts.
There have been four theories on how atherosclerosis develops (2).

The

Encrustation Theory was proposed by Karl Rokitansky in 1851. He suggested that
atherosclerosis begins in the intima with deposition of thrombus and its subsequent
organization by the infiltration of fibroblasts and a secondary deposition of lipid. In
1856, Rudolf Virchow proposed the Lipid Theory in which he thought atherosclerosis
started with the diffusion of lipid into the arterial wall and its interaction with cellular and
extracellular elements causing intimal proliferation leading to the gradual narrowing of
the arterial lumen. Russell Ross, in 1999 then proposed a more unifying theory called the
Response-to-Endothelial Injury Theory. He postulated that atherosclerosis begins with
endothelial injury, making the endothelium susceptible to the accumulation of lipids and
the deposition of thrombus. Yet currently, Fuster and colleagues proposed in 1996 the
now accepted theory which is the Response-to-Vascular Injury theory in which the main
cause of atherosclerosis is the injury to the endothelium by local disturbances of blood
flow at angulated or branch points, along with systemic risk factors (eg, hyperglycemia,
dyslipidemia, cigarette smoking, possibly infection) which perpetuates a series of events
that involve the entire artery.
Consistent with the Response-to-Vascular Injury theory, CAD has a multifactorial
etiology and is the response to many genetic and environmental factors and their
2

interactions (3-7). Long-term prospective clinical and epidemiological studies have
identified several types of risk factors for the development of CAD: smoking history,
older age, male gender, high fat diet, low antioxidant level, infectious agents, personal
history of angina pectoris, family history of MI, obesity, diabetes mellitus, hypertension,
hyperlipidemia (specifically low density lipoproprotein (LDL) cholesterol), increased
plasma triglycerides, and low high-density lipoprotein (HDL) cholesterol (2-8).
New risk factors have been proposed for CAD and include elevated levels of
lipoprotein(a), homocysteine, C-reactive protein (CRP), apolipoprotein E isoforms,
fibrinogen, and plasminogen activator (3-8). Most of these risk factors, old and new, are
likely to be impacted by the underlying genetic factors. Genetic-epidemiological studies
suggest that family history is the most significant independent risk factor for CAD (8-13).
Twin studies also provide an estimate of the genetic component of disease (12). Using
monozygotic and dizygotic twins, the relative risk of death from CAD among male twins
was 8.1 in monozygotic twins in comparison to 3.8 in dizygotic twins (12-13). This
supports the hypothesis that genetic factors contribute to the development of CAD.
1.2 The Molecular Mechanisms of Atherosclerosis
Atherosclerosis leads to the gradual occlusion of the coronary artery lumen
causing myocardial ischemia (7, 14) (Fig. 1). This process starts with the leukocytes
initially tethering and rolling on the surface of activated endothelial cells (ECs), their
arrest and firm adhesion, and then their subsequent transmigration into the media of the
artery. Of note, a very specific class of monocytes containing the gene Lys-6 and Gr-1
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have been found to infiltrate coronary arteries (14). Yet, the gene expression of each step
of this process has been defined.
The initial rolling of leukocytes is mediated mainly by the selectins, a family of
cell adhesion molecules (CAM), expressed on the ECs (15) as well as on the leukocytes
themselves. The main gene expressed here encodes for P-selectin glycoprotein ligand-1
(PSGL-1). Subsequently, the genes that participate in leukocyte arrest and their firm
adhesion is mediated primarily by the genes that express vascular cell adhesion molecule1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on the ECs as well. These
two receptors specifically interact with B1 and B2 integrins expressed on leukocytes (1619). As a result, leukocytes attach to the ECs and start to transmigrate into the media of
the artery. At the same time, the leukocytes are also a rich source of pro-inflammatory
cytokines and secrete TNF-α, IFN-γ, IL-1, and IL-4 which perpetuate the cycle by
promoting the expression of more CAMs, leukocyte adhesion and recruitment (20-23).
The defining process underlying the actual transmigration of leukocytes through
the vessel wall by diapedesis is becoming better defined. Six genes are expressed at the
lateral borders of ECs have been implicated in this process. These are: PECAM-1,
CD99, VE-cadherin, and JAM-A, B, and C (24). The first change that occurs and permits
the transmigration of monocytes is the increase in intracellular free calcium in the ECs.
This is triggered by the cationic proteins released by stimulated neutrophils or by the
cross-linking of E and P-selectin or VCAM-1 (25). As a result, intracellular calcium
activates myosin light chain kinase and the unfolding of myosin II. This causes mild EC
retraction so a space develops allowing the monocytes to easily pass through leaving the
EC layer virtually intact.
4

A number of genes assist in the transmigration of the monocyte. PECAM-1 is a
member of the immunoglobulin gene superfamily that is expressed diffusely on the
surface of leukocytes as well as at the borders of ECs (26, 27). The interaction of
PECAM-1 on the EC cell and the monocyte, specifically via the amino terminal portions
1 and 2 of PECAM-1 form a homophilic interaction. Blocking this interaction with a
domain-specific monoclonal antibody also blocks diapedesis and has been shown to help
prevent CAD (26, 27). Similarly, CD99 is a highly O-glycoslyated molecule that is also
expressed on leukocytes and the borders of ECs (24). Like PECAM-1, it facilitates
monocyte transmigration but at a later stage.

For example, blocking CD99 arrests

monocyte transmigration when the monocyte is part way across the EC border (24).
Consequently, the monocyte initially binds to PECAM-1 and gets further assistance by
CD99 as it passes through the EC layer.
VE-cadherin, which belongs to the class of cadherins and is located in the
adherens junctions between ECs, maintains the EC permeability barrier. It has been
proposed that VE-cadherein must be transiently down-regulated and removed from the
junctional complex during diapedesis (28, 29).

Interestingly, using a monoclonal

antibody against this protein in animal models also promotes the infiltration of monocytes
into the artery.
Finally, the junctional adhesion molecules (JAM), namely, JAM-A, B and C also
localize to the intercellular borders of ECs as well as on monocytes. These proteins form
a homophilic channel between the adjacent ECs allowing the monocytes to pass through
and into the media of the artery. In sum, the genetic pathways of endothelial dysfunction
in ECs are now becoming better defined.
5

Upon its arrival in the intima, the monocytes mature to tissue macrophages. They
express scavenger receptors that bind lipoprotein particles, specifically ox-LDL that have
passively diffused into the area. Over time, the monocytes become described as foam
cells, a hallmark of the arterial lesion, so named because of the foamy appearance of the
macrophages under the microscope (7, 14). Additionally, the foam cells secrete proinflammatory cytokines that amplify the local inflammatory response in the lesion, as
well as generate reactive oxygen species. They also produce matrix metalloproteinases
(MMPs) that degrade the extracellular matrix (30). If a plaque is present, the MMPs can
weaken the strength of the plaque's fibrous cap. When and if the plaque ruptures occurs,
it permits the blood to contact another macrophage product, tissue factor, which promotes
thrombus formation. Eventually the macrophages congregate in a central core and form
plaque. And, the entire cascade of events continues and culminates not only in the
gradual occlusion of an arterial lumen, but this process also sets the stage for the plaque
to rupture, thrombi to form, and result in myocardial infarction.
As this state in inflammation progresses in the artery, vascular SMCs are in
proximity to and physically interact with inflammatory cell types, which play a very
important role in further exacerbating the disease (31). By this time, there is a change in
the phenotype of the vascular smooth muscle cells (VSMCs) from a “contractile” to a
“synthetic” phenotype. Under the influence of the various cytokines that have been
secreted by the macrophages, the VSMCs migrate to the intima. Here, the VSMCs
perform four functions: 1) they secrete proteinases that break down the medial basement
membrane allowing them to migrate to the site of inflammation, 2) they produce various
growth factors such as vascular endothelial growth factor and platelet-derived growth

6

factor that facilitate their proliferation, 3) they secrete a large amount of matrix proteins
such as glycosaminoglycans, elastin, collagen isoforms 1 and 3 that are necessary to
repair the vessel and form a fibrous cap over the lipid-rich core of the lesion, and 4) their
presence provides an element of plaque stability (7, 14). In sum, the entire cascade of
events, triggered by the initial response of the ECs to injury ultimately leads to the
transmigration of monocytes and their differentiation into macrophages, the uptake of
oxLDL leading to foam cells, a perpetual secretion of cytokines that stimulate more
changes in the ECs and VSMCs and lead to a cascade of events that not only occlude the
arterial lumen but in this process causes myocardial ischemia.

7

Fig. 1. Schematic drawing of the structure of coronary arteries. The processes important
to the development of CAD and MI and their targets are indicated. The coronary artery is
composed of three distinct layers, including the intima, media, and adventitia. The intima
consists of extracellular connective tissue matrix (collagen and proteoglycans) bounded
by the endothelium (endothelial cells) on the luminal side and the internal elastic lamina
on the peripheral side. The media contains smooth muscle cells, and the adventitia
consists of connective tissues, fibroblasts and smooth muscle cells.
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1.3 Identifying Novel Pathways in Atherosclerosis
With the identification of the specific molecular pathways and genes involved in
the development of atherosclerosis, we hypothesize that there are novel genes and
pathways to be identified and elucidated to halt disease. Technology is now available to
document the gene expression underlying disease. Sequencing of the entire human DNA
genome has laid the groundwork to study the genetic susceptibility to disease in different
populations.

All this information is available in various databases (32, 33) and

identifying a patient who has these genes (before atherosclerosis develops) may be the
only hope to curtail its development and long-term consequences.
Currently, there are several approaches to study gene expression in
atherosclerosis. These are: genetic linkage studies, genetic association studies, candidate
gene association studies, genomic-wide association studies, and expression profiling. We
shall briefly review these genetic approaches.
Being family-based and using DNA markers (only 1,000 are available at this
time), genetic linkage analysis studies can correlate inherited regions of DNA with family
members who have the disease compared to family members who do not (34). One will
see a family-tree or pedigree mapping the gender and presence of disease among the
entire family often spanning three generations. This approach and method allows one to
determine the regions of the chromosomes that are likely to contain a disease causing
gene.

9

Linkage analysis uses markers, well-characterized regions of DNA, which have
been identified by the Human Genome Project (and other studies) to map chromosome
regions. When one finds a marker that is found associated with a disease, the marker and
the disease-causing gene are said to be linked. This is reflected in LOD score which
compares the likelihood of obtaining the test data if the two loci are indeed linked, to the
likelihood of observing the same data purely by chance. When a high LOD score is
found (usually greater than 3), one does fine mapping of these area to identify
candidate(s) genes and then do further studies to define an underlying, dysfunctional
mechanism. The goal is to find a single-gene (or genes) defect in common with affected
family members and determine its pattern of inheritance. Subsequently, this gene(s) can
be studied in the population at large.
For example, linkage analysis has been successful in identifying specific genes
that may contribute to diseases such as CAD. Two genes include: Myocyte Enhancer
Factor-2 (MEF2A) with myocardial infarction (MI) (34) and Arachidonate 5Lipoxygenase Activating Protein gene (ALOX5AP) with MI and stroke (35).
The MEF2A gene, a member of the myocyte enhancer factor 2 (MEF2) family of
MADS-box transcription factors, has been found to be the gene responsible for an
autosomal dominant form of CAD in a single large family (34). A genome-wide linkage
scan identified that the family’s disease was linked to a single locus on chromosome
15q26. Among the 93 genes found to be significant in this area by fine mapping, MEF2A
was studied because of its known effects on myocardial development and vascular
morphogenesis (34). Our lab sequenced the MEF2A gene and found a 21-bp deletion in
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the last exon of the gene, which was present in all affected members of the analyzed
CAD family. The same 21-bp deletion was absent in both the unaffected family members
and 119 controls (all of which had normal left heart catherizations). Further studies
showed that the in vitro expression of the MEF2A mutant protein indicated that the 7amino acid deletion blocks MEF2A entry into the nucleus and impairs its transcriptional
activity by a dominant-negative mechanism (34).
Subsequent genetic studies by our lab with more than 400 patients with CAD
compared to controls identified three additional missense mutations (Asn263Ser,
Pro279Leu, and Gly283Asp) in exon 8 of MEF2A (often reported as exon 7. These
mutations, found in 1.9% of cases but not in controls, were suggested to reduce the
transcriptional activity of MEF2A by a loss-of-function mechanism, thus playing a
substantial role in the development of CAD (35). With the identification of MEF2A as a
candidate gene based on linkage analysis, this now serves as a platform to identify other
patient populations to find an underlying cause for CAD.
Additionally, the ALOX5AP gene region was linked with MI in 296 Icelandic
families as well as an additional 713 subjects as well as in central European patient (3641). But most importantly, this gene also identified by linkage analysis has led to the
identification of its product, 5-lipoxygenase activating protein (FLAP) which participates
in leukotriene synthesis and a potential therapeutic option to half disease (42).
Compared with linkage studies, genetic association studies use single nucleotide
polymorphisms (SNPs).

The term polymorphism has been used to refer to genetic

mutations that occur with a frequency 1% in the population. The goal is to identify
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differences in the inheritance of particular SNPs among subjects in general, not just
families and find a statistically significant association to disease (43, 44,).

Ideally, one

wants to find at least one or several SNPs within a gene and determine what functional
purpose the SNPs may have and how it might cause the disease (such as CAD). Then,
the findings can be extrapolated to other patients with the disease to see if it can be used
as an identifiable marker. The advantage of this approach is to identify novel pathways
associated with a disease process. Yet, the disadvantage is the massive statistical analysis
making multiple comparisons among groups and accepting a false positive rate of, for
example 0.1%, which would generate 500 false positives. As a result, multiple rounds of
replication are needed.
Candidate gene association studies are more focused on the selection of a limited
group of genes. A candidate gene is a gene located in a chromosomal region suspected
causing a disease. For example, investigators have specifically studied the relationship
between SNPs in the C-reactive protein (CRP) gene and levels of CRP which correlates
directly with risk for atherosclerosis (45). Using a case control design, four SNPs
associated with risk of arrhythmias have been identified in pre-selected genes such as the
cytoskeletal protein paladin (a tyrosine kinase), or two G-protein coupled receptors (46).
Currently, the main focus is on genome wide association studies (GWAS). Using
this approach, one uses over two million identified SNPs that may be separated by merely
1,000 base pairs. This is in contrast to using the DNA markers located approximately
1cM over entire chromosomes. As a result, the chances of identifying a candidate gene
associated or a group of SNPs with a disease such as CAD is more likely.

12

One final approach to identify novel genes associated with CAD is expression
profiling (47-48). DNA microarrays are an orderly, high-density arrangement of nucleic
acid spots on a glass which represents a unique sequence of a gene (48). The target for
these probes come from messenger RNA harvested from a specific tissue, for example,
coronary arteries which are then labeled, incubated on the chip to allow hybridization to
occur, washed and scanned to identify genes that are present. Subsequently, statistical
programs are available (such as GeneSpring from Aligent Genetics) to determine
statistically significant genes between samples (49).
The purpose of our research was to not only identify novel genes associated with
coronary artery but understand the molecular mechanisms that may lead to or prevent this
disease. We started our approach with expression profiling with the microarray using
intact coronary arteries. After identifying 56 novel genes associated with CAD, we
generated our first list of candidate genes to study with the option of looking for SNPs,
mutations, and other associations with CAD. Subsequently, we continued our expression
profiling examining gene expression not only in the internal mammary artery, an artery
resistant to atherosclerosis, but also in pure cell lines of ECs. Using these techniques, we
generated even more candidate genes to study. We ultimately chose two candidate genes,
Testin-2 and the Adenosine A2B receptor. Using in vitro techniques which reflect
processes related to CAD, we invested how these genes (when over-expressed or
silenced) affected monocyte adhesion, cell migration, and the transmigration of
monocytes.
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1.4 Future work.
The most important research questions to the field of CAD are: What are the
specific genes expressed in atherosclerosis? How does their alteration impact the process
of disease? Who expresses these genes? And, can patients without CAD be identified on
the basis of genes alone in an effort to aggressively alter the disease process. In my
research, I hypothesized that there are novel genes yet to be identified that cause CAD.
Using human coronary arteries, I used expression profiling to identify novels genes and
identified novel mechanisms related to the molecular genetics of CAD.

In the future, I

will continue using basic genetic techniques to search for mutations, SNPs, and follow up
association studies to observe the impact of these genes on CAD in the general
population.

It is my goal to not only identified novel genes, but make clinical

correlations to alter the process of atherosclerosis and make a contribution to lower its
morbidity and mortality.
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CHAPTER 2
EXPRESSION PROFILING OF CARDIOVASCULAR DISEASE
Archacki S, Wang Q. Expression profiling of cardiovascular disease. Hum Genomics.
2004; 1(5):355-70.
2.1

Introduction.

Gene expression is thought to be central to the pathogenesis or

progression of coronary artery disease (CAD)/atherosclerosis, congestive heart failure
(CHF) and common congenital heart disease (CHD). Microarray analysis is a powerful
technique for high-throughput, global transcriptonomic profiling of gene expression. It
holds great promise for analyzing the genomic basis of various complex diseases and
permits the analysis of thousands of genes simultaneously, both in diseased and nondiseased tissues and/or cell lines.
Microarrays are made by depositing spots of DNA on a solid support like a coated
glass surface (2). A flat glass surface makes it possible (i) to array molecules in a parallel
fashion, (ii) to miniaturize the procedure and (iii) to use fluorescent dyes for detection
and thus avoid radioactivity. This differs in several ways from conventional methods
such as filter-based supports of charged nylon and nitrocellulose for studying mRNA
expression.

15

A variety of technologies have been used to produce microarrays. Spotted cDNA
arrays, produced by deposition of polymerase chain reaction (PCR) products, and
GeneChip oligonucleotide arrays (Affymetrix; Santa Clara, CA), produced by in situ
synthesis of oligonucleotides, have both been used successfully. Microarrays can now be
tailored to focus on a specific set of genes (e.g. the Cardiochip, with genes related to the
cardiovascular system only). The advantages of cDNA arrays are that they are focused to
a specific pathway or functional class of genes and will identify the gene(s) of particular
interest in the tissue studied. Use of this smaller chip is less expensive, and the same
sample can be used to compare similar genes in several species. The limitation of cDNA
arrays, however, is that only a very limited set of genes can be evaluated. Oligonucleotide
arrays have the advantage of allowing one to monitor every gene in a genome at the same
time, and not to focus on a particular subset of genes. The disadvantage is that this
method is expensive and must be made commercially. At this time, only a few organisms
(human, mouse and rat) are available for studies.
Microarrays can serve to complement other genetic and genomic tools, including
positional cloning (2) and proteomics (3), to understand the underlying biological
pathways that trigger or facilitate the development of CAD/atherosclerosis, CHF or
common CHD. In this paper, we review the current status of microarray studies in
profiling gene expression in cardiovascular disease, with a particular focus on human
tissues and cells.
2.2 Expression profiling of coronary artery disease
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Coronary artery disease (CAD) occurs due to an accumulation of atherosclerotic
plaques (atherosclerosis) in the walls of the coronary arteries. Atherosclerosis leads to
symptoms of stable angina if no clinically apparent plaque rupture or significant breach
of the arterial wall occurs, but it will result in unstable angina, acute myocardial
infarction (MI) or sudden cardiac death once the arterial wall integrity is lost and
thrombosis has occurred.
In the USA and most other Western countries, CAD is the leading cause of
morbidity and mortality. In the USA alone, it caused almost one million deaths in 1999
— twice the number caused by cancer and ten times the number caused by accidents (4).
Despite significant medical advances, MI due to CAD (and strokes) is responsible for
more deaths than all other causes combined.
There are two main theories that explain the development of atherosclerosis. First,
high levels of cholesterol in the blood injure the endothelial cells of a coronary artery,
causing an inflammatory reaction and enabling cholesterol and other fatty materials to
accumulate there. Secondly, repeated injury to the wall of the artery may occur through
various mechanisms involving the immune system or by direct toxicity with substances
such as nicotine or homocysteine, leading to the recruitment and accumulation of
inflammatory cells (5). In both cases, there are changes that can lead to the formation of
atheromas and plaques. These two theories probably overlap and are not mutually
exclusive. To date, several microarray studies have been reported to profile gene
expression in CAD using human tissues; one study from the authors’ group focused on
the identification of genes differentially expressed in CAD and non-CAD coronary
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arteries, and the other studies have characterized gene expression in atherosclerotic
plaques and plaque rupture.
Four microarray studies have so far been reported for the characterization of
atherosclerosis, one of which focused on restenosis after coronary interventions. The
current authors used oligonucleotide arrays to study >12,000 genes for their expression in
human coronary arteries, the target organ of CAD (Table 1) (6). Fifty-six genes showed
differential expression. In the atherosclerotic coronary artery tissues, the expression of 55
genes was increased, whereas only one gene, encoding glutathione-S-transferase (GST), a
reducing agent, showed down-regulated expression. This study detected the expression of
genes previously linked to the generation of CAD, such as osteopontin expressed in
smooth muscle cells, vascular cell adhesion molecule (VCAM)-1 expressed in
endothelial cells and matrix metalloprotease (MMP)-9 expressed in macrophages. This
lends credibility to expression profiling as a valid approach for studying gene expression
in CAD.
The associations of 49 genes appeared to be novel and had not previously been
shown to be associated with CAD. These included genes encoding retinoic acid
responder binding (RAR) protein, butyrophilin, steroidogenic acute regulatory protein
(STAR), PIM-2, STAT-91 and cathepsins K and H. The RAR gene is regulated by
vitamin A signalling pathways and upregulates the expression of the scavenger receptor
CD36 (7); butyrophilin has receptor functions that mediate the transfer of lipid (8); and
cathepsins K and H are lysosomal proteases involved in protein degradation (9, 10).
Acute steroidogenic regulatory protein (STAR) is the rate-limiting step in steroidogenesis
for the transfer of cholesterol into the mitochondria (11). The PIM-2 gene is present in
18

mitogenically stimulated hematopoietic cells (12) and is expressed widely in the media of
coronary arteries (6). The STAT-91 gene is a signal transducer and activator of
transcription in haematopoietic cells (13). Intercellular adhesion molecule 2 (ICAM-2) is
another novel gene whose expression is increased in CAD tissues, and it is expressed
mainly in endothelial cells (6). GST is the only gene whose expression is reduced in CAD
tissues, and it is a reducing enzyme (14). The most significant group of genes identified
in the study were involved in inflammatory processes and consisted of genes expressed
by B and T lymphocytes, as well as macrophages. Other genes included five genes
involved in lipid transfer, oxidation and metabolism; nine genes involved in cell
migration, adhesion and matrix degradation; 12 genes involved in cell necrosis, apoptosis
and proliferation; and several genes with currently unknown functions.
A cDNA microarray study was used to analyze 18,376 genes for changes in
expression in whole-mount human atherosclerotic plaques from the internal and external
iliac arteries, aorta, popliteal artery, posterior tibial artery and the tibio-fibular trunk with
advanced lesions as compared with normal arteries (15). Similarly to the earlier study by
Archacki et al., (6) 17 genes previously connected to atherosclerosis, e.g. actin, cathepsin
S, apoE and P-glycoprotein, were
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Table 1. Expression profiling of coronary arteries.
Target Tissue

Experimental Treatment

Number of Genes
Affected

Intact coronary arties (6)

Severe atherosclerosis
versus non-atherosclerotic
arteries

56

Diffuse survey of several
arteries (15)

Documentation of gene
expression in atherosclerotic
tissue

75

Coronary plaques form
patients with stable or
unstable angina (16)

Ruptured plaque material

5

Atherosclerotic plaque from
human coronary arteries
(17)

Specimen retrieve by novel
helix cutter

201

Human atherosclerotic
plaque (23)

Specimens from ruptured
plaque

Focus on perilipin;
consistently unregulated.
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identified, which validates microarray analysis as a valid approach for studying gene
expression in atherosclerosis (15). The study identified 75 new differentially expressed
genes, 44 of which were unregulated in advanced lesions. Differential expression of
Janus kinase 1(JAK-1), vascular endothelial growth factor (VEGF) receptor-2 and CD31
in atherosclerotic plaques was confirmed with reverse-transcription PCR and
immunocytochemistry. JAK-1 is a protein kinase which may activate platelet-derived
growth factor-b (PDGF) signaling (15). VEGF receptor-2 is a receptor for angiogenic
factor VEGF, and acts as an early marker of vasculature in embryogenesis (15). CD31 is
also an endothelial cell marker that is involved in monocyte and T-cell adhesion to
endothelial cells (15). These studies support the current authors’ hypothesis that
endothelial dysfunction is the earlier triggering event for the development of CAD (2).
Thirty-one genes were downregulated in advanced lesions, whereas the Archacki study
identified only one downregulated gene in diseased coronary artery tissues (6). A
limitation of this study is that various arteries were utilized, and the interpretation of the
data may be challenging as different arteries may have unique characteristics. This study
did not share any genes in common with those found in the current authors’ study,
discussed above, which appears to be a common finding in microarray analysis of
atherosclerosis. The potential explanations for this incongruity may be that different
arteries (coronary artery versus other atherosclerotic tissues) were used in different
studies, and that the arteries used were at different stages of disease.
The third of the afore-mentioned microarray analyses was a small-scale study
with cDNA arrays, in which cDNA probes were hybridized to nylon arrays containing
only 482 genes involved in haemostasis, inflammation and cell adhesion (16). The study
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investigated gene expression in human coronary plaques from patients with stable or
unstable angina. One gene, encoding tissue factor, showed increased expression in
unstable angina samples, whereas five genes, including anticoagulant protein S,
cyclooxygenase-1 (COX-1), interleukin (IL)-7 and the chemokines monocyte
chemotactic protein (MCP)-1 and -2, were expressed at lower levels in unstable angina
samples.
In the fourth microarray study, rather than investigating coronary artery disease
per se, the authors focused on restenosis, the most important limitation of percutaneous
angioplasty procedures (a common surgical treatment for patients with coronary artery
disease) (17). Zohlnhofer et al. retrieved tissue specimens from 16 patients with
symptomatic in-stent restenosis using a novel helix cutter. The control samples included
media specimens from seven gastrointestinal arteries and seven coronary arteries from
cardiac transplantation. Atlas cDNA arrays (human cancer 1.2, human 1.2 cardiovascular,
and stress arrays, Clontech) were used, and a total of 2,435 genes were examined. The
study identified several genes that had previously been reported to be expressed in
smooth muscle cells and regulated in neointima and restenosis. These included
upregulation of thrombospondin-1 (TSP-1), 70-kDa heat shock protein B, COX-1 and
downregulation of desmin. The study also identified two new genes that are connected to
restenosis, FKBP-12 (upregulated) and the gene encoding the mammary-derived growth
inhibitor (MDGI) (downregulated). MDGI is a potent tumour suppressor (18, 19), and
downregulation of MDGI may lead to proliferation and migration of smooth muscle cells,
resulting in restenosis after coronary interventions (20). Upregulation of FKBP-12 is
significant because it is involved in controlling transforming growth factor-b (TGF-b)
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signalling and may prevent cycle arrest, leading to the reocclusion of coronary arteries by
the proliferation of smooth muscle cells (18). This latter study lent support to the testing
of Rapamycin (sirolimus) as a novel pharmacological approach to preventing restenosis,
as it binds to FKBP-12 and down regulates TGF-b inhibitory activity (21). The potential
use of Rapamycin to prevent restenosis is also supported by the report that it inhibits
smooth muscle cell (SMC) migration and proliferation and intimal thickening after
balloon angioplasty in a porcine model of restenosis (22).
In addition to microarray analysis, suppression subtractive hybridisation (SSH)
technology was successfully used to study gene expression patterns in whole-mount
human stable and ruptured plaques (23, 24). The details of the procedures involved in
SSH have been described by Faber et al. (23, 24). Compared with microarray analysis,
SSH is more time-consuming, but it can lead to the identification of low-abundant
sequences which may be missed by microarray technology. Perilipin, a phosphoprotein
present on the surface of intracellular lipid droplets in adipocytes and steroidogenic cells
(25, 26), was found to have a twofold difference in expression and was upregulated in
ruptured plaques. As a result of this finding, it was hypothesised that the overexpression
of perilipin increases triacylglycerol storage by reducing triacylglycerol hydrolysis (27,
28). Consequently, this increase in lipid retention may lead to plaque stabilization and
rupture. Perilipin was found to be consistently expressed in eight ruptured plaques and
was completely absent in stable plaques, identifying it as a unique marker. In addition,
fibronectin and immunoglobulin l chain were downregulated in ruptured plaques.
In summary, the studies discussed above highlight the importance of using
microarrays to identify genes with potential roles in the generation of atherosclerosis,
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including the evolution of plaque and plaque rupture. Novel genes have been identified
which may serve as focal points of future functional and pharmacological studies in an
effort to alter the process of atherosclerosis. Furthermore, the combination of microarray
analysis and positional cloning may provide a powerful synergy in the characterisation of
the molecular bases of human diseases. First, the genes identified by microarray analysis
become the strong candidate genes if they are located in a previously mapped genetic
susceptibility locus for the disease. Secondly, the results from microarray analysis may
provide independent supportive evidence for the new signaling pathway for the
pathogenesis of the disease identified by positional cloning. An excellent example is the
authors’ recent identification of the first non-lipid-related disease-causing gene, MEF2A,
for CAD and MI (2). Using a large family with 13 patients who displayed an autosomal
dominant inheritance pattern of CAD and MI, Wang et al. successfully identified a
significant linkage to CAD/MI on chromosome 15q26 (LOD score 4.19), the first locus
for autosomal dominant CAD and MI (adCAD1). The adCAD1 disease locus contains 93
known or putative genes, and mutational analysis established one of the genes in the
region, MEF2A, as the gene responsible for CAD and MI. A 21 base pair deletion of
MEF2A results in the deletion of seven amino acids in the MEF2A protein (D7aa), and
co-segregates with the disease in the family. It reduces the transcriptional activation
activity of MEF2A by approximately threefold and abolishes the synergistic activation of
transcription by MEF2A in combination with the transcription factor GATA-1 through a
dominant-negative mechanism. Using immunostaining, a strong MEF2A protein signal
was detected in cultured endothelial cells and also within the endothelium of coronary
arteries, which is a barrier between vessels and blood elements such as the platelets and
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macrophages that are central to the pathophysiology of CAD. The authors’ studies
suggest that an early step in the development of CAD/MI may involve deregulation of
specific transcriptional programs in the endothelium. Defective or abnormally developed
vascular endothelium will be more susceptible to inflammation and the diapedesis of
monocytes, and expose the subendothelial matrix to the genesis of atherosclerotic plaque
or thrombosis. Consistent with the authors’ hypothesis, microarray analysis of CAD,
atherosclerosis and restenosis revealed differential expression patterns of several genes
involved in vasculogenesis, angiogenesis and vascular remodeling, including ECGF1and
MMP-9 in the study by Archacki et al. (6), VEGF receptor 2, JAK-1 and CD31 in the
study by Hiltunen et al. (15), TSP-1 in the study by Zohlnhofer et al. (17), and MCP-1
and MCP-2 in the study by Randi et al.(16). It is anticipated that microarray analysis will
be increasingly used in the positional cloning studies for identification of susceptibility
genes for complex human diseases.
2.3 Expression profiling of ischaemic myocardium in animal models
A limitation of using human tissues for microarray analysis is that there is a
tremendous amount of biological variability. A study of human tissues from the
population usually contains patients with several medical problems, taking several
medications and with prior risk factors for atherosclerosis. A study using animal models
can overcome the problem of biological variability. Although very limited to date, gene
expression profiling has been performed on myocardial tissues in several animal models
that have been used to provide information on the process of MI in a controlled setting,
enabling the study of the gene expression profile of MI. The precise mechanisms of
ischaemic injury to the myocardium secondary to atherosclerosis have not been fully
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elucidated. With microarray technology, however, one can start to have a comprehensive
overview of the gene expression patterns occurring in the ischaemic heart (Table 2).
Rabbit hearts that were subjected to two five-minute episodes of ischaemia
(followed by five minutes of reperfusion) and then up to five hours of additional
reperfusion identified 35 genes that were differentially expressed (29). A strong
upregulation of mitogen-activated protein kinase-activated protein kinase-3 (MAPKAPK3) was identified. It was inferred that this gene has a protective mechanism against cell
injury, as a related gene, MAPKAPK-2, is known to be atheroprotective (30). Similarly,
the

same

group

studied

the

same

model
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of

ischaemia

in

rat

hearts.

Table 2. Expression profiling of ischaemic myocardium in animal models.
Target Tissue

Experimental Treatment

Rabbit heart (29)

up-regulation
Two five-minute episodes of Strong
ischaemia followed by five MAPKAPK-3
hours of reperfusion

Rat
(30,31)

Number of gene affected
of

Hearts 20-minute episode of ischaemia Significant up-regulation of HSPfollowed by four hours of 27 and 70
reperfusion

Rat
in
vivo Permanent coronary occlusion
myocardial
infarction model
(32)

731 differentially expressed genes

Rat hearts (33)

Administration of angiotensin- 37 genes clustered into 11
converting enzyme (ACE) functional groups. ACE inhibition
after myocardial infarction inhibits
inhibitor
cardiac hypertrophy

Rat hearts (34)

Ligation of the left anterior Expression of genes associated
descending coronary artery
with a fetal transcription program
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subjected to a 20-minute transient episode of ischaemia followed by four hours of
reperfusion. The purpose of the study was to determine whether activation of protective
genes takes place within four hours following a brief episode of ischaemia, mimicking
angina pectoris (31). Ischaemia led to strong upregulation of mRNA transcripts for heat
shock proteins 70, 27, 105, 86 and 40 kDa, vascular endothelial growth factor, brainderived neurotrophic factor, plasminogen activator inhibitor-1, activating transcription
factor 3, B-cell translocation gene 2 and growth arrest and DNA damage inducible 45
alpha protein. The study demonstrated that a rapid onset ‘genetic reprogramming’ occurs
during a brief episode of ischaemia and can be characterised as protective in nature.
Stanton et al. studied an in vivo rat MI model by causing a permanent coronary
occlusion (32). On a microarray with 4,000 probes, they found a total of 731 genes
differentially expressed during the 16-week experimental period from two regions of the
heart, the left ventricular free wall and the interventricular septum. Upregulated genes
included those encoding atrial natriuretic peptide (ANP), sarcoplasmic/endoplasmic
reticulum Ca2þ-ATPase, collagen, fibronectin, decorin, fibulin, tissue inhibitor of
metalloproteinase-3, fibrillin, laminin, secreted protein acidic and rich in cysteine
(SPARC) and osteoblast-specific factor-2. These genes were classified as belonging to a
remodelling pathway in the post-MI period. The functional clustering of the gene list
showed that the majority of the upregulated genes were classified as cytoskeletal and
extracellular matrix (ECM) proteins, while downregulated genes were classified as
contractile proteins or fatty acid metabolism-related genes, suggesting a profound change
in the energy-generating processes in the ischaemic and then injured myocardial tissue.
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In the setting of MI, the angiotensin-converting enzyme inhibitor, captopril, was
administered to rats for eight weeks after ligation of their left coronary artery (33). In
control animals, there was an increased expression of collagen I and III, thrombospondin4, lysyl oxidase, fibronectin and biglycan eight weeks after MI. There was also the
upregulation of components of the complement pathways and lipopolysaccharide binding
proteins, and VCAM-1. The downregulation of fatty acid metabolising enzymes was also
documented. With captopril treatment, there was a downregulation of hypertrophyrelated genes such as TGF-b3 and insulin-like growth factor binding protein-6. These
results indicate that pharmacological treatment in the post-MI period can have an impact
on gene expression. Many genes were not affected, however, suggesting the need for
more novel forms of therapy to alter ischaemic damage after an MI.
Finally, another rat model employed to study gene expression in the myocardium,
induced with the ligation of the left anterior descending (LAD) coronary artery,
documented gene expression after 24 hours (34). Several genes differentially expressed
included genes associated with cardiac muscle development such as the cell cycle
regulator p18ink4 and the structural proteins, a-myosin heavy chain (a-MHC) and fetal
myosin alkali light chain(MLC). Expression of early growth response factors Egr-1 and
Egr-3 were upregulated by ischaemia, whereas a there was a downregulation of GST.
Other stress responses to ischaemia included an induction in the expression of the
apoptosis regulator Bax, which may contribute to cell death. This gene list may represent
a balance between the cardioprotective and degenerative processes that accompany
myocardial ischaemia.
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In summary, microarrays have been utilised to understand the consequences of
atherosclerosis, which can abruptly cut off the supply of blood and oxygen to the
myocardium. The microarray enables investigators to look at a comprehensive overview
of genetic changes and may stimulate the development of pharmacological therapy to
alter the processes involved in the consequences of MI. It is interesting to note that
several genes were identified by both the human and animal model studies (genes for 70
kDa heat shock protein, fibronectin, VCAM-1 and GST), suggesting that microarray
analysis of animal models is appropriate for some aspects of the characterisation of
human diseases.
2.4 Expression profiling of endothelial cells
The endothelial cell layer of an artery is the first strategic location for the
initiation of atherosclerosis. Dysfunction and/ or injury of endothelial cells play an
important role in atherogenesis (2). The endothelium has many functions — for example,
regulation of tone, coagulation and fibrinolysis, and it secretes several substances.
Expression profiling has been performed for endothelial cell lines to study the impact of
oxidised low-density lipoprotein (LDL), regulators of inflammation [tumour necrosis
factor-a (TNF-a), IL-1b], infection with Chlamydia pneumoniae (CP), antioxidants,
homocysteine and differential patterns of blood flow.
It is hypothesised that areas of the vascular system with turbulent flow are more
likely to develop atherosclerotic plaques than are regions with laminar blood flow (35).
Expression profiling was used to examine the differential expression of genes in human
aortic endothelial cells (HAEC) that were exposed to these two conditions (Table 3) (36).
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In total, more than 130 genes were induced by turbulent flow as compared with laminar
flow. Approximately 50 per cent of the genes surveyed did have a detectable expression
at baseline, but at two hours 3–8 per cent of the expressed genes were upregulated, and
by 24 hours 14.2 per cent, or 50 genes, were downregulated. The study demonstrated that
changes in flow serve as a distinct biomechanical stimulus which has a profound impact
upon the gene expression profile of HAEC in vitro.

31

Table 3. Expression profiling of endothelial cells (EC).
Target Tissue

Experimental Treatment

Number of genes affected

Aortic EC (36)

Disturbed flow and steady
laminar flow

100

Coronary artery (38)

Oxidized low-density
lipoprotein

78

Coronary artery (40)

Infection with Chlamydia
pneumonia

268

Coronary artery (46)

Homocysteine

600

Coronary artery (48)

Nicotine

4

Umbilical vein (49)

BO-653, probocol and BHQ

17

Smooth muscle cells
(SMCs) from plaque (50)

SMC+tumour necrosis
factor (TNF)-alpha

5

Umbilical vein (30)

Interleukin-1beta and TNFalpha

209 EC + 39 in SMCs
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LDL is well established as contributing to the generation of atherosclerosis.
Oxidation of LDL is a key event associated with endothelial cell injury, by leading to the
expression of endothelial cell receptors that bind to inflammatory molecules (37).
Primary human umbilical vein endothelial cells (HUVEC) were exposed to oxidised LDL
for six hours (38). Of the 588 genes evaluated, 78 genes displayed a greater than twofold
change in expression levels: 57 genes were upregulated and 21 genes were
downregulated in response to the oxidized LDL. Oxidised LDL significantly affected the
expression of genes encoding transcription factors, cell receptors, adhesion molecules,
ECM proteins and enzymes involved in cholesterol metabolism. It is interesting to note
that expression of retinoic acid receptor-b (RXR- b) was upregulated in both the turbulent
flow and oxidised LDL studies.
Gene expression has been documented in endothelial cells infected with
pathogens such as human cytomegalovirus (HCMV) or CP. These pathogens are linked
to the development of vascular disease, including atherosclerosis (39), yet the role of
pathogens in vasculopathies has been controversial. Expression profiling has identified
mechanisms by which CP alters coronary artery endothelial cells (40). Twenty of 268
genes on the array were upregulated in human endothelial cells in response to CP,
suggesting that CP infection does not lead to a generalised response in gene expression.
Genes coding for cytokines (IL-1), chemokines (MCP-1 and IL-8) and cellular growth
factors (heparin-binding epidermal-like growth factor, basic fibroblast growth factor
(FGF) and PDGF- b-chain) were the most prominently upregulated in response to the
atypical bacteria.

Additionally, increases in the expression of genes coding for

intracellular kinases and cell surface receptors with signal transduction activities were
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observed. Time course experiments showed that mRNA levels were upregulated within
two hours following infection.
Novel growth factor genes were also identified, and included b-FGF, heparin
binding growth factor (HBGF), PDGF- b and activin A. b-FGF suggested a pathway in
common with endothelial cells and SMCs. HBGF is a growth factor synthesized by
endothelial cells which can act as a potent mitogen for the proliferation of SMCs (41).
Similarly, PDGF-b not only has SMC growth-promoting activity but is also associated
with neointimal proliferation of SMCs (42). PDGF-b-associated protein is also a growth
factor accessory molecule that modulates the activity of specific growth factors (42).
Activin A, or erythroid differentiation protein, has been shown to modulate
monocyte/macrophage function, including immunological activation of monocytes (43)
and the induction of MMP-2 (44). CP induced the expression of E-selectin, ICAM-2 and
VCAM-1 two hours after infection, yet returned to basal levels by 24 hour post-infection
(45). These genes were also upregulated in response to oxidised LDL, and E-selectin and
VCAM-1 were also upregulated in the endothelial cells exposed to laminar or disturbed
flow. These results identify the response of endothelial cells to CP by defining the list of
CP-inducible genes and provide new insights into potential mechanisms of atherogenesis
from these intracellular bacteria.
Several other factors directly alter gene expression in endothelial cells. Elevated
homocysteine levels have been identified as a risk factor for CAD, and it has been shown
to alter gene expression in endothelial cells (46). Using the cardiovascular cDNA
microarray approach, the expression of 600 genes in endothelial cells was screened and a
subset was identified and considered to be modulated by homocysteine (47). They were
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clustered according to the function of the encoded proteins, such as: endothelial motility,
signalling and lipid metabolism. Similarly, oligonucleotide arrays were used to identify
gene expression in endothelial cells exposed to nicotine, the major constituent of cigarette
smoke (48). The most significant changes in gene expression found were the upregulation
of proteins in the inositol phospholipid pathway, namely phosphatidylinositol phosphate
kinase and diacylglycerol kinase. Changes were also detected for transcription factors
cAMP response element binding protein and nuclear factor (NF)-kB.
Takabe et al. examined gene expression in endothelial cells exposed to BO-653,
probucol and BHQ — which act as free radical scavenging antioxidants (49). These
agents were initially developed as anti-atherosclerotic medications. Among 6,416 genes,
17 genes, including those encoding mitochondrial proteins and proteins related to
oxidative stress responses, were induced more than threefold by these three drugs. By
contrast, genes of three subunits of the proteosome (PSMA2, PSMA3, PSMA4) were
downregulated. The gene coding for the cytochrome P-450 1A1 isozyme pathway, a drug
metabolizing phase I enzyme, was expressed only by BHQ treatment.
Cultures of coronary artery endothelium and SMCs derived from a single
coronary artery have been exposed to IL-1b and TNF-a, potent stimulators of
inflammation (50). The most noticeable difference between the cell types was a
considerable greater magnitude and complexity of the transcriptional response in the
endothelial cells. Among the 209 regulated genes in the endothelium, 99 were not
previously linked directly to atherosclerosis including those that had been associated with
leukocyte function (e.g., IL-7 receptor, EBI-3 receptor) and others related to antiviral and
antibacterial defense (e.g., oligoadenylate synthetase, LMP7, toll-like receptor 4,
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complement component 3). In addition, 43 genes likely to participate in signal
transduction (e.g. IL-18 receptor, STK2 kinase, STAF-50, ANP receptor, VIP receptor,
RAC-3, IFP-35) were expressed. This provides evidence that a major effect of TNF-a and
IL-1b is to alter the potential of the endothelial cell to respond to various other external
stimuli.
In summary, multiple pathways are altered in endothelial dysfunction. Expression
profiling has documented the alterations in expression of groups of genes by many
common agents including laminar flow, infectious agents such as CP, as well as toxic
agents like homocysteine, oxidised LDL and nicotine. Alteration of the function of
endothelial cells may serve as the first strategic location for halting the cascade of events
that may follow modification of gene expression in these cells. Each experimental
protocol discussed above elicited an alteration in the expression of a unique cluster of
genes. Although most genes were not found in common among the studies, this may be
attributed to the unique response of the endothelial cell under the various conditions.
Nevertheless, this may provide further medical strategies and targets for down regulating
the inflammatory response which ultimately leads to atherosclerosis.
2.5 Expression profiling of vascular SMCs
The proliferation, migration and invasion of SMCs throughout a coronary artery
make a significant contribution to atherosclerosis. Late occlusion of autologous
saphenous vein grafts (SVGs) is due to medial and neointimal thickening secondary to
migration and proliferation of SMCs and the subsequent formation of atherosclerotic
plaques. This process is the main cause of restenosis after percutaneous transluminal
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coronary angioplasty (PTCA). Understanding SMC proliferation may provide insights
into the pathogenic mechanisms of CAD, as well as restenosis after PTCA. Expression
profiling of SMCs has identified alterations in gene expression that may be related to the
transition of quiescent, contractile SMCs to proliferative SMCs.
Human vascular SMCs were exposed to iloprost, a prostacyclin (PGI2)analogue
which activates cyclic adenosine 3’,5’ monophosphate signalling, which is associated
with maintaining SMCs in a quiescent state (Table 4) (51). PGI2 is known to be
atheroprotective, as it has been
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Table 4. Expression profiling of smooth muscle cells (SMCs).
Target tissue

Experimental design

Human vascular SMCs (50) Exposure of cells to iloprost
SMCs from coronary artery Quiescent
(63)
SMCs

and

Number of genes affected
83

invasive 47

Human aortic SMCs (64)

Exposure to tumour necrosis Focus on eotaxin and CCR3
factor-alpha
receptor

Saphen vein grafts (68)

Comparison with ungrafted 6
veins

Human aorta (70)

Alpha-Tocopherol treatment

Focus on connective tissue
growth factor

Arterial SMCs (75)

Butyrate

58
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shown to exert many effects such as vasodilation, inhibition of platelet aggregation,
modulation of cholesterol metabolism (52), as well as preventing SMC proliferation and
migration (53, 54). A total of 83 genes were differentially expressed six hours after
iloprost exposure. Several of these genes account for the atheroprotective response to
iloprost. MAP kinase phosphatase-1 (MKP-1) has been regarded as a critical
counteracting factor for several transcription factors (p38, JNK, ERK), leading to the
downregulation of stimuli inducing the proliferation of SMCs (55). The zinc finger
protein, hEZF, is associated with a growth arrest, as it has been shown to inhibit DNA
synthesis in fibroblasts overexpressing this gene (56). The gene, Cyr61, was found to be
downregulated by iloprost. This gene plays a role in mediating cell adhesion and
migration, and augments growth factor-induced DNA synthesis in fibroblasts (57). Other
critical genes include: has2 (of uncertain physiological consequence), stanniocalcin (cell
protection against ischaemia (58), plasminogen activator inhibitor-1 (its downregulation
may enhance fibrinolytic activity (59), MCP-1 (its downregulation may prevent
monocyte attachment to SMCs (60), heme oxygenase- 1 (inhibits SMC proliferation (61)
and COX-1 (promotes the synthesis of prostaglandins, and thus is a positive
autoregulatory mechanism for enhancing prostaglandin levels (62). Downregulation of
MCP-1 and COX-1 was identified in atherosclerotic plaques from human patients with
unstable angina (16).
Microarray analysis using 558 cardiovascular-associated genes identified 47
genes differentially expressed in proliferating and non-proliferating human arterial SMCs
(63). Most of the genes in the study were associated with the ECM and cell motility. The
main gene groups identified included matrix organising proteins, ECM proteins, cell
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adhesion proteins, and extracellular communication and cytoskeleton motility proteins.
Genes previously associated with SMC migration and invasion, such as those coding for
tissue inhibitor of metalloproteinases (TIMP)-2, TIMP-3 and MMP-3, were confirmed by
the array data. Reduced expression of several cytoskeletal proteins, such as vimentin,
fibronectin, cytokeratins and b1- integrin, were shown in the invasive phenotype.
Furthermore, angio-associated protein, a-E-catenin and brain ANP receptor were
downregulated, whereas TFPI-2 was strongly upregulated in invasive proliferating
SMCs. Consequently, the data document the expression profile of essential genes in
SMCs involved in the invasive process.
Microarray analysis with 8,600 genes identified .20-fold increases in steady-state
eotaxin mRNA, and follow-up immunohistochemical studies with tissue samples from
seven non-diseased and 14 atherosclerotic arteries demonstrated overexpression of
eotaxin protein and its receptor, CCR3, in cultured human aortic SMCs treated with TNFa (which induces vascular inflammation), whereas their expression was negligible in
normal vessels (64). This was the first study to report the expression of eotaxin by human
atheroma. While this was known to be a potent eosinophil chemoattractant and activator
(65, 66), no eosinophils were identified in the target tissue.

Similarly, CCR3 had

previously been observed in macrophages, mast cells, neutrophils and endothelial cells in
endobronchial biopsies of the atopic asthmatic lung (67). The implications of the study by
Haley et al. are that TNF-a may recruit and activate macrophages and mast cells through
the CCR3 receptor (64). This study may lead to the generation of either eotaxin- or
CCR3-null mice, which might be resistant to atherogenesis.
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In addition to SVGs being used for coronary artery bypass grafting, left and right
internal mammary arteries have also been used (68). The SVG is the standard conduit for
coronary artery bypass grafting to all areas of the heart except the LAD coronary artery.
Accelerated atherosclerosis occurs in venous conduits such that during the first year after
bypass surgery, 15 per cent of vein grafts occlude; between one and six years, the graft
attrition rate is 1–2 per cent per year; and between six and ten years, it is 4 per cent per
year (69). Thus, within the first decade of bypass surgery, most bypass grafts will be
occluded or significantly diseased. A major component of this occlusion is the
proliferation of SMCs. Differentially expressed genes in the saphenous vein have been
documented and correlate with expected gene expression patterns, including upregulation
of c-jun and CDK-10. In addition, previously unidentified gene expression patterns were
detected, such as the upregulation of HSP-70, fibronectin-1, erbB-3 proto-oncogene and
c-myc.
The effect of a-tocopherol treatment on gene expression in human aortic SMCs
has been studied because it may accelerate wound repair and tissue regeneration during
atherosclerosis (70). This medication is also often recommended because of its
antioxidant properties (71). The expression of the connective tissue growth factor
(CTGF) gene was induced by a-tocopherol 1.8-fold. It was hypothesised that this gene is
involved in normal repair processes and is permanently overexpressed in pathological
events (70). a-tocopherol may either stimulate the synthesis of CTGF or interfere with the
effect of TNF-a on downregulation of this gene.
cDNA array technology has been utilised to unravel the molecular basis of the
antiproliferative effect of butyrate on vascular SMCs. Butyrate is a natural fatty acid
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which has been shown to inhibit SMC proliferation in in vitro cell culture systems (72). It
is derived from the microbial metabolism of dietary fibre in the colon, where it is
produced in high levels (73). It can function as an anti-inflammatory agent by
suppressing intestinal inflammation (74), and may alter gene expression by reversibly
inhibiting histone deacetylase, causing the hyperacetylation of histones and thereby
leading to selective changes in gene expression (73). To assess the involvement of gene
expression in butyrate-inhibited vascular SMC proliferation, proliferating vascular SMCs
were exposed to butyrate (75). A total of 111 genes exhibiting moderate (two- to
fivefold) to strong (fivefold) differential expression were identified.

Analysis of these

genes indicates that butyrate treatment mainly alters the expression of four different
functional classes of genes, which include: 43 genes implicated in cell growth and
differentiation, 13 genes related to stress response, 11 genes associated with vascular
function and eight genes normally present in neuronal cells. cDNA expression profiles
indicate that butyrate-inhibited vascular SMC proliferation involves a combined action of
a proportionally large number of both positive and negative regulators of growth, which
ultimately causes growth arrest of vascular SMCs (75). For example, the downregulated
genes included pRb (required for G1 to S phase entry), S phase-specific PCAN, G2/M
phase-specific cyclinB1 and cdc2, and p55cdc. The downregulation of these critical
positive regulators of cell cycle progression indicates that butyrate exerts its
antiproliferative effect by altering key positive regulators of all phases of cell cycle
progression. Furthermore, butyrate also appeared to block SMC proliferation by
upregulating negative regulators of cell growth or differentiation inducers such as
p21waf1, p14INK4B/p15INK5B and clusterin. Consequently, the identification of the
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molecular mechanisms of butyrate-inhibited proliferation is important, not only to
understand the molecular basis of butyrate-induced SMC proliferation, but it may be used
as a therapeutic agent to prevent restenosis of arteries in humans.
In summary, smooth muscle cell proliferation contributes to the formation of
atherosclerotic lesions and restenosis after angioplasty, and microarray studies have
identified multiple genes that are involved in this process. Understanding the molecular
mechanisms involved may provide novel insights into pharmacological approaches to
preventing SMC migration.
2.6 Expression profiling of inflammatory cells
Inflammatory cells play an important role in the development of CAD. First,
monocyte recruitment is a key event in the ormation of the earliest vascular lesion, the
fatty streak. Secondly, macrophage uptake of modified LDLs via scavenger receptors
gives rise to foam cells in the atheroma, and these secrete growth factors, cytokines and
inflammatory mediators that influence the growth and development of other cell types
within the atherosclerotic lesion, generating plaques. Microarrays have been used to
profile gene expression changes in the inflammatory cells in relation to the formation of
atherosclerotic lesions.
Gene expression of macrophages has been analysed using microarrays containing
approximately 16,000 human cDNAs (Table 5) (76). The human monocytic leukaemia
cell line (THP-1) was treated with oxidised LDL. The cells were then activated by
treatment with lipopolysaccharide (LPS), and RNA was harvested at zero, one and six
hours after LPS addition. Oxidised LDL treatment affected the expression of 57 of 127
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genes in macrophages. Among them are genes that code for potent intracellular and
extracellular signaling molecules such as NF-kB, A20 and numerous cytokines and
chemokines. Oxidised LDL pretreatment resulted in a significant change in LPS-induced
NFkB activation. Some of the oxidised LDL effects were mediated by the nuclear
receptors RXR and peroxisomal proliferator-activated receptor-g.
To further define the mechanisms by which LDL particles affect macrophages
and foam cells, a large-scale gene expression analysis of cholesterol-loaded macrophages
was carried out (77). Oxidised LDL-treated and time-matched control untreated cells
were hybridised to microarrays containing 9,808 human genes. Two hundred and sixtyeight genes were found to be differentially expressed at least twofold at one or more time
points. These patterns of regulation were classified into seven clusters. Shiffman et al.
identified patterns of gene expression of known and novel molecular components of the
cellular response that are implicated in the growth, survival, migratory, inflammatory,
and matrix remodelling activity of vessel wall macrophages (77). The data indicate that
oxidized LDL loading of THP-1 cells did not elicit any measurable immediately
transcriptional response from the genes studied until day 4. The novel and most highly
upregulated genes identified were: DSCR1, LARC/MIP-3 a, CD73/50-nucleotidase,
epithelial membrane protein-1, uridine phosphorylase and two expressed sequence tags
(ESTs). The incidence of these genes indicates that the previously published data on
oxidised LDL loading of macrophages only partially describes the changes that occur in
some inflammatory cells. The most highly downregulated genes included promoters of
the anti-microbial potential of macrophages (carbonic anhydrase, cytochrome b-245,
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Table 5. Expression profile of inflammatory cells.
Target tissue

Experimental design

Number of genes affected

Macrophages (76)

Oxidized low-density
lipoprotein

268

Human monocytic
leukaemia cell line (77)

Lipopolysaccharide

57

Macrophages (78)

Exposure to copper

7

Macrophages (80)

Exposure to arsenic

62

THP-1 cells (81)

Biomechanical forces

3

Macrophages (86)

Exposure to androgens

27 genes exclusively
upregulated in males
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differentially expressed at least twofold at one or more time points. These patterns of
regulation were classified into seven clusters. Shiffman et al. identified patterns of gene
expression of known and novel molecular components of the cellular response that are
implicated in the growth, survival, migratory, inflammatory, and matrix remodelling
activity of vessel wall macrophages (77). The data indicate that oxidized LDL loading of
THP-1 cells did not elicit any measurable immediately transcriptional response from the
genes studied until day 4. The novel and most highly upregulated genes identified were:
DSCR1, LARC/MIP-3 a, CD73/50-nucleotidase, epithelial membrane protein-1, uridine
phosphorylase and two expressed sequence tags (ESTs). The incidence of these genes
indicates that the previously published data on oxidised LDL loading of macrophages
only partially describes the changes that occur in some inflammatory cells. The most
highly downregulated genes included promoters of the anti-microbial potential of
macrophages (carbonic anhydrase, cytochrome b-245, RNase A2, CD64) and three
involved in cell cycle progression or synthesis of precursors involved in cell division
(GOS2 protein, thymidylate synthetase, lamin B1).
Similarly, DNA microarrays were used to define the changes in gene expression
profile in response to copper exposure of human macrophages (78). Serum copper has
been shown to be associated with cardiovascular disease (a 3.5-fold increased risk of
acute MI) but its mechanism of action has not been identified (79). The results showed
that expression of 91 genes were altered. Copper increased the expression of seven
cholesterogenic genes (3-hydroxy-3-methylglutaryl coenzyme A synthase, IPP
isomerase, squalene synthase, squalene epoxidase, methyl sterol oxidase, H105e3 mRNA
and sterol-C5-desaturase) and LDL receptor, and decreased the expression of CD36 and

46

lipid-binding proteins. Thus, copper activates cholesterogenic genes in macrophages
involved in LDL uptake and de novo cholesterol biosynthesis. This leads to lipid
accumulation in the inflammatory cells and thus the arterial wall.
Gene expression was also studied in lymphocytes exposed to arsenic, which is
associated with an increased risk for vascular disease (80). Patients were exposed to low,
intermediate or high levels of arsenic as determined by monitoring serum levels. A total
of 62 genes showed a significant difference in the intermediate and high levels of blood
arsenic, as compared with low levels. These genes included those encoding IL-1 b, IL-6,
chemokine C-C motif ligand2/MCP-1, chemokine C-X-C motif ligand 1/growth-related
oncogene-a, chemokine C-X-C motif ligand2/growth-related oncogene- b, CD14 antigen
and MMP-1.
The effect of biomechanical forces on macrophage functions in atherosclerosis
was determined by microarrays with 1,056 genes (81). Mechanical deformation at 1Hz
was applied to a thin transparent membrane on which the cells were cultured. This stress
induced only three genes to more than 2.5-fold higher expression at three and six hours:
prostate apoptosis response-4 (3.0-fold at three hours, 6.7-fold at six hours), IL-8 (4.3fold at six hours) and the immediate-early response gene, IEX-1 (2.6-fold at six hours).
IL-8 may be important in the initiation and amplification of inflammation and
angiogenesis in atherosclerosis, because it is chemotactic for vascular SMCs, T
lymphocytes and neutrophils (82). It also triggers the firm adhesion of monocytes to the
vascular endothelium (83). IEX-1 is an NF-kB-inducible immediate-early gene which
inhibits

apoptosis

(84).

It

may

also

participate

in

the

differentiation

of

monocytes/macrophages. PAR-4 is known to be a widely expressed protein which
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confers sensitization to apoptosis induced insults (85). Consequently, this study
demonstrated that human monocytic cells respond to mechanical deformation with
induction of immediate-early and inflammatory genes. This suggests that mechanical
stress in vivo, such as that associated with hypertension, may play an important part in
atherogenesis and instability of coronary artery plaques through biomechanical effects on
vascular macrophages.
Human monocyte-derived macrophages from healthy male and female donors
have been exposed to androgen (dihydrotestosterone) in an effort to detect genderspecific changes in gene expression (86), as it has already been established that there is a
gender difference in the severity of disease, with men having more severe coronary artery
disease than women (87). In macrophages harvested from males, treatment with androgen
resulted in the differential upregulation of 27 genes, whereas none was upregulated in
female harvested macrophages. Some of these genes directly related to the process of
atherosclerosis, including the upregulation of acyl coenzyme A:cholesterol acyl
transferase I and lysosomal acid lipase (LAL) (which plays a role in the delivery of
lipoproteins to cells) (88), caveolin-2, CD40, leukotriene B4 receptor and cadherin-19
(the latter three play a role in inducing cell surface receptors for monocyte attachment
(89)). Functional studies to complement the microarray results showed a direct clinical
correlation with LAL, in that there was a consistent increase in activity with 125I-AcLDL
exposure. It can be concluded that androgen exposure as it occurs naturally in the male
gender is directly responsible for inducing genes associated with the development of
atherosclerosis and may account for gender differences in the incidence of CAD.
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2.7 Expression profiling of CHF.
CHF is a term used to describe any condition in which the heart is unable to
generate an adequate pressure to pump blood throughout the body. This condition causes
symptoms such as shortness of breath (dyspnea), fatigue, weakness and swelling (edema)
of the legs and sometimes in the abdomen (ascites). An estimated 4.8 million Americans
have CHF (90), and half of all patients diagnosed with CHF will be dead within five
years. Each year, there are an estimated 400,000 new cases. Increasing prevalence,
hospitalizations and deaths have made CHF a major chronic condition in the USA. It
often occurs as the end stage of cardiac disease, referred to as ischemic cardiomyopathy
(ICM) due to severe CAD. Expression profiling of human cardiac tissues has been
employed to identify genes whose expression is linked to CHF, and these studies are
summarized below.
Oligonucleotide microarrays were used to profile seven non-failing (NF) and
eight failing (F) human hearts with a diagnosis of end-stage dilated cardiomyopathy
(Table 6).91 Of 6,606 genes on the microarray, 103 genes in ten functional groups were
differentially expressed between F and NF hearts. In failing hearts, K means clustering
revealed two potentially novel pathways associated with up-regulation of atrial natriuretic
factor and brain natriuretic peptide and with increased expression of ECM proteins. A
dendrogram or genetic profile of the two tissues distinguished two failing hearts with
distinct etiologies (familial and alcoholic cardiomyopathy, respectively). The study
demonstrated that there is a unique molecular signature in failing hearts.
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Similarly, a ‘genomic portrait’ of heart failure derived with microarrays was
obtained from end-stage dilated cardiomyopathy (DCM) using the CardioChip with nonredundant 10,848-element human cardiovascular-based ESTs (92). More than 100
transcripts were consistently differentially expressed in DCM .1.5-fold (versus pooled NF
hearts). ANP was also found to be upregulated in DCM (19-fold compared with NF
hearts) as well as numerous sarcomeric and cytoskeletal proteins (e.g. cardiac troponin,
tropomyosin),

stress

response

proteins

(e.g.

HSP-40,

HSP-70)

and

transcription/translation regulators (e.g. CCAAT box binding factor, eIF-1AY).
Downregulated genes were classified as cell-signaling channels and mediators,
particularly those involved in calcium pathways [calcium/calmodulin-dependent kinase,
inositol 1,4,5-trisphosphate receptor, and sarcoplasmic reticulum Ca 2þ-ATPase
(SERCA)]. Several novel, cardiac-enriched ESTs were also co-expressed. The study
demonstrated a common expression pattern among the sets of samples with DCM, and
documents a gene list that may serve as possible targets for therapeutic intervention
specific to cardiac tissue.
Also using patients with either DCM or hypertrophic cardiomyopathy (HCM) at
end-stage CHF, Hwang et al. generated a list of predictive markers for these two diseases
(93). Similarly to previous studies, ANP and SERCA were found to be increased and
decreased, respectively, and this was consistent in all of the tissues studied. Other genes
having the same expression levels in both DCM and HCM tissues included: copper/zinc
superoxide dismutase, heat shock protein 90, elongation factor-2, calcium-activated
neutral protease, decorin and CD59. Genes found to be differentially expressed between
DCM and HCM included atrial myosin alkali light chain, calsequestrin, lipocortinand
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lumican, which were upregulated, while myc transcriptional activity and b-dystrobrevin
were downregulated. In total, the study documented 192 genes. As in the previous studies
reviewed, ANP and SERCA displayed the same expression patterns consistently in both
populations of samples.
In a study by Steenman et al., the expression profiles of four specific
pathophysiological cardiac situations was analyzed: i) left ventricle (LV) from NF heart;
ii) LV from F heart affected by DCM; iii) LV from F heart affected by ICM; and iv) right
ventricle (RV) from F heart affected by DCM or ICM (94). Microarrays representing
approximately 12,000 human genes were utilized. The authors identified 1,306 genes
with a similar expression profile in all four cardiac situations. The upregulation of
MLC1emb, calponin and SM22 represented a reversal to developmental gene expression
such as occurs in cardiac remodeling and CHF. Smooth muscle myosin heavy chain and
smooth muscle a-actin represented a dedifferentiation process. Several apoptosis-related
genes were identified in F LV and/or RV samples, with CDKN1A showing the most
marked activation. Stress-inducible metallothionein was also upregulated; this functions
as an antioxidant and inhibits the production of atrial natriuretic factor (95). Novel genes
included AF1a, a transmembrane protein (96), and SH3BGR. Relatively few genes were
differentially expressed between F LV and F RV samples, yet the most marked difference
was found in the gene profiling, an actin-binding protein being implicated in the control
of actin polymerization and cytoskeletal reorganization (97). Finally, no genes were
significantly differentially expressed between DCM and ICM F hearts, which indicates
that all hearts were clinically in failure.
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In a separate study, oligonucleotide arrays have identified specific genes
expressed in patients with CHF, screening over 7,000 genes in two NF and two F human
hearts with diagnoses of end-stage ICM and DCM (98). Genes were categorized into five
groups: (a) cytoskeletal and myofibrillar genes [myomesin, non-sarcomeric myosin
regulatory light chain-2 (MLC2) and ss-actin ]; (b) genes responsible for the degradation
and disassembly of myocardial proteins (alpha-1-antichymotrypsin, ubiquitin and
gelsolin); (c) genes involved in metabolism [ATP synthase alpha-subunit, succinate
dehydrogenase flavoprotein(SDH Fp) subunit, aldose reductase, and TIM-17 preprotein
translocase]; (d) genes responsible for protein synthesis [elongation factor- 2(EF-2),
eukaryotic initiation factor-4AII and transcription factor homologue-HBZ17 ]; and (e)
genes encoding stress proteins (a- B-crystallin and m-crystallin). The study focused on
the novel gene SLIM1 as being consistently downregulated in CHF. Although the precise
function of SLIM1 has not been determined, it is hypothesized that it may act as a
scaffold for interaction between thin filaments and the cytoskeleton (99), in a similar way
to muscle LIM protein (ML). MLP knockout mice have been shown to develop DCM
(100). All of the identified genes may contribute to development of the heart failure
phenotype and represent compensatory mechanisms to sustain cardiac function in failing
human hearts.
Similarly, Steenbergen et al. used DNA microarray profiling to investigate
changes in the expression of genes involved in the apoptosis that occurs in human
idiopathic DCM hearts that have progressed to CHF (101). They documented altered
gene expression consistent with a pro-apoptotic shift in the TNF-a signaling pathway.
Specifically, they found decreased expression of TNF- a- and NF- kB-induced anti-
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apoptotic genes such as growth arrest and DNA damage-inducible (GADD) 45-b, Flice
inhibitory protein (FLIP) and TNF-induced protein 3 (A20) genes. They also observed a
significant decrease in the phosphorylation of BAD at Ser-112, which is also consistent
with a role for apoptosis in heart failure.
One option for improving left ventricular function in CHF is the use of a left
ventricular assist device (LVAD). The unloading of the F heart with an LVAD can
decrease cardiac mass and myocyte size and has the potential to improve contractile
function. Several studies have documented changes in gene expression brought about by
the presence of an LVAD. The effect of chronic ventricular unloading on myocardial
gene expression was compared before and after LVAD support in seven patients with
idiopathic DCM and end-stage CHF (102). On average, 1,374 genes were reported as
‘increased’ and 1,629 ‘decreased’ after LVAD support. Upregulated genes included a
large proportion of transcription factors, genes related to cell growth/apoptosis/DNA
repair, cell structure proteins, metabolism and cell signaling/communication. LVAD
support resulted in downregulation of genes coding for cytokines. Similarly, Chen et al.
performed transcriptional profiling using a spotted cDNA microarray with 12,814 unique
clones on paired samples of LV obtained before and after placement of a left ventricular
assist device in 11 patients.103 The most significantly upregulated gene was the Gprotein-coupled receptor APJ, the specific receptor for apelin. Blaxall et al. also
examined gene expression, performing oligonucleotide arrays with LV samples from six
male patients which were harvested during LVAD placement and at the time of
explantation (104). These authors documented a significant difference in the
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corresponding LVAD mediated regulation of gene expression and were able to
distinguish, in a blind manner, patients with different CHF etiologies.
Finally, microarrays were utilized on paired samples of human tissue from
patients with CHF with and without an LVAD (105). After several statistical analyses of
the data, approximately 85 upregulated genes were identified. The focus of the study was
on apelin, which was the most significantly upregulated gene, and was localized
primarily in the endothelium of the coronary arteries after the mechanical offloading by
the LVAD. This finding implies an important paracrine signaling pathway in the F heart.
The identification of this gene led to the measurement of serum apelin levels. These were
found to be increased in the serum of patients with F hearts and may serve as a biological
marker in patients with CHF.
In summary, microarray analysis of CHF can reveal the underlying molecular
mechanisms regulating hypertrophy and proliferation, as well as apoptosis of
cardiomyocytes. These studies revealed the dysregulation of various molecular pathways
involved in CHF.
2.8 Expression profiling of CHD
Congenital heart defects account for the largest number of birth defects in humans
(4). The application of expression profiling in patients with CHD is still in its infancy. To
date, only one microarray study has documented gene expression in CHD.
Microarray analysis was carried out in cardiac samples collected during cardiac
surgery, from six normal samples and from 55 patient samples with various cardiac
defects (106).

Human Unigene Set-RZPD 2 cDNA arrays with 12,657 known genes
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were used. The study identified specific molecular signatures for tetralogy of Fallot
(TOF), ventricular septal defects (VSDs) and right ventricular hypertrophy (RVH), each
of which has a distinct gene expression profile. TOF and RVH were found to be
associated with genes of various functional classes, and can be clearly distinguished by
different molecular signatures. The TOF signature consists of many genes involved in the
cell cycle and cardiac development (e.g. upregulation of SNIP, A2BP1and KIAA1437,
and downregulation of STK33, BRDG1and TEKT2) and the upregulation of ribosomal
proteins S6, L37a, S3A, S14 and L13A. The RVH signature includes genes mainly
involved in the stress response, cell proliferation and metabolism — for example, the
upregulation of ADD2. VSDs have been associated with a specific signature consisting of
downregulation of genes for ribosomal proteins S11, L18A, L36, LP0, L31 and MRPS7,
and downregulation of genes involved in cell proliferation, differentiation and apoptosis
(e.g. AMD1, RIPK3, EGLN1, SIAHBP1 and ARVCF). Several ion channel genes,
including SLC26A8, SLC16A5, SLC4A7, KCNS2and KCNN3, were found to be
differentially expressed in VSD tissues. The study also identified heart chamber-specific
expression of many genes. The human heart consists of two atria and two ventricles. The
atria have been found to have higher expression of genes for ECM or actin modulation,
such as CST3 and PCOLCE, translation factor EEF1A and the DNA helicase REQL4,
and a potassium channel subunit KCNIP2. Genes with higher expression in the ventricles
encode proteins for cytoskeleton contraction, metabolism–energy turnover and cell
cycle–growth, and include TMP1, FHL1, and ANKRD2.
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2.9 Conclusions
The availability of cDNA and oligonucleotide microarrays with several thousand
human genes makes it possible to study global changes in gene expression in CAD, CHF
and CHD. These studies have identified novel genes and pathways involved in the
generation of these diseases at both the organ/tissue level (coronary arteries, cardiac
tissues) and cell level (endothelial cells, vascular SMCs, macrophages). It is important to
note that several studies have confirmed the expression of genes previously linked with
these disease processes, suggesting that expression profiling with microarrays is a valid
approach for identifying gene expression alterations associated with disease. Yet, many
more novel genes have also been identified, and will serve as a valuable resource for
identifying novel pathways involved in the generation of disease. With the continued use
of this technology, and an accelerated application to these diseases, we will eventually
identify a common group of genes which will be able to serve as markers for these
disease processes on a global scale. It is important, however, to note that different studies
have identified different sets of genes associated with these diseases. Thus, the
microarray results remain to be replicated in an independent set of samples, and caution
needs to be taken when interpreting these results. In addition, a major limitation of
microarray analysis is that it is usually difficult to distinguish whether the identified
differential gene expression patterns are the cause or the consequence of the disease.
Follow-up studies with transgenic overexpression or knockout of the gene of interest in
animal models are needed to solve this issue. Furthermore, microarray analysis is biased
to the genes on the arrays, and cannot be used to evaluate low-abundant transcripts.
Microarray analysis also results in false-positives; it is therefore crucial that results are
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confirmed using conventional technologies, such as quantitative real-time PCR,
quantitative reverse-transcription PCR, Northern blot, Western blot or immunostaining
analyses. Finally, the expression level of mRNA does not necessarily reflect the
expression of the protein, and the pathogenic mechanism of a disease may involve protein
modifications such as phosphorylation and glycosylation. Under these circumstances,
proteomics will prove to be a powerful, alternative technology. The first proteomics
analysis has been performed for CAD by the authors of this paper, and the study
identified the ferritin light chain as a significant marker for diseased coronary arteries (3).
It is important to point out that proteomics can analyze far fewer genes than can
microarrays, as the resolution of the common two-dimensional gel separation of protein
extracts is limited to only a few thousand protein spots. Proteomics also shares some
common limitations with microarray analysis; for example, it cannot be used to evaluate
low-abundant proteins/genes.
Nevertheless, microarray analysis can generate novel hypotheses relating to the
pathologies of these diseases, and further studies with animal models, molecular biology,
cell biology and biochemistry will validate these hypotheses and provide novel insights
into the pathogenesis of disease. These studies will eventually generate novel diagnostic
and therapeutic markers, and identify potential drug targets which will serve to bring
about more effective management of cardiovascular disease.
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CHAPTER 3
INTRODUCTION
IDENTIFICATION OF NEW GENES DIFFERENTIALLY EXPRESSION IN
CORONARY ARTERY DISEASE BY EXPRESSION PROFILING
ABSTRACT
Genetic factors increase the risk to coronary artery disease (CAD). To date, a
limited number of genes that potentially contribute to development of CAD have been
identified. In this study, we have performed large-scale gene expression analysis of
∼12,000 human genes in nine severely atherosclerotic and six nonatherosclerotic human
coronary arteries using oligonucleotide microarrays. Fifty-six genes showed differential
expression in atherosclerotic coronary artery tissues; expression of 55 genes was
increased in atherosclerotic coronary arteries, whereas only one gene, GST, encoding a
reducing agent, showed downregulated expression. The expression data of selected genes
were validated by quantitative RT-PCR analysis as well as immunostaining. The
associations of 49 genes with CAD appear to be novel, and they include genes encoding
ICAM-2, PIM-2, ECGF1, fusin, B cell activator (BL34, GOS8), Rho GTPase activating
protein-4, retinoic acid receptor responder, ß2-arrestin, membrane aminopeptidase,
cathepsins K and H, MIR-7, TNF-α-induced protein 2 (B94), and flavocytochrome 558.
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In conclusion, we have identified 56 genes whose expression is associated with CAD,
and 49 of them may represent new genes linked to CAD.
Archacki SR, Angheloiu G, Tian XL, Tan FL, DiPaola N, Shen GQ, Moravec C, Ellis S,
Topol EJ, Wang Q. Identification of new genes differentially expressed in coronary artery
disease by expression profiling. Physiol Genomics. 2003;15(1):65-74.
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3.1 Introduction.
Coronary artery disease (CAD) and myocardial infarction (MI) are the leading
causes of death in the United States and other Western countries. An estimated 7.5
million living Americans have experienced MI, and 12.6 million have CAD (1).
Approximately 1.1 million Americans developed MI in 1999, and the mortality rate was
more than 45%.
CAD is a multifactorial disorder influenced by both genetic and environmental
factors and their interactions. Genetic-epidemiological and twin studies strongly suggest
that genetic factors contribute to the development of atherosclerosis (9). Case-control
studies have been used to identify genes that are associated with increased risks to CAD
and MI. These genes include the thrombospondin (TSP) genes (TSP-1, TSP-2, and TSP4)43, LTA gene encoding lymphotoxin-α, (29) connexin 37, (52) and the genes encoding
plasminogen-activator inhibitor type 1, stromelysin-1,(52) apolipoprotein E (ApoE),
Lp(a) or Apo(a), Apo AI, ApoCIII, ApoIV, fibrinogen, tissue-type plasminogen activator
(TPA), plasminogen activator inhibitor (PAI-1), von Willebrand factor (VWR), platelet
glycoprotein IIIa, lipoprotein lipase, cholesterol ester hydrolase, cholesterol ester transfer
protein (CETP), factor V, factor VII, angiotensin converting enzyme, angiotensinogen,
and endothelial nitric oxide synthase (49).
Various biochemical methods including Northern blot, Western blot, and
immunostaining have also been employed to identify genes that are associated with CAD.
Previous studies have implicated the upregulation of specific genes in atherosclerotic
tissue including chitotriosidase (4) lumican (27), VCAM-1 (10), ICAM-1 (10), matrix
metalloproteinase-9 (MMP-9) (42), and osteopontin (24) (as well as the downregulation
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of endothelial nitric oxide synthase (25). Recently, subtraction suppression hybridization
(SSH) was employed to identify genes that are differentially expressed in stable and
ruptured atherosclerotic plaques (a major cause of thromboembolic complications) in
human coronary arteries. Only a limited number of genes associated with plaque rupture
were identified by SSH: the perilipin gene was found to be upregulated, and genes for ßactin, fibronectin, and immunoglobulin-λ chain were downregulated (8).

DNA

microarray technology was also performed on arteries such as common, internal, and
external iliac artery, aorta, popliteal artery, posterior tibial artery, and tibiofibular trunk to
define a group of 75 novel genes expressed in atherosclerotic plaques; however, the
coronary arteries, the target organ of CAD, were not investigated (12).
To summarize, only a small number of genes that potentially contribute to the
pathogenesis of CAD have been identified. No microarray analysis has been performed
on human coronary arteries from patients with CAD. Therefore, in this study we used
oligonucleotide microarrays with ∼12,000 unique genes to identify genes that are
differentially expressed in atherosclerotic human coronary arteries.
3.2 Material and Methods
3.2.1 Tissue Sampling of Human Coronary Arteries
Coronary arteries were obtained from explanted hearts through the Cleveland
Clinic Heart Transplant Program and unmatched or rejected donor hearts from Lifebanc
of Northeast Ohio (Table 1). Informed consent was obtained from all participants
according to the standards established by the Cleveland Clinic Foundation Review Board
on Human Subjects. Coronary artery segments measuring 5 mm in length were harvested
immediately after heart extraction and cleaned of adjacent adipose and myocardial tissue.
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The adventitial layer remained intact. The coronary arteries were harvested immediately
upon explantation of the heart in the surgical suite and snap-frozen in liquid nitrogen and
stored at -80°C as previously described until used (22).
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Table 1. Patient characteristics.
Atherosclerosis

No Atherosclerosis

Sample Age/Yrs Race/Sex % LAD Disease SampleAge/YrsRace/Sex % LAD Disease

D1

49

W/M

75

N1

62

W/M

ND

D2

59

W/M

95

N2

59

W/M

ND

D3

69

W/M

75

N3

55

W/F

ND

D4

52

W/M

75

N4

75

W/M

ND

D5

60

W/M

80

N5

47

W/M

ND

D6

68

W/M

95

N6

74

W/M

ND

D7

47

W/M

95

D8

56

W/F

75

D9

61

W/M

75

D1-9, patients with atherosclerosis; N1-6: patients without detectable atherosclerosis;
ND, no detectable atherosclerosis; LAD, lateral anterior descending.
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We selected a segment of the proximal lateral anterior descending (LAD) with
obvious intraluminal plaque on inspection. The presence or absence of atherosclerosis
was determined by a cardiovascular pathologist’s diagnosis made upon gross examination
of transverse coronary sections visually and microscopically. The atherosclerotic
coronary arteries had an intraluminal stenosis of >75%, all of which had similar
complexities (stage IV according to the American Heart Association classification), and
non-CAD tissues had no detectable atherosclerosis.
3.2.2 RNA Isolation and Oligonucleotide Arrays
Total RNA was isolated from the coronary arteries using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. RNA quality was confirmed
visually on a 1% denaturing agarose gel, and RNA concentration was measured using a
spectrophotometer. Double-stranded complementary DNA (ds-cDNA) was synthesized
from 15 µg of total RNA using the SuperScript Choice System (Invitrogen) with an
HPLC-purified oligo-dT primer containing a T7 RNA polymerase promoter (Genset, La
Jolla, CA) as instructed by the manufacturer. In vitro transcription was performed with 1
µg of ds-cDNA using the Enzo BioArray RNA transcript labeling kit (Enzo Diagnostics,
Farmingdale, NY). Fragmentation of biotinylated cRNA (20 µg), hybridization, washing,
and staining were performed following the instructions by Affymetrix.
3.2.3 Data Extraction and Statistical Analysis.
The Human Genome U95A Array (Affymetrix) was used. Each array contains
∼12,000 unique genes. One microarray was used for each human coronary artery after
the quality and integrity of the RNA/cRNA sample was validated with a test array. To
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make comparisons across microarrays, data sets on the arrays were normalized to a
targeted total fluorescence of 300 representing total cRNA hybridized on the array.
We used GeneSpring 4.2 (Silicogenetics) for data analysis. Nine atherosclerotic
coronary arteries (group D) were compared with six normal arteries (group N). All
samples were treated as one group of replicates. We used the distribution of all genes in
the 50th percentile to generate the median value for group comparisons, and all raw data
with a score less than zero were set to zero. The algorithm to generate a list of genes that
showed a statistically significant difference (P < 0.05) between the two groups was
described previously (40). Genes were further filtered by an absolute call: present (P) or
marginally present (M) in at least six of nine samples for the diseased group or four of six
samples for the normal group, for upregulated genes and downregulated genes,
respectively. The final list consisted of 56 genes.
3.2.4 Quantitative RT-PCR
Quantitative real-time polymerase chain reaction (quantitative RT-PCR) was used
to validate our microarray findings. Reverse transcription was performed with 5 µg of
total RNA from all 15 samples used for microarray analysis using the SuperScript Choice
System (Invitrogen). Quantitative RT-PCR was performed in ABI Prism 7700 Sequence
Detection System using SYBR Green (Applied Biosystems) following the manufacturer’s
instructions with the following standard PCR conditions (94°C 10 min, and 94°C 30 s,
58°C 1 min, 72°C 45 s for 35 cycles, then 10-min extension at 72°C). Relative expression
values were calculated as previously described (54). Primers were designed based on
sequences from the GenBank and to span exon-intron junctions to prevent amplification
of genomic DNA. The gene ß2-microglobulin was used as an internal control.
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3.2.5 Immunostaining
The cryosections (6 µm) of coronary arteries were fixed with paraformaldehyde
(4%) and permeabilized with Triton X-100 (0.2%). The primary antibodies used include
the antiserum for MMP-9 (clone 56–2A4 ICN Biomedica), ICAM-2 (Santa Cruz
Biotechnology), osteopontin (Calbiochem), PIM-2 (Santa Cruz Biotechnology), CD31
(Becton-Dickinson), and α-smooth muscle actin (Sigma) (1:250). The secondary
antibodies conjugated with either FITC or Cy3 were used for visualization (1:250). The
sections were counterstained with 4’,6-diamidino-2-phenylindole (DAPI; Vectashield
with OAD; Vector Laboratories, Burlingame, CA). The immunostained slides were
visualized with a Zeiss Axiophot fluorescence microscope, and the images were captured
with Photometrics SmartCature.
3.3 Results
3.3.1 Identification of 56 Genes That Are Differentially Expressed in CAD Coronary
Arteries
We profiled nine coronary arteries from CAD patients and six non-CAD arteries
using the Affymetrix Human Genome U95A Arrays. The mean age of the CAD group
(group D) is 58 ± 7.7 yr and did not have a statistical difference from that of the normal
group (group N) (62 ± 10 yr) (P > 0.05) (Table 1). Between the two groups (N vs. D),
there were not any statistically significant differences (P > 0.05) in percent of genes
expressed (58 ± 17% vs. 54 ± 15%), Q-score (2.28 ± .34 vs. 2.45 ± 48), or background
noise (43.68 ± 9.5 vs. 54.9 ± 24.6), respectively. The average mean (SD) difference of the
housekeeping genes was not statistically significant (N vs. D) (P > 0.05): ß-actin (17,074
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± 4,259 and 16,081 ± 4,674), GAPDH (8,957 ± 314 vs. 9,341 ± 1,417) and ß2microglobulin (8,541 ± 2,028 vs. 8,526 ± 2,817), respectively. These results indicate low
variability and high reproducibility of our microarray analysis.
Of the ∼12,000 genes analyzed by oligonucleotide arrays, we performed two
independent analyses using Wilcoxon Mann-Whitney parametric test and the Student’s ttest for genes that were differentially expressed (Fig. 1). Using a P < 0.05, the Wilcoxon
ANOVA test generated 420 potentially differentially expressed genes between the two
groups. At the same time, we used a Student’s t-test (P < 0.05), which considers both
absolute differences between the two groups, to generate a list of 372 genes. Combination
of both statistical tests generated a list of 401 genes. From this gene list, 177 genes, or
44%, were upregulated by 1.5-fold, whereas 76 genes, or 19%, were downregulated.
Sixty-one genes of the 177 upregulated genes met our criteria of a minimum expression
level of 400, the average raw score of ∼12,000 genes on each array, whereas 1 gene out
of 76, or 1.3%, downregulated genes met this criteria. The final gene list generated by
filtering these genes based on the call of present (P) or marginally present (M) consisted
of 56 genes associated with CAD.
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Fig. 1. Algorithm of statistical protocols used for our comprehensive cut-off points for
data mining. All genes were initially filtered by a Welch test and Welch ANOVA that
met the critical value of P < 0.05 for both tests. Genes were filtered with a mean average
difference of 400 units for the diseased group for upregulated genes and normal group for
downregulated genes. Genes were further filtered by an absolute call: present (P) or
marginally present (M) in at least six of nine samples for the diseased group or four of six
samples for the normal group for upregulated genes and downregulated genes,
respectively. The final list consisted of 56 genes.
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Table 2. Classification of differentially expressed genes in five groups based on their
molecular activity
GenBank ID
Inflammation
M12886*
M13755*
X14046*
M33552*
L09708*
U24578*
X00457*
M83664*
D32129*
U15085*
J00194*
AL022723*
M13560*
AF029750*
X57809*
M18645*
Y14737*
X72475*
U80114*
X92997*

Gene Description
T-cell receptor ß-chain
(TCRB)
Interferon-stimulated
protein, 17 kDa/15 kDa

Molecular Activity Fold
Relevant for CAD Change

Marker of T cells
presence (23)
Released from
lymphocytes and
monocytes (7)
CD37 antigen
Expressed on
leukocytes(36)
Lymphocyte-specific Modulates leukocytes
protein 1 (LSP1)
migration (15)
Complement
Recruitment of
component 2 (C2)
monocytes to intima
(10)
Complement C4b
Associated with
precursor (C4B)
immune complex
disease (46)
MHC, SB class II, SB- Membrane protein,
α
signal peptide (16)
MHC, class II, DP, ß-1
Cell surface
glycoprotein (34)
MHC, class I, A
MHC, class II, DM-ß
Regulates antigen
presentation (37)
MHC, class II, DR-α Cell surface protein
induced by INF-γ (41)
MHC, class I, F
Human Ia invariant γ- Antigen processing
chain
(20)
TAP binding protein
Ig superfamily;
(tapasin) (NGS-17)
interacts with MHC
class I (28)
Ig λ, light chain
Ig, C-region, V-region
λ-4
Ig heavy chain
Ig κ, light chain, VJC
region
Ig heavy chain,
variable region V4-31
Ig λ, light chain, VJC
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↑
↑
↑↑
↑
↑↑
↑
↑
↑↑
↑
↑
↑
↑↑
↑
↑
↑↑↑↑
↑↑↑↑
↑↑↑
↑↑↑↑
↑↑↑↑
↑↑↑↑

*

U88964

AF004230*
AF060228*

AB006782*
M92357*

region
HEM45

↑
Cellular proliferation
and differentiation
(32)
↑↑
MIR-7 (leukocyte Ig- Activation of MHC Ilike receptor) (MIR cl- recognizing killer cells
(48)
7)
↑
Retinoic acid receptor
Upregulates
responder (RARRES3)
expression of
scavenger receptor
CD36 (51)
Galectin-9
Chemoattractant for
↑
eosinophils (14)
↑↑↑↑
TNFα-induced proteinExpression in
2 (B94 protein)
endothelial cells (2),
angiogenesis

Cell
necrosis/apoptosis/proliferation
M87503*
Interferon stimulatory
transcription factor-3γ
(ISGF3-gamma)
*
Z93930
X-box binding protein
1 (TREB5) (XBP1)
*
B144 NK cell
AF000424
triggering receptor
(LST1)
STAT-91
M97935*
U53446*
AL049946*
AF106941*
M63193*
L06797*
S59049*
X78817*

Serves as the DNA
recognition subunit of
ISGF-3 (47)
Regulation of MHC
class II expression (39)
Inhibits lymphocytic
proliferation (6)

Regulates transcription
of proteins induced by
INF-α (35)
Inhibits epithelial cell
DOC-2 (mitogengrowth in ovarian
responsive
cancer (21)
phosphoprotein)
Hypothetical protein
Regulates smooth
(similar to perlecan) muscle cell quiescence
(19)
Arrestin-ß2
Turns off G-protein
coupled receptor
activation (18)
ECGF1
Promoter of
angiogenesis (13)
Chemokine (CXC
G protein-coupled
motif) receptor (fusin)
receptor
B-cell activator gene
Role in
(BL34, GOS8)
leukomogenesis (50)
Rho GTPase activating Regulation of GTP
protein-4 (CI)
binding proteins (44)
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↑
↑
↑
↑
↑
↑
↑
↑↑
↑↑
↑↑
↑↑

U77735*

PIM-2 oncogene

Present in
mitogenically
stimulated
hematopoietic cells (3)

↑↑↑

Cell migration/adhesion and
matrix degradation
U21128

Lumican

↑

M73255

VCAM-1

Role in cell migration,
proliferation, tissue
repair (27)
Modulates attachment
of macrophage (10)

M30257
X15606

VCAM-1 precursor
ICAM-2 (CD102)

J04765

Osteopontin

M22324*

Membrane alanine
aminopeptidase
N/CD13 (IGFIR)

J05070
X16832*

Matrix
metalloprotease-9
Cathepsin H

X82153*

Cathepsin K

Lipid
transfer/oxidation/metabolism
D38255*
U90546*
X79389*
U29615
M21186*

Steroidogenic acute
regulatory protein

↑↑↑
↑

Mediates adhesion of
lymphocytes (10)
Promotes migration of ↑↑
macrophages, cell
adhesion (24)
↑↑
Cell surface
glycoprotein, role in
motility and
angiogenesis (11)
Vascular remodeling ↑↑↑↑
(42)
↑
Macrophage
hydrolase, possible
role in MHC assembly
(45)
↑
Macrophage
collagenase, role in
matrix degradation
(53)

Transmembrane
transfer of cholesterol
(38)
Butyrophilin (BTF4)
Transmembrane
transfer of lipids (26)
Glutathione-SReducing agent (17)
transferase 1 (GST)
Chitotriosidase
Marker for the
presence of
macrophages (4)
Flavocytochrome 558 Membrane-bound
oxidase, generates
superoxide (30)
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↑↑↑

↑
↑
↓
↑↑
↑↑

Unspecified functions
AB00087*
AF055001*

Small inducible
cytokine, subfamily A19
KIAA0025

AI743134*

EST

AI932613*

EST

AI147237*

EST

Unspecified

↑↑↑↑

Homocysteineinducible protein
Glia derived nexin
precursor
Ig related protein
precursor
Ig heavy chain V-III
region

↑
↑
↑↑↑↑
↑↑↑↑

EST, expressed sequence tag; ECGF, endothelial cell growth factor; GTP, guanosine
triphosphate; ICAM, intercellular adhesion molecule; Ig, immunoglobulin; IL,
interleukin; ISGF, interferon stimulatory gene factor; MHC, major histocompatibility
complex; MIR, macrophage Ig-like receptor; STAT, signal transducer and activator of
transcription; TNF tumor necrosis factor; VCAM vascular cell adhesion molecule.
*

Novel gene associated with CAD. Fold changes, upregulated: 1.5–2 (↑), 2.1–2.5 (↑↑),
2.6–3 (↑↑↑), 3.1 + (↑↑↑↑). Fold changes, downregulated: 1.5–2 (↓). Numbers in
parentheses are reference citations
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3.3 2 Altered expression of inflammation genes in CAD tissues.
This group includes six genes encoding the major histocompatibility complexes
(MHCs), six genes encoding immunoglobulins, complement component 2 and 4b,
retinoic acid receptor responder, MIR-7, HEM45, CD37 antigen, T-cell receptor ß-chain,
lymphocyte-specific protein 1, human Ia invariant γ-chain, tapasin, 17 kDa/15 kDa
interferon-stimulated protein, galectin-9, and tumor necrosis factor-α-induced protein-2
(B94). In the diseased coronaries, all the genes encoding immunoglobulins showed the
highest fold changes in expression; consistent with the hypotheses that infection may play
a role in the pathogenesis of CAD or an immune response to athero-antigens is driving
this response (10).
3.2.3 Altered expression of cell necrosis/apoptosis/proliferation genes in CAD tissues.
This group include genes encoding interferon stimulatory factor-3γ, XBP1 (TREB5),
B144 NK cell triggering receptor (LST1), STAT-91, DOC-2 (mitogen-responsive
phosphoprotein), a hypothetical gene with homology to perlecan, arrestin-ß2, plateletderived endothelial cell growth factor (ECGF1), chemokine G-coupled receptor (fusin),
B-cell activator gene (BL34, GOS8), fusin, Rho GTPase activating protein-4, and PIM-2.
3.3.4 Altered expression of cell migration/adhesion and matrix degradation genes in
CAD tissues.
Genes in this group include the lumican, VCAM-1 and its precursor, ICAM-2,
osteopontin precursor, membrane alanine aminopeptidase (IGF1R), MMP-9, and
cathepsin H and K genes.
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3.3.4 Altered expression of lipid transfer/oxidation/metabolism genes in CAD tissues.
This group includes genes for steroidogenic acute regulatory protein, butyrophilin
(BTF4), glutathione-S-transferase (GST), flavocytochrome 588, and chitotriosidase.
3.3.5 Altered expression of genes with unknown functions in CAD tissues.
This group includes three expressed sequence tags (EST) and two genes predicted
to encode a small inducible cytokine and a homocysteine-inducible protein.
To summarize, our microarray analysis has defined 56 genes that are differentially
expressed in CAD tissues. These genes can be classified into five functional groups. It is
interesting that among the 56 genes associated with CAD, only one gene, GST, was
downregulated, whereas the rest of genes were upregulated.
3.3.6 Clustering of Differentially Expressed Genes
The 56 differentially expressed genes in CAD were grouped using a hierarchical
clustering method referred to as a gene tree. The resultant gene tree recapitulates the two
distinct study populations, i.e., those with CAD compared with nondiseased arteries. The
gene tree program clusters them in subgroups with similar genetic profiles (Fig. 2).
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Fig. 2. Hierarchical clustering of 15 coronary arteries and 56 genes. The gene tree of nine
diseased coronary arteries (D) and six normal coronary arteries (N) recapitulates the
distinction between the two groups based on their similarity in gene expression. The trust
shows fold changes with upregulation [up to 5x (in red)] and downregulation [starting at
0 (in blue)].
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3.3.7 Validation of Changes in Gene Expression by Quantitative RT-PCR
To validate our microarray data, quantitative RT-PCR was performed using
SYBR Green for 13 genes (Table 3). Consistent changes were observed between
quantitative RT-PCR and microarrays for all 13 genes examined. The only gene
downregulated on our microarray, GST, also showed decreased expression by
quantitative RT-PCR. The other 12 genes showed increased expression by microarray
analysis were also found to be upregulated by quantitative RT-PCR. These data provide
validation of our gene expression patterns identified by microarrays.
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Table 3. Confirmation of microarray analysis with quantitative real-time PCR
Gene Name

Accession No.

GeneChip

SYBR Green

Chititriosidase
Retinoic acid receptor responder
Galectin-9
PIM-2
STAT-91
ICAM-2
Cathepsin K
Cathepsin H
ß2-arrestin
EST-1
EST-2
Lumican
Matrix metalloprotease-9
GST
Osteopontin precursor

U29615
AF060228
AB006782
U77735
M97935
X15606
X16832
X82153
AF106941
AI743134
AI932613
U21128
J05070
X79389
J04765

2.1
1.7
1.6
2.7
1.6
1.5
1.5
1.6
1.8
1.7
4.0
1.5
4.7
-0.65
2.3

4.0
3.4
1.4
2.3
1.2
1.5
2.2
1.8
2.6
1.4
1.4
4.2
3.4
-0.07
2.9

Values represent fold changes in gene expression.
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3.3.7 Validation of Changes in Gene Expression by Immunostaining.
To further validate the data from the microarray analysis, immunostaining was
performed for four proteins encoded by the genes differentially expressed in CAD,
including osteopontin (OPN), MMP-9, ICAM-2, and PIM-2 oncogene. The four coronary
arteries from CAD patients are different from those used for the microarray analysis.
Representative immunostaining images are shown in Figs. 3 and 4. OPN (green signal)
was expressed diffusely in the media and fibrous tissue of the coronary artery and
colocalized with a smooth muscle cell-specific marker, the monoclonal anti-α smooth
muscle actin (red signal) (Fig. 3A). OPN showed stronger staining in the CAD coronary
arteries than normal tissues (Fig. 3A), consistent with our microarray results.
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Fig. 3. Protein expression of osteopontin (A) and ICAM-2 (B) in normal and CAD
coronary arteries. A: immunostaining images showing colocalization of osteopontin
(green) and smooth muscle α-actin (red) and increased expression of osteopontin in CAD
coronary arteries. B: immunostaining images showing colocalization of ICAM-2 (green)
and endothelial cell-specific marker CD31 (red) and increased expression of ICAM-2 in
CAD coronary arteries. L, lumen; M, medial layer; E, endothelial cell layer; F, fibrous
tissue; CAD, coronary artery disease.
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Fig. 4. Protein expression of matrix metalloproteinase-9 (MMP-9; A) and PIM-2 (B) in
normal and CAD coronary arteries. A: immunostaining images showing increased
expression of MMP-9 (red) in CAD coronary arteries. B: immunostaining images
showing increased expression of PIM-2 (green) in CAD coronary arteries. L, lumen; M,
medial layer. Note that coimmunostaining with CD31 and smooth muscle α-actin was not
performed because the available antibodies are monoclonal (MMP-9 and PIM-2
antibodies) (e.g., the same anti-mouse secondary antibody will not be able to distinguish
the primary antibodies for PIM-2 or CD31).
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Immunostaining signal for ICAM-2 (green) colocalized with the signal for CD31 (red),
an endothelial cell-specific marker (Fig. 3B). ICAM-2 expression is also increased in
CAD tissues. MMP-9 has been shown to be expressed in macrophages (42). As shown in
Fig. 4A, the immunostaining signal for MMP-9 (red) was very strong and diffusively
distributed throughout the media in coronary arteries with atherosclerosis, whereas very
little staining was detected in normal tissues. PIM-2 appeared to be expressed widely in
the media layer of coronary arteries (green) (Fig. 4B). PIM-2 expression was increased in
the CAD coronary arteries compared with arteries without the disease. Taken together,
the immunostaining data illustrate the distribution and expression patterns of osteopontin,
ICAM-2, MMP-9, and PIM-2 in the normal and diseased coronary arteries. Increased
expression of these four proteins was observed in the diseased tissues compared with the
normal ones. These data further validate results from our microarray array analysis and
correlate the increased expression of the mRNA of these genes with increased protein
expression.
3.4 Discussion
This is a large-scale study in which microarray analysis has been used to profile
gene expression patterns using intact, human atherosclerotic and nonatherosclerotic
human coronary arteries. We have identified 56 genes that are differentially expressed in
patients with CAD, and 49 genes were not previously linked to CAD. Interestingly, 55
genes are upregulated and one gene, GST, is downregulated in CAD tissues (Table 2).
Previous studies have implicated increased expression of chitotriosidase (4), lumican
(27), VCAM-1 (10), ICAM-1 (10), MMP-9 (42), and OPN (24) in atherosclerosis. These
results are confirmed by our microarray analysis (Table 3). This suggests that the
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microarray technology is a powerful tool for identification of gene expression patterns
associated with CAD.
In the clustering of the nine diseased and six nondiseased human coronary
arteries, the gene tree identifies two distinct gene expression patterns: the diseased
coronary arteries are clustered as a group, and the nondiseased arteries segregate as an
independent group (Fig. 2). Of interest to note is among the patients with CAD, samples
D8 and D9 clustered together. These two samples had the most significant occlusion
(90% in D8 and 100% in D9) of the left main artery adjacent to the proximal LAD
revealed by left heart catheterization.
The majority of genes associated with CAD identified in this study represent new
links to CAD processes. Our microarray analysis identified 49 new genes that were not
previously shown to be associated with CAD (Table 3). Some of these genes include the
following: retinoic acid responder binding (RAR) protein, butyrophilin, steroidogenic
acute regulatory protein (STAR), PIM-2, STAT-91, and cathepsins K and H. The RAR
gene is regulated by vitamin A signaling pathways and has been shown to upregulate the
expression of the scavenger receptor CD36 through RAR in the human monocytic cell
line THP-1 (52). Butyrophilin is a structural component of the human milk fat globule
and have receptor functions that mediate the transfer of lipid (26). Both cathepsins K and
H are lysosomal proteases that are involved in protein degradation. Cathepsin K is a
collagenase that cleaves both type I and type II collagens at their helical domains (53).
Cathepsin H has been shown to be upregulated 30-fold in aortic abdominal aneurysms
compared with normal aortas (45). STAR is another novel gene identified. It has been
shown that in humans and genetically manipulated mice, STAR is required and is the
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rate-limiting step in steroidogenesis for the transfer of cholesterol into the mitochondria
(38). Two more novel genes include PIM-2, which is a "proviral integration site of
murine" leukemia virus, is present in mitogenically stimulated hematopoietic cells (3),
and STAT-91, which is a signal transducer and activator of transcription in hematopoietic
cells (35). GST is the only gene whose expression is reduced in CAD tissues, and it is a
reducing enzyme (17).
Many lines of evidence support the notion that inflammation plays a critical role
in atherosclerotic lesion pathology. Histological analysis of unstable or ruptured
atherosclerotic plaques from patients with acute coronary syndromes identified
inflammatory cells including T cells, monocytes, and macrophages. Later studies showed
that atherosclerosis was associated with the presence of inflammatory proteins (CRP,
cytokines, chemokines) and increased expression of adhesion molecules (ICAM-1,
VCAM-1, E-selectin, P-selectin) as inflammatory responses from vascular cells (31, 33).
Our study emphasizes the importance of inflammation in CAD. The largest group of
CAD-associated genes identified in this study consists of genes involved in inflammation
(Table 2). It is, however, important to note that the association of many genes in this
group (e.g., genes encoding T-cell receptor ß-chain, 17 kDa/15 kDa interferon-stimulated
protein, ICAM-2, CD37 antigen, tapasin, MIR-7, retinoic acid receptor responder, B94,
etc.) is novel.
The immunostaining results support our microarray analysis showing not only the
upregulation of the mRNA expression, but also increased protein expression. Four
proteins demonstrated upregulation in atherosclerotic arteries include osteopontin, MMP9, ICAM-2, and PIM-2. One component of atherosclerosis is smooth muscle proliferation
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followed by connective tissue matrix deposition. Osteopontin, a protein secreted from
smooth muscle cells, showed an upregulation in the atherosclerotic arteries and reflects
the dynamic process of smooth muscle recruitment and proliferation. MMP-9 is secreted
from macrophages, and participates in the structural remodeling of the artery as occurs
with inflammation. Both proteins were found to be upregulated in the medial layer of the
artery which is a site of structural remodeling, lipid deposition, and recruitment of
inflammatory cells. PIM-2, an oncogene expressed by hematopoietic cells, also showed
upregulation in the diseased arteries, although its definitive function has not been
established. ICAM-2 is a protein expressed in endothelial cells as shown in Fig. 3B and
showed an increased expression in CAD; however, its precise function in endothelial
cells and in atherogenesis remains to be established.
We compared our gene list with another list of 75 genes connected to
atherogenesis and identified by a separate DNA microarray analysis and found that the
expression of the gene for immunoglobulin-λ (VJC) was upregulated in both studies.
Surprisingly, other genes in our list do not match any genes identified by Hiltunen et al.
(12). This discrepancy may be explained by different tissue samples used in the two
studies, coronary arteries in our study compared with common, internal and external iliac
artery, aorta, popliteal artery, posterior tibial artery, and tibiofibular trunk used in the
other study.
It is important to note that microarray technology does have its limitations as
previously described (5). Furthermore, our study is a genetic profile of the CAD coronary
artery tissues at a single time point (a more advanced atherosclerotic stage), and may
provide only limited information for the continuous process of atherogenesis. Another
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limitation of the present study is the small sample size due to difficulties in obtaining
human coronary artery tissues. In addition, the majority of tissues used were male tissues
as 8/9 CAD and 5/6 normal tissues are male-derived samples. Future studies with an
increased sample size, female samples in particular, will further validate our results.
In conclusion, this study represents a large-scale microarray analysis to study
gene expression patterns of atherosclerosis using human coronary arteries. We identified
56 genes that are potentially involved in the pathogenesis of CAD or can be used as
biomarkers for diagnosis of CAD. Our study also identified 49 genes that are not
previously linked to atherosclerotic human coronary arteries. Further analysis is required
to determine the exact role of each gene, if any, in development of CAD.
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CHAPTER 4
INTRODUCTION
GLOBAL GENE EXPRESSION STUDIES OF ATHEROSCLEROSIS-RESISTANT
INTERNAL MAMMARY ARTERIES AND ATHEROSCLEROSIS-SENSITIVE
CORONARY ARTERIES IDENTIFIES AN ANTI-ATHEROSCLEROTIC ROLE FOR
TES IN ATHEROSCLEROSIS
ABSTRACT
Objective - Internal mammary arteries (IMA) are resistant to the development of
atherosclerosis, whereas the coronary arteries are athero-prone. We hypothesize that
genes differentially expressed in IMA vs. coronary arteries are involved in resisting
atherosclerosis.
Methods and Results - Microarray analysis identified 29 genes differentially expressed in
IMA compared to coronary arteries and identified a novel gene, TES (encoding Testin),
not previously associated with atherosclerosis. Western blot analysis showed higher TES
expression in IMA than LAD. RT-PCR and Western blot analyses showed that TES was
consistently down-regulated at both mRNA and protein levels in patients with coronary
artery disease compared with patients without disease. This indicates that reduced TES
expression may be involved in the development of atherosclerosis. Consistent with this
hypothesis, knockdown of TES expression by siRNA promoted oxLDL-mediated
monocyte adhesion and transendothelial migration of monocytes, while overexpression of
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TES in endothelial cells (ECs) blunted these processes. Overexpression of TES reduced
cell migration of ECs, whereas knockdown of TES expression promoted cell migration.
Conclusion - The results indicate that the human IMA and LAD are distinctly different in
gene expression. This study identifies TES as a novel atherosclerotic-resistant gene,
which has anti-atherosclerotic properties.
Submitted to Human Molecular Genetics, February 2011.

4.1 Introduction
Atherosclerosis is the leading cause of death and disability for both men and
women in the world (1). A common treatment for coronary artery disease (CAD) is
coronary artery bypass grafting (CABG) surgery. While several arteries and veins can be
used as blood conduits in this procedure, internal mammary artery (IMA) grafts have
demonstrated significantly better long-term results with lower complications irrespective
of age, gender, race, or left ventricular function (2, 3). For example, the patency of IMA
grafts seven to ten years after CABG is 85 to 95 percent when compared to saphenous
vein grafts, which readily re-occlude with atherosclerosis, hypertrophies, or become
fibrotic (4). Furthermore, the IMA patency 20 years after surgery is even >90% when the
graft serves the LAD territory (4). Interestingly, the only disease-prone site of an IMA
graft is at the anastomotic site grafted to the coronary artery suggesting surgical trauma as
the inciting factor (5). Recommendations are that its use for CABG is preferred in all
situations (6, 7).
The proximal LAD is the coronary artery to which the IMA is most frequently
grafted with resultant improved long-term survival (7). A high-grade proximal LAD
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stenosis is a major risk factor for sudden death. An acute coronary occlusion in the LAD
is more likely to cause a fatal myocardial infarction (MI) compared to all the other
coronary arteries with the exception of the left main trunk (4). The IMA are comparable
in size to the proximal LAD, and both arteries are arteries subject to the same proatherogenic environment; yet the IMA is atherosclerotic-resistant and the proximal LAD
is athero-prone (7). The contrasting properties of these two arteries is an interesting
subject to identify the molecular mechanisms of this differential propensity to develop
and not to develop disease.
We hypothesize that gene expression differences are the key to distinguish the
IMA from the proximal LAD with respect to their sensitivities to the development of
atherosclerosis. To test this hypothesis, we used oligonucleotide microarrays to identify
the genes that are differentially expressed in the IMA compared with the LAD. We
found 29 genes whose expression levels were statistically different. The functions of
these genes provide insights as to why the IMA is resistant to the progression of
atherosclerosis and may aid in the development of therapeutic options to prevent such
life-threatening disease in the coronary artery. One of these 29 genes, namely the TES
gene, was selected for follow-up functional studies to define its role(s) in the
pathogenesis of CAD.
The human TES gene (protein product is Testin) is homologous to the mouse
testosterone-responsive gene, TESTIN that encodes a Sertoli cell secretory protein. The
human TES gene is located on chromosome 7q31.2 and encodes a 421 amino acid protein
that contains a PET domain at the N-terminus (amino acids 92-195) and three LIM
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domains at the C-terminus (LIM1 amino acid, 236-296, LIM2 301-357,LIM3 361-414).
The LIM domains are responsible for interactions with zyxin, paxillin, Mena-VASP, αcatenin, talin, Arp7a, actin, alpha-actinin, and Gripp (8). The interactions of TES with
these proteins identify its role as a cytoskeleton associated factor and a scaffolding
protein that may be involved in cell adhesion, cell spreading, cell migration, and the
reorganization of the actin cytoskeleton. The PET domain is involved in protein-protein
interactions between Testin and actin stress fibers and may mediate the organization of
the cytoskeleton. In fact, the knockdown of TES expression by siRNA leads to a loss of
actin stress fibers, supporting its role in the regulation of the cytoskeleton (9). Testin
localizes in the cytoplasm and appears to be a component of focal adhesions and cell-tocell junctions.
The functional role of TES in CAD is previously unknown. In this study, we
identified TES as a novel gene which is expressed in coronary arteries and may confer a
resistance to atherosclerosis. We found that the expression of TES is significantly higher
in the IMA than the LAD, and its expression is lower in the LAD tissues from CAD
patients than from non-diseased coronary arteries.

Functional studies for cellular

properties relevant to atherosclerosis, including monocyte adhesion to ECs, oxLDLinduced transendothelial migration of monocytes, and EC and VSMC cell migration,
were used to define the cellular mechanisms by which TES may confer a resistance to
atherosclerosis.
4.2 Material and Methods
4.2.1 Tissue Samples of Human Arteries
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Arteries were obtained from explanted hearts through the Cleveland Clinic Heart
Transplant Program, unmatched or rejected healthy donor hearts from LifeBanc of
Northeast Ohio and the Cuyahoga County Coroner’s office. Each LAD was carefully and
thoroughly examined for the presence or absence of atherosclerosis by microscopic
examinations of consecutively dissected serial segments of the entire artery by
cardiovascular pathologists.
intraluminal plaque.

We selected a segment of the proximal LAD without

Informed consent was obtained from the participants (or their

families at post-mortem exam) according to the standards established by the Cleveland
Clinic Foundation Institutional Review Board on Human Subjects and the Cuyahoga
County Coroner. Arteries were cleaned of adjacent adipose and myocardial tissue in
explanted hearts or from cadavers (10). The adventitial layer remained intact.

The

specimens were snap-frozen in liquid nitrogen and stored at -80°C as previously
described until used (11).
The initial cohort of patients for expression profiling with microarrays all were
not affected with CAD, and came from both explanted hearts (the coronary artery) and
autopsy (the internal mammary artery) (Online Table 1). For follow-up RT-PCR and
Western blot analyses, we compared the arterial gene expression between these two
arteries harvested from the same patient but from a larger group (n=30).
4.2.2 RNA Isolation and Oligonucleotide Arrays
Total RNA was isolated from the arteries using TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions.

Microarray analysis was performed as previously

described by us as well (12, 13).
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4.2.3 Extraction of Microarray Data and Statistical Analysis
The Human Genome U95A Array (Affymetrix) was used. Each array contains ~12,000
unique genes. GeneSpring (Agilent technologies) was used for data mining as previously
described (12). We generated the statistical algorithm as followed on the web site
(www.agilent.com).

4.2.4 Real time RT-PCR Analysis
Results from the microarray analysis were validated for selected genes by real time RTPCR with SYBR Green (VWR). Specific primer pairs were designed for each selected
gene (Integrated Biotechnologies, Inc.) (Online Table 2). Relative expression values
were calculated as previously described (12, 13).
microglobulin was used as an internal control.
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The expression level of β2-

Online Table 1.

Characteristics of study subjects from which coronary/IMA tissue

samples were utilized for microarray and/or expression analyses.
Initial Microarray
Cohort

Age

Gender/
Race

Clinical description

Microarray 1 – coronary

62

WM

Dilated cardiomyopathy

Microarray 2 - coronary

59

WM

Dilated cardiomyopathy

Microarray 3 -coronary

55

WF

Motor vehicle accident (MVA)

Microarray 4 - coronary

49

WM

Cerebrovascular accident (CVA)

Microarray 5 - coronary

40

WM

Restrictive cardiomyopathy

Microarray 6 - coronary

46

WM

MVA

Microarray 1 - IMA

84

WM

asthma

Microarray 2 - IMA

55

WM

Alcoholism

Microarray 3 - IMA

47

WF

MVA

Microarray 4 - IMA

57

WM

Arrhythmia

Microarray 5 -IMA

55

WM

Arrythmia

Replication studies

Age

Gender/
Race

Postmorten examinations

1

48

WM

MVA

2

46

WM

Epilepsy, alcoholic cardiomyopathy

3

53

WM

Asthma

4

41

WM

CNS hemorrhage

Case No.

Case No.

92

5

54

WM

MVA

6

46

WF

Domestic violence

7

50

WM

Suicide via carbon monoxide poisoning

8

53

BM

Head trauma

9

22

WM

Subdural hematoma

10

61

WM

Laryngeal cancer

11

54

WM

Epilepsy

12

38

WM

Heroin overdose

13

86

WM

Suicide

14

53

WF

Trauma/fall

15

81

WM

Trauma

16

50

BM

Arrythmia

17

46

WM

Gun shot wound to chest

18

56

WF

Asthma, hypothyroid, depression

19

43

WM

Alcohol abuse

20

71

WF

Suicide

21

48

WF

Dilated cardiomyopathy

22

55

WM

Depression

23

55

WM

Recurrent arrythmias

24

50

WM

Arrythmia

25

62

WM

Cirrhosis

26

62

WF

Colon cancer

27

52

WM

Trauma, hypertension

28

70

WM

CVA

93

29

60

WM

Trauma

30

52

WM

Suicide

94

Online Table 2. Primer pairs used for RT-PCR analysis.
Gene Name
HSP70

Primer Pairs
F 5' – AGGAGATCTCGTCCATGGTG-3'
R 5'-CCCAGGCAAAGATCAGGAC-3'

ATF3

F 5'-GTCGGAGAAGCTGGAAAGTG
R 5'- GGCTTCAGGGTTTTGGGTAT-3'

GLUT-3

F 5'-TGCTTTCTGCTCCCAGTTTT
R 5'-GCACAGCTTGCAGTGTTGAT

NR4A1

F 5'-TCCAGCCTTCTTTTCCTTCA
R 5'-CAAGGTGTGGAGAAGTGGGT

TINUR

F 5'-AGTCTGAGGAGATGATGCCG
R 5'- GAGACTGGCGTTTTCCTCTG

CD163 Antigen

F 5'-GATTTGCTCAAAGGGAGCAG
R 5'-TAACTGTCCCAGCCGTCAT

CDH7

F 5'-GCTTTCCATGGGATTCAAGA
R 5'-CGTTCCCGCATTATGGTACT

CALB2

F 5'-GCTCCAGGAATACACCCAAA
R 5'-CAGCTCATGCTCGTCAATGT

AQP7

F 5'-CTACACGGCCATTCTCCACT
R 5'-ACCACGAGGATGCCTATCAC

F13A1

F 5'-GGAATACGTCATTGGTCGCT
R 5'-TTCT GGGT6TTCGACTGGTTC

COL16A1

F 5'-GCCTGTCTCGTTTGACCTC
R 5'-TTTCTGCCTTCTGGCTGATT
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ASAH1

F 5'-GCCTGCAAAGATGTGTCTGA
R 5'-CCTATACAAGGGTCAGGGCA

C1Q

F 5'-TCCAGATATGGAGGCCTGAC
R 5'-TTCACTCAGCAGCATTCACC

CYB5A

F 5'-AATGGCTTCTTTTCTCCGT
R 5'-GGTGATCCCTGCCATCTCT

RAS-A PLA2

F 5'-GCAGCCGTAGAAGCCATAAC
R 5'-GAGCTAGGCCAGTCCATCTG

C7

F 5'-TGGTTTTCCTCAATGGAAC
R 5'-AGATGAGATCACCCCACTGC

DUSP6

F 5'-TTTGCAGCATGCTTGACTTT
R 5'-GAGCCCATGATTTGGTGTCT

SLA

F 5'-AAATGCTCAGCTCCAGGAAA
R 5'-ATACTGCAAGCATGTTCCCC

GLUL

F 5'-GCTCTGAGAGATGGGACAGG
R 5'-TGCTTTGGGCAGTTACACAG

FACL1

F 5'-TGCAAAGTTCATTTCCTGGG
R 5'-TTAGTGCAAGCC CTGTTGTG

TESTIN-2

F 5'-ATTCTAGAGAGGAGGGGACCCATAG
R 5'-ATAAGCTGATAGCTATGGCTCGATA

RGS5

F 5'-ATTGATCCTTCCCTTGGACC
R 5'-TGGAAACATTTGACCCACAG

Clone DKFZ
586O031

F 5'-TCCTTTGACCCCTTCATCAG
R 5'GAATAAGCCAGGGGGAA
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ID-H2

F 5'-AAATGCCCTTTCTGCAGTTG
R 5'-TCCTTCTGGTATCACGTCTCC

FKHL7

F 5'-TTCAGCGTGGACAACATCAT
R 5'-CTTGCAGGTTGCAGTGGTAG

RAMP1

F 5'-TCCTCTACCCCTTCATCGTG
R 5'-GGGGGCTTCCAGGTTAATAC

LMNA

F 5'-AGTCTGCTGAGAAGGAACAGCAA
R 5'-AGCTTGATGTCCAGAAGCTC

PECAM1

F 5'-GCTTCCCTTAGCACTTTCTCCTT
R 5'-CTCTGCCTCCCAGGTTCAAATGAT

HBGR2

F 5'-TGCTTTCTGCTCCCAGTTTT
R 5'-GCACAGCTTGCAGTGTGGAT

β2microglobulin

5-‘ CGCTACTCTCTCTTTCTGGCC
R-5’CGGCAGGCATACTCATCTTT
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4.2.5 Cell Culture and Transfection
Endothelial cells (ECs) were harvested from the proximal LAD coronary artery
and IMA were purchased from Cell Applications, Inc. The cells were isolated from nondiseased human arteries and cryo-preserved at the second passage. Cells were grown
with standard media supplied ready-for-use from Cell Applications, Inc.
ECs were transfected with the TES expression plasmid using Amaxa (Program U001) and the HUVEC Nucleofactor Kit (Cat No. VPB-1002). The human TES gene was
PCR amplified with primers containing in-frame restrictions sites EcoR 1 (GCCAAT
TCC TAA GAC ATC CTC TTC TT) and BamH 1 (AAG GAT CCA GAT GGA GCT
GGA AAA). The PCR fragment was digested with EcoR 1 and BAMH 1 and sub-cloned
into pcDNA3.1A (5.5 kb-6X histidine tagged vector) (Invitrogen). The identity of the
construct was verified by direct DNA sequence analysis of the entire insert using the
BigDye Terminator Cyclic Sequencing Ready Reaction Kit (Applied Biosystems) in a
3100 Genetic Analyzer (Applied Biosystems). Cells were used for assays 24 and 48
hours after transfection.
Small interfering (si) RNA for TES was purchased from Integrated DNA
technologies: Sense--rGrCrA rGrCrA rCrCrU rGrCrC rArUrG rArArC rUrCrC rUrGG T
and Antisense--rArCrC rArGrG rArGrU rUrCrA rUrGrG rCrArG rGrUrG rCrUrG
rCrArG. Cells were transfected with the siRNA using Polyjet (SignaGen Laboratories).
The optimal dose to interfere with TES mRNA expression was 1 µM.
4.2.6 Preparation of Protein Extracts by the Delipidation Method
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The IMA tissues or proximal LAD coronary arteries (0.2 g/sample) were lysed in
a homogenization buffer for 15 minutes at 35οC using the delipidation method as
previously described (13). Protein extracts from the IMA or LAD ECs vs. VSMCs
grown in vitro were prepared with M-PER Mammalian Protein Extraction Reagent
(Pierce) and quantified with BCA Protein Assay Kit (Pierce).
4.2.7 Western Blot Analysis
Western blotting was performed as previously described (12, 13).

The primary

antibodies used included the antiserum for CD31 (PharMinger), and GAPDH (Santa
Cruz). The antibody against Testin was kindly provided by Yingli Zhong. Quantification
of bands was made with Melanie 2D gel software analysis (SIB).
4.2.8 Immunostaining
Cryo-sections (6-µm) of the proximal LAD were fixed with paraformaldehyde (4%) and
permeablized with Triton X-100 (0.2%) as previously described (12) and incubated with
anti-TES. Anti-Rabbit IgG conjugated with FITC (Sigma) was used to visualize TES.
The sections were counterstained with DAPI for staining nuclei (Vectashield with OAD,
Vector Labs).

The immunostaining signals were visualized with a Zeiss Axiophot

fluorescence microscope and the images were captured with Imageplus 6.0.
4.2.9 Monocyte Adhesion Assay
Fully confluent ECs were grown in CoStar96 well plates after being seeded at a density
of 5,000 cells/well and stimulated with oxidized-LDL (oxLDL) (Sigma) (0.25 mg/mL)
for six hours. Human HL-60 pro-myelocytic leukemia cells were cultured in Iscove’s
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modified Dulbecco’s media, fluorescently labeled with Calcein AM (Invitrogen) for 60
minutes at 37ºC and seeded into each well coated with ECs at a density of 3x105 per well.
After one hour, the media were aspirated and wells were washed gently with PBS three
times. Fluorescent intensity was measured in each of the 96-wells with a standard
fluorometer with the CytoFluoroII program (Applied Biosystems) (exit: 485/20, emission
530/30, gain of 65) to determine the fluorescent units in each well. The rational for using
HL-60 cells is that they represent immature monocytes in vivo which attach to and
transmigrate through ECs and then differentiate into different mature lineages.
4.2.10 Cell Migration Assays
ECs and VSMCs were transfected as mentioned above and plated at a density of 0.5x106
cells per cm2 in 35 mm six well plates. The media were changed 24 hours later. Then,
the confluent monolayers were wounded with a single edge razor and cells on the right
side of the wound were removed. After 48 hours, the cells were stained with Coomassie
Brilliant Blue for 10 minutes followed by Glacial acetic acid/methanol destaining buffer,
and photographed with Image-Pro Plus and analyzer 7.0 (Mediacybernetics).

The

number of cells which migrated passed the wound were counted under a 4x power field.
4.2.11 Transmigration of Monocytes Assay
HL-60 cells (3x105) were pippeted into 0.4 µm pore chambers (Corning) within a Boyden
chamber, which had TES transfected ECs plated 24 hours prior and then exposed to 0.25
µg of ox-LDL. FBS was used as a chemo-attractant and diluted in serum-containing
DMEM media. The HL-60 cells were collected and counted from the bottom chamber 48
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hours after their administration with a Bright-Line Hemacytometer (Hausser Scientific)
using an Olympus CKX 41 microscope. Each experiment was repeated in triplicate.
4.2.12 Statistical Analysis. The difference between the two groups of variables was
compared by the paired Student t-test. A P value of < 0.05 was considered as significant.
4.3 Results
4.3.1 Microarray Analysis Identified 13 Genes Showing Increased Expression Levels
and 16 Genes Showing Reduced Expression Levels in IMA Compared with LAD
To identify the genes differentially expressed between IMA and LAD, we carried
out a microarray analysis with Human Genome U95A arrays (Affymetrix). Each array
contains ~12,000 unique genes. A cohort of six proximal LAD coronary arteries and five
left IMA, all from non-CAD study subjects, were studied. Before any analyses were
performed, all data were screened for any genes with a negative average difference value
(and negative values set to zero). The average difference after log-transformation
between LAD and IMA was compared by using Student's t-test and a Welch ANOVA.
This initially generated a list of 2,219 genes. Then, we filtered the gene list by accepting
genes that were flagged as “present” on all 11 chips and eliminated them if flagged as
“marginally present or absent”. This generated a list of 53 genes. Finally, we filtered the
list with a set difference of 3-fold. This resulted in our final list of 29 genes (Online
Table 3).
Twelve genes including ATF3, TINUR, LMNA, HSP70, TES, and RGS5 showed
increased expression in IMA compared to LAD. By contrast, expression of 17 genes
including CALB2, RASF-A-PLA2 and PECAM1 were lower in IMA than in LAD (Online
Table 3).
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To confirm these microarray results, we randomly selected 7 of the 29 genes,
including HSP70, HBGR2, TINUR, CD163 Antigen, CDH7, AQP7, and F13A1, for real
time RT-PCR analysis with the RNA samples used for the original microarray analysis.
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Online Table 3. List of differentially expressed genes in the IMA vs. LAD.

Gene Name

ATF3

HBGR2

Gene Product

GenBank
Number

Fold
Change
on Array

Function

Human
activating
transcription
factor 3

L19871

↑8.3

Meets the criteria
of an antiatherosclerotic
gene (1,2)

Human
glutamate
receptor 2

L20814

↑7.2

Studied in CNS
(3)

TINUR

NGFI-B/nur77
beta-type
transcription
factor homolog

S77154

↑6.5

Protects from
apoptosis and
reduces human
macrophage lipid
loading and
inflammatory
responses (4)

LMNA

LAMIN A/C

M13452

↑6.5

Defects
associated with
premature
atherosclerosis
(5)

Heat Shock
Protein 70

M11717

↑6.1

AB008109

↑5.9

HSP70

RGS5
regulator of

Cytoprotection
(6)

Gown-regulated
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G-protein
signaling 5

GLUT3

cDNA
DKFZp586B2022(TES)

in atherosclerotic
caps, negative
modulator of
AT1 receptor (
7)

↑4.4

Facilitated
glucose
transporter (8)

AL050162

↑4.3

Maintains
structural
integrity (9)

Human glucose
transporter-like
protein-III

strong similarity
to mouse
TESTIN 2

M20681

NR4A1

Human TR3
orphan receptor

L13740

↑3.7

Prevents SMC
proliferation
(10,11)

COL16A1

Homo sapiens
alpha-1 type
XVI collagen

M92642

↑3.2

Inducible in
CD14+
monocytes (12)

FKHL7

Homo sapiens
forkhead/winged
helix-like
transcription
factor 7

AF078096

↑3.1

Development of
the anterior
chamber of the
eye (13)

Id-2H

Inhibitor of

D13891

↑3.1

Noninvasive
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DNA binding 2

phenotype in
endothelial cells
breast cancer
cells; negative
regulator of
adipogenesis
(14)

RAMP1

Receptor
activity
modifying
protein

AJ001014

↑3.0

Expressed in
coronary artery
and myocardium,
promotes
vasodilation (15)

CALB2

Calretinin

X56667

↓6.3

Calcium binding
protein

CD163 antigen

M130

Z22971

↓5.5

Enhances heme
oxygenase-1
activity
cytoprotective
responses (16)

CDH7

Cadherin-7

AF047826

↓5.4

Preserves
membrane
integrity, induces
smooth muscle
cell migration
and apoptosis
(17)

Hypothetical
protein

AL050141

↓4.9

Hypothetical
protein

cDNA DKFZp586O031
(from clone
DKFZp586O031)
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DUSP6

Dual specificity
phosphatase 6

AB013382

↓4.7

Phosphotyrosinekinase enzyme

C7

Complement
protein C7
precursor

J03507

↓4.5

Up-regulated in
plaque (18)

CYB5A

Cytochrome b5

L39945

↓4.3

Oxidative
Pathways

FACL1

Human longchain acylcoenzyme A
synthetase

L09229

↓4.3

Metabolism of
carboxylic acids

SLA

Src-like adapter
protein

D89077

↓3.8

It is expressed in
T-lymphocyte
(19)

RASF-A PLA2

Phospholipase
A2, group IIA

M22430

↓3.7

Amplifying the
inflammatory
component of
many disease
(20)
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AQP7

Aquaporin

AB006190

↓3.6

Involved in
water, glycerol
and urea
transport (21)

GLUL

Glutamine
synthase

X59834

↓3.5

Detoxification
peroxides (22)

F13A1

Factor XIII
subunit a

M14539

↓3.3

Resistance to
fibrinolysis (23)

ASAH1

Acid ceramidase

U70063

↓3.2

Protects from
TNFα induced
cell death (24)

C1Q

C1q B-chain of
complement
system

X03084

↓3.1

Shown to reduce
atherosclerosis
(25)
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Real time RT-PCR analysis showing the median fold changes are in general
agreement with that from the microarray analysis (Online Table 4).
4.3.2 Assessment of Expression of a Selected Set of 11 Genes in IMA and LAD Arterial
Samples from an Independent Cohort of 30 Human Subjects
Among the 29 genes identified by the microarray analysis (Online Table 3), we
selected 11 genes for further validation studies (Table 1). This set of genes was selected
based on their physiological relevance to atherosclerosis because of their expression or
function in atherosclerotic relevant cells (ECs, VSMCs and macrophages). Real time
RT-PCR analysis was carried out for each gene using matched IMA and LAD samples
simultaneously harvested from 30 independent subjects. The analysis confirmed that the
genes RGS5, LMNA, TES, and NR4A1 showed (median values are documented) two-fold
or more expression in IMA than in LAD (Table 1). Genes PECAM1, F13A1, and RASFA-PLA2 showed two-fold or less expression in IMA compared to LAD (Table 1).
4.3.3 Expression of TES Is Increased in IMA in Comparison to LAD
Our major focus of this study was to identify novel genes associated with a
resistance to atherosclerosis. The genes with increased expression in the IMA compared
to the LAD documented in our replication studies, namely four genes (RGS5, LAMNA,
TES, and NR4A1) would be strong candidates that biologically might confer resistance to
atherosclerosis. TES stood out to be a novel gene that was not previously related to
atherosclerosis, whereas the other three genes have been studied for their properties
related to atherosclerosis and vascular biology. Thus, TES was selected for further
functional characterization for its relevance to atherosclerosis. To confirm the real time
RT-PCR results showing increased TES expression in
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Table 4.
analysis.

Validation of the results from microarray analysis with real time RT-PCR

Gene Name

GenBank
Number

Fold-Change on
Array

Fold-Change with
RT-PCR

GLUL

L20814

↑7.2

↑12.1

TINUR

S77154

↑6.5

↑3.7

HSP70

M11717

↑6.1

↑7.8

CD 163 Antigen

Z22971

↓5.5

↓5.6

CDH7

AF047826

↓5.4

↓7.4

AQP7

AB006190

↓3.6

↓9.8

F13A1

M14539

↓3.3

↓5.4
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the IMA compared to the LAD, Western blot analysis was performed with proteins
extracted from the IMA and proximal LAD tissues. The analysis showed significant upregulated expression of Testin (P=0.014) in the IMA compared to the LAD (Figure 1a).
Similarly, RGS-5, HSP70, ATF3, TINUR had increased expression in IMA via Western
blot, while PECAM-1, RASF-A-PLA2, F13A1, and CD163 antigen had decreased
expression in the IMA (correlating with mRNA expression, data not shown).
To localize the site of expression of Testin in these arteries, we carried out
immunostaining studies of IMA and LAD tissues sections with an anti-Testin antibody.
The immunostaining signal for TES co-localized with the EC marker CD31, indicating
strong Testin expression in arterial endothelial cells (Figure 1b). The immunostain signal
for Testin was stronger in the IMA than in LAD (Figure 1b).

Moreover, some

immunostain signal for Testin was also detected in the media of the IMA, most likely
localizing in VSMCs (Figure 1b).

4.3.4 TES/Testin Expression in LAD Is Decreased in CAD Patients Compared to NonCAD Subjects
Because the expression level of TES is higher in the atherosclerotic resistant IMA
than in the atherosclerotic prone LAD, we hypothesized that TES is involved in
contributing a resistance to atherosclerosis. To test this hypothesis, we assessed the
expression levels of the TES gene in coronary arteries from 10 CAD patients in
comparison to 10 non-diseased coronary arteries by real time PCR analysis. Expression
of TES was markedly reduced by six-fold in CAD patients compared to non-CAD
subjects (P=0.000049) (Figure 2a).
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Fig. 1. Western blot analysis of IMA vs LAD for TES expression and cellular
localization of TES in these arteries. Western blot analysis was performed with proteins
extracted from the IMA and LAD (n=10), a representative comparison is shown (a). The
expression level of Testin is higher in the atherosclerotic resistant IMA than in the
atherosclerotic prone LAD (n=10/group) (P=0.014). The immunostaining signal for TES
co-localized with ECs stained with CD31, a marker for ECs, in both IMA and LAD (b).
In the IMA, the Testin signal was detected in ECs. Some TES signal was also detected in
the artery, mostly likely VSMCs (c).
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Fig 2. Decreased TES/Testin expression in coronary arteries from CAD patients. TES
mRNA expression from 10 non-diseased coronaries compared to 10 diseased coronary
arteries by real-time RT-PCR. The mRNA expression of TES in patients with CAD is
significantly lower than in non-CAD individuals (a). Testin expression by Western blot
analysis in an additional cohort of 10 CAD patients and 10 non-CAD individuals shows
Testin expression is lower in patients with CAD. GAPDH was used as loading control
(b).
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Western blot analysis of protein extracts from LAD with a different cohort of 10
CAD patients and 10 non-CAD controls further confirmed that Testin expression was
decreased in diseased coronaries in comparison with disease-free arteries (Figure 2b)
(P=0.00023).

The reduced TES expression is expected to correlate with decreased

resistance to atherosclerosis and the development of CAD.
4.3.5 Testin Affects oxLDL-Mediated Monocyte Adhesion to LAD ECs
To identify a cellular mechanism for the association between TES/Testin
expression and its sensitivity to atherosclerosis, we characterized the effects of overexpression of TES in LAD ECs and VMSCs by transient transfection with an expression
construct of a 6xHis-tagged TES (empty vector as the negative control) or knock-down of
TES expression by RNA interference (scrambler as control). Western blot analysis
showed successful over-expression of Testin in LAD ECs and VSMCs with transient
transfection of the TES expression plasmid compared to the vector, and that the TES
siRNA effectively reduced the expression levels of Testin in LAD ECs and VSMCs
compared to the scrambler siRNA (Figure 3a and Figure 4a).
Because adhesion of blood monocytes to the ECs of coronary arteries is a
significant step in initiating atherosclerosis, we first assessed the effect of overexpression of TES and knock-down of TES expression in LAD ECs on monocyte
adhesion. As shown in Figure 3b, treatment of ECs with oxLDL dramatically increased
the adhesion of monocytes to the ECs, yet over-expression of TES decreased the
adhesion of monocytes to ECs (compare TES to Vector; P=0.022). At the same time,
knockdown of TES expression increased adhesion of monocytes to ECs, (Figure 3b;
compare siRNA to scrambler; P=0.000000021).
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4.3.6 Testin Is Involved in Cell Migration of LAD ECs and VSMCs
Because cell migration also plays an important role in the development of
atherosclerosis, the effects of over-expression of Testin and knock-down of Testin
expression on EC and VSMC migration were examined using a scratch assay. Overexpression of Testin significantly inhibited the migration of ECs (Figure 3c, compare
TES to Vector; P=0.000000079), and similar results were obtained for VSMCs (Figure
4b compare TES to Vector; P=0.00048). Knockdown of Testin expression increased
migration of both ECs and VSMCs (Figure 3c and Figure 4b, compare siRNA to
scrambler). These results suggest that Testin plays an important role in cell migration of
both ECs and VSMCs.
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Fig. 3. Functional characterization of Testin in ECs. Western blot analysis shows that
Testin was successfully overexpressed in LAD-derived ECs by transient transfection
(empty vector as control) and that Testin expression was successfully knocked down by
TES siRNA (scrambler as control). GAPDH served as loading control (a). Studies on
monocyte adhesion to ECs. The treatment of ECs with oxLDL dramatically increased
their adhesion to monocytes. Over-expression of Testin (compare TES to Vector) in ECs
appeared to decrease adhesion of ECs to monocytes, knockdown of Testin expression in
ECs increased adhesion of ECs to monocytes .(compare siRNA to scrambler) (b). EC
Migration assays. Over-expression of Testin in ECs significantly inhibited the migration
of ECs (compare TES to vector, while knockdown of Testin increased EC migration
(compare siRNA to scrambler) (c). These results suggest that Testin plays an important
role in EC cell migration.
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Fig. 4. Functional characterization of Testin on VSMC migration. Western blot analysis
shows that Testin was successfully overexpressed in LAD-derived VSMCs by transient
transfection (empty vector as control) and that Testin expression was successfully
knocked down in VSMCs by TES siRNA (scrambler as control). GAPDH served as
loading control (a). VSMC migration assays. Over-expression of Testin significantly
inhibited the migration of VSMCs (compare TES to vector, while knockdown of Testin
increased VSMCs migration (compare siRNA to scrambler) (b). These results suggest
that Testin plays an important role in VSMC cell migration.
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4.3.7 Testin Is Involved in Transmigration of Monocytes across oxLDL-treated LAD
ECs
While Testin did play a significant role in affecting the adhesion of monocytes to
ECs, we also hypothesized that Testin might also be involved in the transendothelial
migration of monocytes, which is a critical process in development of CAD.
Consequently, Testin was over-expressed in ECs derived from the LAD coronary arteries
and the cells were exposed to oxLDL (0.25 mcg/mL for 24 hours). The effect of Testin
overexpression in ECs on the transmigration of HL-60 monocytes was measured after 24
hours by plating monocytes onto confluent ECs adherent to the bottom of the Boyden
Chamber (Figure 5).

Overexpression of Testin in ECs significantly reduced

transmigration of monocytes across the EC layer (Figure 5, compare TES to vector,
P=0.00000000051).

Knockdown of Testin expression by TES siRNA increased

transmigration of monocytes across the EC layer (Figure 5, compare siRNA to scrambler,
P=0.028). The results indicate that Testin plays a significant role in the migration of
monocytes across the EC layer, a cellular process critical to atherosclerosis.
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Fig. 5. Effect of overexpression or knockdown of Testin expression in ECs on
transendothelial monocyte migration. Testin was over-expressed in LAD-derived ECs,
which were exposed to oxLDL. The overexpression of Testin in ECs significantly
reduced transmigration of monocytes across the EC layer (compare TES to vector).
Knockdown of Testin by siRNA increased transmigration of monocytes across the EC
layer (compare siRNA to scrambler). The results indicate that Testin plays a significant
role in the migration of monocytes across the EC layer.
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4.4 Discussion
This study was designed to identify the genes that confer a resistance to or
protection from atherosclerosis by investigating the fundamentally different gene
expression patterns between the atherosclerotic-resistant IMA and the atheroscleroticprone proximal LAD coronary artery in human subjects.

The study successfully

identified a novel gene, TES (protein product Testin), whose expression level was
associated with the sensitivity to the development of atherosclerosis. The expression
level of TES/Testin was higher in the IMA compared to the LAD at both the mRNA and
protein levels. Similarly, the expression level of TES/Testin was significantly higher in
non-diseased coronary arteries than that in diseased arteries.

Therefore, increased

TES/Testin expression may be associated with resistance to atherosclerosis, whereas
decreased TES/Testin expression is associated with a susceptibility to CAD.
This study was the first microarray analysis to use human tissue samples to
compare global gene expression differences between IMA to LAD. We identified 29
genes differentially expressed between the two arteries, and follow-up replication studies
with RT-PCR and Western blot analyses identified four genes with increased expression
in the IMA compared to the LAD, including RGS5, LAMNA, TES, and NR4A1. RGS5
encodes a regulator of G-protein signaling and was up-regulated by 5.9-fold in the IMA
compared to the LAD. Consistent with our results, a previous study showed that RGS5
expression was lost with the development of atherosclerosis and yet expressed in fibrous
atherosclerotic caps (14). LAMNA encodes the Lamin A/C that is an important
component of the nuclear lamina. Mutations in LAMNA are causes of premature aging
in the Hutchinson’s Gilford progeria syndrome and Werner Syndrome in which
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premature atherosclerosis is one of the phenotypes (15). The NR4A1 gene encodes the
TR3 orphan receptor. Transgenic overexpression of the TR3 orphan receptor resulted in
five-fold inhibition of neointimal formation after carotid artery ligation, whereas
transgenic overexpression of a dominant negative variant increased neointimal formation
by three-fold. This suggests that NR4A1 confers a resistance to atherosclerosis (16).
Our study also identified genes with down-regulated expression in the IMA
compared to the LAD. These included: PECAM1, F13A1, and RASF-A-PLA2, which
showed two-fold or less expression in IMA compared to LAD. PECAM-1 was downregulated by 3-fold in the IMA. This gene mediates the attachment of monocytes to the
endothelium and transendothelial migration. When PECAM-1 expression was blocked,
the consequences were reduced myocardial infarct size due to decreased neutrophil
accumulation in the myocardium (17), suggesting a protective role for this gene in
atherosclerosis. Factor XIIIA is involved in blood coagulation in which it cross-links
fibrin molecules in a clot, stabilizing thrombi, and produces a “resistance to fibrinolysis”
(18).

The product of RASF-A-PLA2, namely Phospholipase A2 (Group 2A) is

responsible for “amplifying” the inflammatory component of many disease processes
including atherosclerosis (19). Showing multiple genes that were documented to resist or
promote atherosclerosis, microarray analysis of the IMA vs. LAD is an effective
approach to identify novel protective or susceptibility genes involved in atherosclerosis.
Employment of this interesting strategy in the present study identified a novel gene, TES,
which is associated with a resistance to atherosclerosis.
The pathogenesis of atherosclerosis starts with the adhesion of monocytes to ECs,
followed by their transendothelial migration into the media of an artery. The monocytes
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differentiate into macrophages which release cytokines, amplifying the inflammatory
process and culminating in foam cells, the migration of VSMCs and the formation of
plaque. Functional studies with the overexpression of TES or the knockdown expression
of TES suggest that the cellular mechanisms by which TES mediates the development of
atherosclerosis may be related to the transendothelial migration of monocytes as well as
EC and VSMC migration and monocyte adhesion to the endothelium. The molecular
mechanism for TES-associated atherosclerotic resistant properties is unknown.

The

function of TES in the coronary artery may parallel its function in the testes where it
serves a role as being part of the tight junction between adjacent, germinal epithelial
Sertoli cells (8). Here, TES contributes to the blood-testes barrier to protect the
developing germ cells from the systemic circulation and blunt the diffusion of proteins
that can damage the developing gametes. Correspondingly, TES may retard the binding
to and passage of monocytes through the endothelial cells into the intima, the initial event
leading to atherosclerosis.
We showed that overexpression of TES decreased monocyte adhesion to ECs and
inhibited migration of ECs and VSMCs, while knockdown of TES increased the
migration of these cells.

This finding is supported by a report showing that the

overexpression of TES in chicken embryo fibroblasts, a working model for the study of
focal adhesions, decreased their motility (9). The involvement of TES in cell migration is
most likely related to its interactions with multiple cytoskeletal proteins including mena,
zyxin, paxillin, actin, alpha-actinin, VASP and Talin, which are involved in
reorganization of actin fibers and cell motility (8), although a direct link remains to be
established. The relationship between EC migration and atherosclerosis is not known.
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However, TES inhibition of VSMCs migration may be more applicable to its contribution
to a resistance of atherosclerosis.
A previous study by Qin et al used suppression subtractive hybridization (SSH)
with three pooled porcine mRNA samples to identify the gene expression differences in
the IMA and LAD denuded of the endothelial cells (19). Qin et al identified 24 genes,
but none of the genes expressed in pigs were found in common with our final list
expressed in humans. The difference may be caused by the fact that Qin et al focused
only on VSMCs, or by different tissue samples used by the two different studies.
Furthermore, the SSH is limited by the number of genes to be analyzed or cDNA clones
selected for sequencing, whereas the microarray analysis is more a global strategy that
analyze more than 12,000 genes simultaneously.
There are a few limitations of our study. Our initial cohort of LAD samples for
expression profiling came from heart transplants at Cleveland Clinic. Because IMA were
not available from the same heart transplantation patients, we matched the LAD samples
with the IMA samples from autopsy. To minimize this complication, we carried out our
replication studies in an independent population of 30 study subjects, and used matched
IMA and LAD samples excised and compared from the same individuals. It is also
important to point out that we focused only one aspect of the IMA, namely, its genetic
profile. This information complements two other areas that may explain the molecular
basis for this artery’s lack of stenosis. For example, the IMA may not get atherosclerosis
because: 1) based on its anatomy, it is a conduit with steady laminar blood flow which
down-regulates the expression of cell adhesion molecules--processes associated with
endothelial dysfunction in contrast to the proximal LAD known to have turbulent flow
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(21, 22); 2) based on its histology and cell composition, it contains a unique internal
elastic lamina (IEL) that is continuous, lacks perceivable gaps and serves as a barrier to
the passage of inflammatory cells into the sub-intima and media of the artery, which is
based on several electron microscopic studies of this artery (23). Nevertheless, our
findings that a decreased expression level of TES correlates with the development of
CAD and that TES plays an important role in cellular processes relevant to
atherosclerosis suggest that the different genetic profiles of the IMA and LAD may be a
significant factor for a resistance to atherosclerosis by the IMA.
In conclusion, we performed the first global gene expression profiling study on
the human atherosclerotic resistant IMA as compared to the atherosclerotic-prone
proximal LAD coronary artery. This study identified a novel gene, TES, which is
associated with resistance to disease. We showed that TES expression was significantly
decreased in LAD tissues from patients with CAD compared to non-CAD patients.
Functional studies showed that the association between TES and CAD may be related to
monocyte adhesion, transendothelial migration of monocytes and VSMC migration.
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CHAPTER 5
THE FUNCTIONAL SIGNFICANCE OF THE ADENOSINE A2B RECEPTOR
IN THE INTERNAL MAMMARY ARTERY
ABSTRACT
The endothelium is the initial target that leads to cardiovascular disease. Knowing that
the internal mammary arteries (IMA) are resistant to the development of atherosclerosis,
which contrasts with coronary arteries (Cor) which are athero-prone, we hypothesize that
genes over-expressed in the endothelial cells (ECs) of these two arteries will identify
genes that resist atherosclerosis. Methods and Results—Microarray analysis showed 95
genes differentially expressed in the ECs of IMA vs Cor.
significant different gene was the adenosine A2B receptor.

The most statistically
This indicates the A2B

receptor may be involved in a resistance to atherosclerosis. Western blot analysis showed
higher A2B expression in the IMA than in coronary arteries with or without disease from
proteins harvested from these human arteries and ECs. Overexpression of A2B in ECs
blunted: monocyte adhesion, cell adhesion molecule expression, migration, and the
transendothelial migration of monocytes-- processes directly associated with the
development of atherosclerosis. Knockdown of A2B expression by siRNA promoted
these processes. Conclusions—ECs derived from the IMA and Cor are distinctly different
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in gene expression, which may be responsible for their differential sensitivities for
atherosclerosis. This study defined how the A2B receptor may act as an atheroscleroticresistance gene, which blunted monocyte adhesion and cell adhesion molecule
expression, EC migration and retarded the transendothelial migration of monocytes.

125

5.1 Introduction
Endothelial cells (ECs) are the initial target affected by numerous risk factors that
lead to atherosclerosis. Additionally, ECs respond to turbulent blood flow, vasomotor
tone, and inflammatory cytokines--all of which play critical roles in target-organ damage.
Interestingly, the human internal mammary arteries (IMA) are resistant to atherosclerosis
despite being exposed to the same risk factors as the coronary artery. They have proven
better long-term patency rates (1).
The IMAs resistance to disease may be the result of its superior endothelial
function, because it produces more antithrombotic vasodilators such as prostacyclin and
nitric oxide (NO) as well as more endothelium-derived hyperpolarizing factor than
saphenous veins (2). Even in patients with CAD, atherosclerotic lesions rarely affect the
IMA. This reinforces the fact that ECs harvested from different areas respond differently
to the risk factors for CAD.
Since endothelial dysfunction is a key factor in atherogenesis, the current study
investigated the gene expression of the ECs harvested from IMA and Cor to distinguish
these arteries’ differential sensitivities to the develop atherosclerosis and identify novel
molecular mechanisms.

Using oligonucleotide microarrays, we found 95 genes that

were differential expressed, and the most statistically significant gene identified was the
adenosine A2B receptor (A2B), an integral membrane protein. Consequently, A2B was
selected for follow-up functional studies to define its role(s) in ECs and how it may
promote a resistance to atherosclerosis.
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Four subtypes of adenosine receptors have been identified: A1, A2A, A2B, and A3.
Based on pharmacologic studies, these receptors have been classified into adenylyl
cyclase inhibitory (A1 and A3) and stimulatory (A2) categories (3). The A2 receptors are
further subdivided into 2A and 2B. The A2B receptor maps to chromosome 17q11.2-p12,
and it consists of a single intron that interrupts the coding sequence in the region
corresponding to the 2nd intracellular loop between Leu111 and Arg112.3
Although the A2B receptor’s primary ligand is adenosine which results in
termination of superventricular tachycardias and causes vasodilation (3), the biological
mechanism(s) underlying the functional properties of the A2B receptor are not known.
However, several studies have made observations. Recent evidence obtained using A2B
knockout (KO) mice showed that these mice had a phenotype associated with
atherosclerosis (4). The A2B-KO mice displayed a significant increase in proinflammatory cytokines under baseline conditions, and following a challenge with
lipopolysaccharide. At the same time, the A2B-KO mice had up-regulated levels of the
adhesion molecules E-selectin, P-selectin, and ICAM-1 in the vasculature with increased
leukocyte adhesion (5). Similarly, a femoral artery injury model with A2b-KO mice vs
the wild type showed that the A2b receptor prevented vascular lesion formation in the
artery that resembles human restenosis after angioplasty (5). It was reported that BAY
60-6583, a highly selective A2B receptor agonist, limited infarct size in rabbit hearts (6).
In vivo studies have also shown that vascular permeability and pulmonary inflammation
are significantly increased in A2B KO mice subjected to hypoxia (3). These studies
support the A2B receptor as an atherosclerotic-resistance gene.
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In this study, we identified the A2B receptor as the most statistically significant
gene differential expressed in the ECs of the IMA vs the Cor. We confirmed the
expression of A2B is higher in human IMA tissues and disease-free coronary arteries and
lower in coronary arteries with atherosclerosis. Functional studies including monocyte
adhesion and cell migration, oxLDL-induced transendothelial migration of EC were used
to define the molecular mechanisms by which A2B may confer a resistance to endothelial
dysfunction which generates disease.
5.2 Material and Methods
5.2.1 Tissue Samples of Human Arteries
Arteries were obtained from explanted hearts through the Cleveland Clinic Heart
Transplant Program, unmatched or rejected healthy donor hearts from LifeBanc of
Northeast Ohio and the Cuyahoga County Coroner’s office. The LAD was carefully
examined for the presence or absence of atherosclerosis by microscopic examinations of
consecutively dissected serial segments of the entire artery by cardiovascular
pathologists. We selected a segment of the proximal LAD without intraluminal plaque.
Informed consent was obtained from the participants (or their families at post-mortem
exam) according to the standards established by the Cleveland Clinic Foundation
Institutional Review Board on Human Subjects and the Cuyahoga County Coroner.
Arteries were cleaned of adjacent adipose and myocardial tissue in explanted hearts or
from cadavers. The adventitial layer remained intact. The specimens were snap-frozen in
liquid nitrogen and stored at -80°C as previously described until used (7).
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5.2.2 Immunostaining of human arteries. The cryo-sections (6-µm) of IMA and coronary
arteries were fixed with paraformadehyde (4%) and permeablized with Triton X-100
(0.2%) as previously described (8).

The primary antibodies used were: CD64

(macrophages) (Santa Cruz), Adenosine A2B receptor (BD Technologies), Platelet
endothelial cell activating molecule (PECAM-1) (Santa Cruz), CD31 (PharMinger) and
monoclonal anti-α-SMC-actin (clone 144) conjugated with cys3 (Sigma). The secondary
antibody conjugated with cys3 (Sigma) or FITC (Sigma) were used for visualization
(1:250). The sections were counterstained with DAPI (Vectashield with OAD, Vector
Labs, Burlingame, CA).

The immunostaining signals were visualized with a Zeiss

Axiophot fluorescence microscope and the images were captured with Imageplus 6.0.
5.2.3 Cell Culture and Transfection
Endothelial cells (ECs) harvested from the proximal LAD coronary artery and
IMA were purchased from Cell Applications, Inc. The cells were isolated from nondiseased human arteries and cryo-preserved at the second passage. Cells were grown
with standard media supplied ready-for-use from Cell Applications, Inc. All cells were
used between the 3th and 6th passage and grown in a humidified incubator at 37ºC, 5%
CO2 and 95% air.
The Adenosine A2B receptor plasmid was a generous gift from Michelle Wong
(Emory University). All cells were used for assay 48 hours after transfection.
Small interfering (si) RNA for A2B was purchased from Integrated DNA
technologies: Sense--rGrCrA rGrCrA rCrCrU rGrCrC rArUrG rArArC rUrCrC rUrGG T
and Antisense--rArCrC rArGrG rArGrU rUrCrA rUrGrG rCrArG rGrUrG rCrUrG
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rCrArG. Cells were transfected with the A2B plasmid, siRNA, empty vector, or scrambler
using Polyjet (SignaGen Laboratories). The optimal dose to interfere with A2B mRNA
expression was 1 µM.
5.2.4 Real time RT-PCR and Expression profiling
Total RNA was isolated from the ECs using TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. ECs were grown in six well plates to
confluence for 48 hours and then exposed to various experimental conditions.
To identify the genes differentially expressed between the ECs cells of the IMA
and Cor, we carried out microarray analysis with Human Genome U133 arrays
(Affymetrix). Four microarrays were used to compare the IMA and the Cor. Each array
contained ~33,000 unique genes. GeneSpring (Agilent technologies) was used for data
mining as previously described (8). We generated the statistical algorithm as followed on
the web site (www.agilent.com).

Results from the microarray analysis were validated

for selected genes by real time RT-PCR with SYBR Green PCR (VWR) using the
original cDNA for microarray analysis as well as from the total RNA extracted from
another group of independent tissues. Relative expression values were calculated as
previously described (8, 9). The expression level of β2-microglobulin was used as an
internal control. Specific primer pairs were designed for each selected gene of interest
(Integrated Biotechnologies, Inc.) (Supplemental Table 2).
5.2.5 Western Blot Analysis.
The IMA or Cor tissues (0.2 g/sample) were lysed in a homogenization buffer for 15
minutes at 35οC using the delipidation method as previously described (9). Protein
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extracts from the IMA or LAD ECs grown in vitro were prepared with M-PER
Mammalian Protein Extraction Reagent (Pierce) and quantified with BCA Protein Assay
Kit (Pierce).
Protein lysates from each experiment (25 µg/ lane) were separated by 12% SDSPAGE Ready Gels (Bio-Rad) and transferred to nitrocellulose membranes.

After

incubation in blocking solution (5% nonfat milk) (Bio-Rad), membranes were incubated
with the primary antibodies: Adenosine A2B Receptor, VCAM-1 (Serotec), or ICAM-1,
(Santa Cruz) overnight at 4ºC. Membranes were washed three times for 10 minutes
(0.1% Tween 20) and then incubated with the secondary antibody, GAPDH (Santa Cruz)
for one hour at room temperature. Signals in the membranes were detected with the ECL
system (Amersham). Relative intensities of protein bands (and signals on immunostains)
were analyzed by Melanie (Swiss Institute of Bioinformatics).
5.2.6 Monocyte Adhesion Assay
Fully confluent ECs were grown in CoStar96 well plates after being seeded at a density
of 5,000 cells/well and stimulated with oxidized-LDL (oxLDL) (Sigma) (0.25 mg/mL)
for six hours. Human HL-60 pro-myelocytic leukemia cells were cultured in Iscove’s
modified Dulbecco’s media, fluorescently labeled with calcein AM (Invitrogen) for 60
minutes at 37ºC, washed three times with PBS, and then seeded into each well coated
with transfected ECs (A2B, empty vector, siRNA, or Scrambler) at a density of 3x105 per
well. After one hour, the media was aspirated and wells were washed gently with PBS
three times. Fluorescent intensity was measured in each of the 96-wells with a standard
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fluorometer with the CytoFluoroII program (Applied Biosystems) (exit: 485/20, emission
530/30, gain of 65) to determine the fluorescent units in each well.
Endothelial cells were incubated with ox-LDL (12.5, 25, 50, or 100 µg/mL) for 3,
12, 24, or 72 hours to determine the maximal expression of selected cell adhesion
markers. Control cells were incubated for the same time periods with native LDL. Each
experiment was repeated in triplicate.
5.2.7 Cell Migration Assays
ECs were transfected as mentioned above and plated at a density of 0.5x106 cells per cm2
in 35 mm six well plates. The media was changed 24 hours later. Then, the confluent
monolayers were wounded with a single edge razor and cells on the right side of the
wound were removed. After 48 hours, the cells were stained with Coomassie Brilliant
Blue for 10 minutes followed by Glacial acetic acid/methanol destaining buffer, and
photographed with Image-Pro Plus and analyzer 7.0 (Mediacybernetics) under 4X power.
The number of cells which migrated passed the wound was counted. Each experiment
was repeated in triplicate.
5.2.8 Transmigration of Monocytes Assay
HL-60 cells (3x105) were pippeted into 0.4 µm pore chambers within a Boyden
chamber (Corning), which had transfected ECs plated 24 hours prior and then exposed to
0.25 µg of ox-LDL. FBS was used as a chemo-attractant and diluted in serum-containing
DMEM media. The HL-60 cells were collected and counted from the bottom chamber 48
hours after their administration with a Bright-Line Hemacytometer (Hausser Scientific)
using an Olympus CKX 41 microscope. Each experiment was repeated in triplicate.
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5.2.9 Statistical Analysis. The difference between the two groups of variables for these
functional assays related to atherosclerosis was compared by the paired Student t-test. A
P value of < 0.05 was considered as significant
5.3 Results
5.3.1 Endothelial cells from IMA Bind Less Monocytes in vivo and in vitro
To begin to identify the ECs role in the resistance of the IMA to atherosclerosis,
we did an immunostain with CD64, a marker for macrophages. The rational for this
experiment is that atherosclerosis is defined as an inflammatory process (ie the binding
and infiltration of monocytes through the ECs) leading to endothelial dysfunction.
Immunohistochemical stained tissue sections of IMA and Cor showed a significant
(P=0.000516) difference in the presence and binding of monocytes (Figure 1A). The Cor
bound significantly more monocytes that were not only attached to the EC layer, but also
can be seen to have transmigrated into the media of the artery. By contrast, the signal for
CD64 was limited to the intraluminal surface of the IMA.
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Fig. 1. The IMA contains less inflammatory cells. A, an immunostain of coronary artery
vs internal mammary artery with CD64 (red) a marker on macrophages shows the IMA
contains less inflammation. B. The endothelial cells derived from the IMA vs coronary
artery show the IMA endothelial cells bind significantly less monocytes when exposed to
ox-LDL.
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In vitro, when we exposed the two groups of ECs to ox-LDL compared to native,
unoxidized LDL for 24 hours (0.25mcg/mL), there was also a significant (P=0.000083)
up-regulation of the binding of monocytes to the ECs derived from the Cor compared to
the IMA (Figure 1B). The presence of ox-LDL did not appear to activate monocyte
adhesion in the IMA derived ECs. In sum, human IMA tissue contained significantly less
inflammatory cells adherent to the EC layer as well as in the media, which is a significant
contrast to the Cor which had a preponderance of inflammatory cells. At the same time,
the ECs harvested from Cor readily bound more monocytes in vitro when exposed to
oxLDL while the ECs harvested from the IMA did not. This lack of inflammation may
be attributed to unique genetic properties of the ECs of these two arteries.
5.3.2 Human IMA tissues and its ECs cells express less cell adhesion molecules.
The main molecular mechanism in which monocytes attach to the ECs cells is via
cell adhesion molecules (CAMs). VCAM-1 and ICAM-1 are critical for the development
of atherosclerotic lesions in which they are not expressed under baseline conditions but
are rapidly induced by pro-atherosclerotic conditions. These CAMs were significantly
up-regulated in the Cor vs IMA as seen by:

immunostain (Figure 2A, P=0.0042 for

VCAM-1; P= 0.017 for ICAM-1), by RT-PCR (Figure 2B, P=0.013 for VCAM-1;
P=0.024 for ICAM-1), and by Western blot analysis from protein extracted from these
tissues (Figure 2C, P=0.0000889 for VCAM-1; P=0.0023 for ICAM-1). The CAMs were
also up-regulated in the ECs derived from these two arteries (Figure 2D, P=0.0043 for
VCAM-1; P=0.0073 for ICAM-1). In sum, the differential expression of CAMs between
the Cor vs IMA in both the arterial tissues and their ECs in vitro indicates that there is a
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Fig. 2. The IMA expresses less cell adhesion molecules. A, an immunostain of IMA vs
coronary artery for VCAM-1 and ICAM-1 show these adhesion molecules are downregulated in the IMA. B, These cell adhesion molecules are also down-regulated at the
level of transcription seen by RT-PCR, which also correlate with their translation noted in
protein extracted from these two arteries. C, The IMA also expresses less cell adhesion
molecules noted via Western blot analysis from protein extracted from these two tissues.
D, The endothelial cells harvested from these two arteries also express these cell adhesion
molecules less in vitro.
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different propensity of these two arteries to develop atherosclerosis. The process is
known to be initiated by monocyte binding directly to these CAMs on the ECs.
5.3.3

Microarray Analysis Identifies 95 Statistically Significant Genes in the IMA

Endothelial Cells Compared to the Coronary Artery Endothelial cells.
To identify the genes differentially expressed between the ECs in the IMA and
Cor and elucidate the differences that may account for the different tendencies of these
arteries to develop atherosclerosis, we carried out microarray analysis with Human
Genome U133 arrays (Affymetrix). Each array contains ~33,000 unique genes.

A total

of 95 genes were differential expressed (supplemental data). The top three genes that
were most statistically significant were: Adenosine A2b receptor (P=1 x 10-6), Dynein (P
=1.21 X 10-5), and Ninjurin-1(P=1.01 X 10-5) (Table 1).
At the same time, we validated a subset of these 95 genes that may be physiologically
more relevant to a resistance to ECs in the IMA and their known expression in ECs
(Table 2).

These included 10 up-regulated genes and two down-regulated genes:

Mesotrypsin (PRSS3), Antichymitropsin (SERPINA3), plasminogen activator (PLAT),
trypsin inhibitor (PRSS2), Thromboxane A2 receptor (TBXA2R), Heme oxygenase-1
(HMOX1), Tissue factor pathway inhibitor 2, IL-1 receptor, Aminopeptidase (ANPEP),
Heparin cofactor II (SERPIND1), and two down-regulated genes, namely, TNF-αinduced protein-1(TNFAIP1), and Activated leukocyte adhesion molecule (ALCAM). A
review of these genes (Table 2) demonstrates that the ECs derived from the IMA are less
atherogenic compared to the Cor. The resistance to thrombus formation is an inherent

137

genetic phenotype of the ECs derived from the IMA and may contribute to its lack of
disease.
5.3.4 Adenosine A2B Receptor Expression is Increased in the IMA compared to the
coronary arteries with and without atherosclerosis.
The Adenosine A2B receptor was the most statistically significant gene found to
be differentially expressed in the EC of IMA and the Cor. An immunostain for this gene
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Table 1. The top three statistically significant genes differentially expressed in the
endothelial cells derived from the IMA vs coronary artery.
Gene Name

GenBank

Fold
change
on
array

RT-PCR

Description

Adenosine
A2b receptor

NM_000676

↑1.7

↑ 5.1

integral membrane
protein stimulates
adenylate cyclase
activity in the
presence of
adenosine

Dynein

NM_006141

↓2.1

↓ 3.7

a motor protein
which converts the
chemical energy
contained in ATP
into the mechanical
energy of
movement.

ninjurin 1

NM_004148

↑2.5

↑ 2.9

cell surface
adhesion
molecule that
promote growth
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Table 2. Interesting genes differentially expressed in the IMA vs coronary artery
endothelial cells.

Gene Name/Symbol

GenBank

Fold
change
on
array

RTPCR

NM_002771

↑20.9

↑18.3

plays a unique and highly
specialized role in the
degradation of trypsin
inhibitors (22)

Description

Mesotrypsin (PRSS3)

AW007273

Antichymitropsin
(SERPINA3)

NM_001085

↑10.3

↑9.4

a plasma protease inhibitor
and member of the serine
protease inhibitor class

plasminogen activator
(PLAT)

NM_000930

↑13.6

↑10.6

involved in the breakdown
of blood clots (23); a serine
protease found on
endothelial cells,

trypsin inhibitor
(PRSS2)

NM_002770

↑15.0

↑12.3

It is an important antiinflammatory substance
(24)

Thromboxane A2
receptor (TBXA2R)

NM_001060/
D38081

↑4.2

↑3.0

a potent vasoconstrictor
which regulates blood
pressure (25)

Heme oxygenase-1
(HMOX1)

NM_002133

+6.6

+4.1

an inducible stress protein,
confers cytoprotection
against oxidative stress
(26)

TNF-alpha-induced
protein 1 (endothelial)
(TNFAIP1)

NM_021137

↓7.0

↓6.5

Inhibition of tumor
necrosis factor-α; reduces
atherosclerosis in
apolipoprotein E knockout
mice (27)
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Activated leukocyte
adhesion molecule –
(ALCAM)

AA156721

↓7.1

↓8.0

an important mediator
involved in leukocyte
migration into the CNS
(28)

Tissue factor pathway
inhibitor 2

L27624

↑5.7

↑5.0

exhibits antiproliferative
action after vascular
smooth muscle injury in
addition to the ability to
inhibit activation of the
extrinsic coagulation
cascade (29)

IL-1 receptor

AK026803

↑2.3

↑3.0

involved in the
pathogenesis of
atherosclerosis by a variety
of mechanisms, including
endothelial activation with
expression of leukocyte
adhesion molecules,
increased gene expression
of clotting factors and
inhibitors of fibrinolysis,
induction of chemokines,
and increased proliferation
of vascular smooth muscle
cells (30)

Aminopeptidase (ANPEP)

NM_002133

↑6.6

↑4.0

Aminopeptidase is a zincdependent enzyme
produced and secreted by
glands of the small
intestine.

Heparin cofactor II
(SERPIND1)

NM_000185

↑9.2

↑8.0

inactivates thrombin action
at the injured vascular wall
(31)
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in both arteries co-localized its expression with CD31, a marker for ECs (Figure 3A).
The A2B signal was more frequent in the IMA compared to the Cor (P=0.0031).
We further tested the expression level of this gene in three groups of ten human
patients by RT-PCR and Western blot analysis. This included testing the expression of
the A2B gene in the IMA and the coronary artery with and without disease (average extent
of disease in the coronary arteries was a 75-95% occlusion of the lumen).

The

Adenosine A2B receptor had a similar level of expression in the IMA at both the level of
transcription (Figure 3B, P=0.125) and translation (Figure 3C, P=0.231) compared to the
Cor. Yet, the expression of the A2B receptor was lower in the diseased coronary arteries
compared to the IMA (P=0.0007) and non-diseased coronary artery (P=0.0034).

In

sum, microarray analysis identified a gene, namely that A2B receptor that was found to be
differentially expressed at the transcriptional and translation level and whose expression
was down-regulated in diseased coronary arteries.
5.3.5 Adenosine A2B receptor affects ox-LDL mediated monocyte adhesion to Cor ECs.
To identify a cellular mechanism for the Adenosine A2B receptor and its
association with atherosclerosis, we over-expressed the Adenosine A2B receptor by
transient transfection. Western blot analysis showed successful over-expression of the
Adenosine A2B receptor in ECs (compared A2B plasmid to vector) and its knock-down
expression (compare siRNA to scrambler) (Figure 4A).
Because adhesion of blood monocytes to the endothelium of coronary arteries is a
significant step in initiating atherosclerosis, we first assessed the effect of overexpression of adenosine A2B on monocyte adhesion. The treatment of ECs with oxLDL
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dramatically increased monocyte adhesion (Figure 4B, compare siRNA to scrambler,
P=0.0000000067), while the over-expression of the A2B receptor significantly blunted the
binding of monocytes to the ECs (Figure 4B, compare A2B plasmid
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Fig. 3. Increased adenosine A2B receptor expression in the IMA vs. coronary arteries.
A, an immunostain co-localized the A2B receptor (green signal) to the ECs (red signal),
yellow is overlay. B, By RT-PCR from patient samples, the A2B receptor was
significantly up-regulated in the IMA. C. Western blot analysis also showed the A2B
receptor was up-regulated in five random patient’s IMA vs coronary artery.
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Fig. 4. Functional characterization of the A2B receptor in ECs. A. Western blot analysis
shows the A2B was successfully overexpressed in EC by transient transfection (empty
vector as control) and that A2B expression was successfully knocked down by A2B
siRNA (scrambler as control). B, Studies on monocyte adhesion. Treatment of ECs with
oxLDL dramatically increased their adhesion to monocytes. Over-expression of A2B
(compared A2B to vector) in ECs appeared to decrease adhesion of ECs to monocytes,
knockdown of A2B expression in ECs increased adhesion of ECs to monocytes (compare
siRNA to scrambler). C, Western blot analysis for cell adhesion molecules (VCAM-1,
ICAM-1, P&E selectin) were significantly down-regulated along with siRNA for A2B
compared to vector (and native cells).
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with vector, P=0.000203). The results show the A2B receptor affects monocyte adhesion
to ECs exposed to oxLDL which induces the expression of CAMs. Additionally, when
we did Western blot analysis to assess the impact of

A2B over-expression on the

expression of cell adhesion molecules (VCAM-1, ICAM-1), the A2B receptor downregulated their expression. Consequently, the atheroprotective effect of the A2B receptor
may affect the expression of CAMs.
5.3.6 Adenosine A2B receptor affects EC migration.
The impact of the Adenosine A2B receptor on EC migration was examined using a
scratch wound assay.

Over-expression of the A2B receptor significantly slowed the

migration of ECs (Figure 5, compare A2B vs vector, P=0.000076). Knock down of the
Adenosine A2B receptor increased migration of the EC (Figure 5, compare siRNA to
scrambler, P=0.00024). These results suggest that the Adenosine A2B receptor plays an
important role in cell migration.
7.3.6 Adenosine A2B receptor is Involved in Transmigration of Monocytes across ECs.
The Adenosine A2B receptor was over-expressed in ECs derived from the
coronary arteries and exposed to oxLDL (0.25 mcg/mL for 24 hours). The effect on the
transmigration of HL-60 monocytes was measured after 24 hours by plating monocytes
onto confluent transfected ECs adherent to the bottom of the Boyden Chamber (Figure 6).
Over-expression of the Adenosine A2B receptor significantly reduced transmigration of
monocytes across the EC layer (Figure 6, compare A2B to vector, P=0.00000000037).
Knockdown of the Adenosine A2B receptor increased transmigration of monocytes across
the EC layer (Figure 6, compare siRNA to Scrambler, P=0.0147). The results show that
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the Adenosine A2B receptor plays a significant role in retarding the migration of
monocytes across the EC layer, a cellular process relevant to atherosclerosis.
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Fig. 5. EC migration assay. Over-expression of A2B in ECs significantly inhibited the
migration of ECs (compare A2B to vector, while knowckdown of A2B increased EC
migration (compare siRNA to scrambler). These results suggest that A2B plays an
important role in EC cell migration
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Fig. 6.
Effect of over-expression or knockdown of A2B expression in ECs on
transendothelial monocyte migration. A2B was over-expressed in ECs which were
exposed to oxLDL. The over-expression of A2B in EC significantly reduced
transmigration of monocytes across the EC layer (compare TES to vector). Knockdown
of A2B by siRNA increased transmigration of monocytes across the EC layer (compare
siRNA to scrambler). The result indicate that A2B plays a significant role in the
migration of monocytes across the EC layer.
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5.4 Discussion
Since the endothelial cells (ECs) are the initial site generating disease, the current
study investigated the genetic profile of the ECs that were harvested from IMA compared
to coronary arteries to identify genes that may account for the IMAs lack of
atherosclerosis. The internal mammary artery (IMA) is the vessel of choice for coronary
artery bypass grafting because of its resistance to developing atherosclerosis. This has
been attributed, in part, to its superior endothelial function (10).
The rational for these studies began when we did immunostains on cross-sections
of the IMAs and coronary arteries with CD64, a marker for macrophages. There was a
dramatic difference in the preponderance of inflammatory cells attached to and
transmigrating passed the ECs in the coronary artery compared to the IMA.
Furthermore, VCAM-1 and ICAM-1, cell adhesion molecules (CAM) expressed in
activated ECs which bind monocytes, were also much higher in the ECs of the coronary
than IMA. Subsequently, when we exposed ECs derived from these arteries to ox-LDL,
the ECs derived from the human coronary artery dramatically up-regulated the CAMs
and bound more monocytes compared to the IMA. This suggested that different genetic
mechanisms are active in the ECs of these two arteries. It also reinforces the fact that the
coronary artery has an inherent propensity to progress toward disease.
Using microarray technology, we identified the most statistically significant gene
differentially expressed in the IMA vs Cor ECs: the adenosine A2B receptor. It was upregulated in the IMA by 1.8-fold. Consequently, we showed that the over-expression of
the A2B receptor in the ECs derived from the coronary artery down-regulated monocyte
adhesion and cell adhesion molecules, the migration of ECs, and blunted the
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transendothelial migration of monocytes—processes relevant to the genesis of
atherosclerosis, while knock out of this gene promoted these processes.
The signaling mechanisms that are mediated by the Adenosine A2B Receptor have
not been fully elucidated. The Adenosine A2B Receptor is coupled to Gs proteins and
when activated can up-regulate cAMP production (11). Increases in cAMP levels have
been associated with the inhibition of cellular functions such as proliferation, DNA,
protein and collagen synthesis (11). Similarly, Adenosine A2B Receptor activation can
also increase intracellular levels of calcium that can lead to activation of other signaling
pathways (11).

Finally, A2B knockout mice was associated with increased levels of

inflammatory cytokines and chemokines and it was shown to be mediated through NFkappaB and p38 activation (12). The effects of the Adenosine A2B Receptor may be
mediated by the simultaneous activation of different signal transduction pathways.

It

appears to play an athero-protective role in the IMA and is naturally over-expressed
compared to the coronary artery.
The genetic profile of a subset of genes noted by expression profiling also portray
the ECs derived from the IMA as atherosclerotic-resistant. For instance, we found the
ECs in the IMA have genes that are up-regulated and linked with a resistance to thrombus
formation:

plasminogen activator (13), trypsin inhibitor (14), activated leukocyte

inhibitor (which may contribute to the significant down regulation of the CAMs in the
IMA ECs) (15), tissue factor inhibitor (16), heparin cofactor II (17), as well as provide
protection against oxidative stress such as heme oxygenase-1 (18), and TNF-alphainduced protein-1 (19). It is interesting to point out that the IMA expresses many genes
previously associated with a resistance to atherosclerosis has them naturally expressed.
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Thus, microarray analysis of the IMA vs. LAD is an effective approach to identify novel
protective or susceptibility genes involved in atherosclerosis. Employment of this novel
strategy identified the A2B receptor which is associated with a resistance to
atherosclerosis in this study.
The limitations of this study are that the definitive mechanism of action of the A2B
receptor has yet to be completely elucidated. We have defined the function of the A2B
receptor on basic, functional processes related to atherosclerosis. A current review of the
literature shows that the molecular pathways that are activated by this receptor are
defined pharmacologically with several agonists and antagonists (3).

And, multiple

pathways are involved demonstrating the global impact this receptor may have on many
biological systems. In the future, we will need to utilize the A2B deficient mice to define
the specific genetic alterations.
In conclusion, we documented the genetic profile of the ECs derived from the
athero-resistant IMA which contrasts with those of the athero-prone coronary artery. We
have shown that the gene expression differences are the key to define the IMA and
coronary artery’s tendencies to develop atherosclerosis, which may be mediated, in part,
to the adenosine A2B receptor. These results provide insights as to why the IMA is
resistant to the progression of atherosclerosis and will help us understand the
mechanisms, which may prevent such life-threatening disease in the coronary artery.
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CHAPTER 6
DISCUSSION OF THESIS
Coronary artery disease (CAD) remains the leading cause of death not only in the
United States, but world-wide (1). The statistics and unfortunate facts about CAD are
often the introductory statements made by most original research articles that are
investigating some aspect of atherosclerosis. Despite the identification of its risk factors,
the aggressive medical management, the surgical options, and the recommendations by
physicians to patients to alter specific lifestyle behaviors (i.e. quit smoking, lose weight,
consume a low cholesterol/fat diet and exercise more), the incidence of CAD is remains
at an all time high. Consequently, more research is needed in primary prevention.
The hope to alter the morbidity and mortality and development of CAD in this
generation may reside in genetics (2). Atherosclerosis may be the “effect” directly
“caused” by specific genes; and we need to target those causes. The new approach to
prevent CAD in this decade is to identify genetic mutations or single nucleotide
polymorphisms (SNPs) and categorize them as an “at high risk for CAD genotype”.
Consequently, we can identify and target these genes and/or their protein products earlyon to interrupt the molecular mechanisms that lead to disease and hopefully well before
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one develops it.

Additionally, physicians need to continue to reinforce risk factor

modification.
In our research, we started with the general hypothesis that there are novel genes
yet

to

be

identified

that

are

not

only

associated

with

coronary

artery

disease/atherosclerosis, but can cause this disease. We started our genetic studies directly
with the target organs: human coronary arteries. The arteries came from patients who
had such advanced CAD (i.e. ischemic cardiomyopathy) that the only treatment option
available was a heart transplant. There were no further options for by-pass grafting,
stenting, or to even increase medical management. In fact, one can assume that not only
were these patients failing medical management over their lifetime, but they had a
dominant underlying genetic basis influencing their medical response to treatment. The
final option: to get an entirely new heart and coronary arteries.
We performed expression profiling on the human coronary arteries with and
without disease in an effort to study the differences in gene expression (3). The hearts
with severe coronary artery disease came from patients with a diagnosis of ischemic
cardiomyopathy, while the non-diseased hearts came from patients whose ‘normal’ hearts
were ultimately rejected for donation at Life Banc usually because a suitable recipient
was not available.

This provided us with the opportunity to analyze the genetic

differences between age-matched patients who had advanced disease compared to no
detectable disease.
Using expression profiling with the “microarray” or “genechip” from Affymetrix,
we found 56 genes were differentially expressed between patients with and without CAD
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(3). Consequently, we performed a literature search on every gene to document what was
not only known about it, but how its protein product may have contributed to
atherosclerosis. In this setting, we also identified novel genes as future prospects to
study.

We categorized these genes into five categories relevant to the genesis of

atherosclerosis. These included: 1) inflammation, 2) cell necrosis/apoptosis/proliferation,
3) cell migration/adhesion and matrix degradation, 4) lipid transfer/oxidation/metabolism,
and genes with 5) unspecified functions.
This list of 56 genes provided the scientific community with the opportunity to
see for the first time, the genes expressed not only in the human coronary artery but also
to view these genes in the context of advanced coronary artery disease. In addition, we
utilized an intact, coronary artery which showed gene expression not only in situ but also
in the context of multiple other genes and cell types as well as in the setting of all the risk
factors that impact a coronary artery. This is quite a contrast to other studies which
exclusively study endothelial, smooth muscle, or inflammatory cells in vitro (4).
From our final list of 56 genes, three genes demonstrate the usefulness of studying
an intact artery by expression profiling.

These genes include: 1) the immunoglobulin

superfamily, 2) lumican, and 3) chiotriosidase. For instance, this study demonstrated that
the immune system may make a significant contribution to atherosclerosis. This was
demonstrated by the fact that there was a large representative of genes that code for the
immunoglobins and infiltrated the arterial tissue. These finding lend support to the
observation that bacteria, such as Chlamydia pneumonia, may be an underlying factor in
the genesis of CAD (5). Consequently, this finding will focus more attention as to how to
prevent CAD in the setting infections or blunting an arterial immune response.
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Lumican is a gene that was reported to be overexpressed during the woundhealing process in the cornea of the eye (6). The identification of this gene with our
approach of using intact coronary artery re-defined the role of a gene that may not have
been studied outside the field of optholomology.

Subsequently since our publication,

lumican has been found to be expressed by intimal and medial VSMCs in coronary
atherosclerosis, and it contributes to collagen fibrillogenesis of coronary atherosclerosis
(7).
Similarly, chitotriosidase had been simply identified as a marker on inflammatory
cells. The chitinase enzyme family hydrolyzes chitin, a structural component found in
the cell walls of many living species such as the fungi, nematodes, protozoan parasites,
and insects (8). However since our publication, serum chitotriosidase activity has been
considered to be a strong inflammatory marker of CAD (9). In sum, our initial study
found several novel genes that might not have been related to atherosclerosis, and offered
opportunities to identify novel pathways and mechanisms that may lead to disease. At
the same time, we also detected genes previously associated with CAD (such as ICAM-1,
VCAM-1, and osteopontin) (3). This demonstrates that microarray technology is a valid
approach to study the genetics of atherosclerosis.
There are three main limitations of our initial study. These are: 1) extracting intact
total mRNA from tissue (which represent gene expression), 2) the use the microarray
technology, and 3) statistical analysis. To begin with, we harvested mRNA from the
coronary arteries and documented global gene expression. With this approach, one often
captures the genes that are significantly up-regulated and may not represent very small
amounts of mRNA and/or genes with a low expression—representative of genes that may
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make a contribution to regulatory pathways.

An alternative method is subtractive

hybridization which actually does target genes with a very low expression.
At the same time, mRNA is a very fragile molecule that can degrade within
minutes after extraction from tissues or cells. The variations in handling tissues and the
method of RNA extraction from samples can result in different levels of gene expression.
At this point in time, there is no universal protocol to maximize the efficiency of mRNA
extraction. One has to adhere to experimental technique, consistency in the timing and
sampling of tissue, and even duplicate experiments using a single reference RNA. These
are realistic means by which sources of error can be minimized. Fortunately, we were
able to harvest our coronary arteries immediately upon explantation, place them in liquid
nitrogen, and store them at -80C until they were used. This approach would minimize
mRNA degradation.
At this point in time, a universal, standardized approach to microarray data
analysis is problematic. For instance, microarray data is difficult to exchange between
institutions because of the lack of standardization in the type of chips used (current there
are oligonucleotide arrays, spotted arrays, cDNA arrays), assay protocols, and especially
analysis methods. Currently, there are on-going projects to improve the exchange and
analysis of data generated. For example, the "Minimum Information About a Microarray
Experiment" (MIAME) checklist helps define the level of detail that should exist and is
being adopted by many journals as a requirement for the submission of papers
incorporating microarray results (10). The MicroArray Quality Control (MAQC) Project
is being conducted by the US Food and Drug Administration (FDA) to develop standards
and quality control measures which will eventually allow the use of MicroArray data in
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drug discovery, clinical practice and regulatory decision-making (11). And, The MGED
Society has developed standards for the representation of gene expression experiment
results and relevant annotations (12).
Similarly, statistical challenges in data analysis are now taking into account
effects of background noise and a standard normalization of the data. These includes:
Image analysis, data processing and background subtraction (based on global or local
background noise), determination of spot intensities and intensity ratios, visualisation of
data and log-transformation of ratios, global or local normalization of intensity ratios.
And finally, which method to detect significant changes: t-test, ANOVA, Bayesian
method Mann–Whitney test methods should be tailored to microarray data sets. This
takes into account multiple comparisons or cluster analyses. These methods assess
statistical power based on the variation present in the data and the number of
experimental replicates and can help minimize Type I and type II errors in the analyses.
Unfortunately, the same gene chip raw data can still generate different final gene lists
based on how one analyzes the data.
In our research to find and study novel genes associated with atherosclerosis, we
also studied CAD from two different perspectives:

1) proteomics and/or protein

expression and 2) examining the genetic profile of the internal mammary artery (IMA),
which by contrast to the coronary artery, is resistant to disease. Although the main
details of the proteomics approach are not included in this research, the summary of our
findings is. Both of these approaches contributed to novel molecular mechanisms to
identify genes associated with or contribute to CAD.
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Using proteomics, one documents the differential expression of proteins which
separates proteins based on their molecular weight and the pI (isoelectric point) (13). It
provides yet another perspective on the molecular pathways involved in CAD and
complements genomics. In this next step of our research, we compared the proteins
extracted from diseased and non-diseased coronary arteries. The same coronary arteries
that were utilized with the initial study to identify novel genes were also utilized for
proteonomics. This was the natural next step to investigate after documenting the gene
expression profile.
Proteomics has several advantages. First, the fold changes in the level of gene
transcription may give only an estimate of its level of translation into a protein. One
naturally makes the assumption that if a gene is up-regulated, then its protein product is
as well.

Yet, the mRNA that is transcribed may be degraded rapidly or not even

translated into a functional protein product. Consequently, a gene may be transcribed
into mRNA, but this does not guarantee a protein product. Second, many proteins
experience post-translational modifications that profoundly affect their activities; for
example some proteins are not active until they become phosphorylated. Third, many
transcripts give rise to more than one protein, through alternative splicing or alternative
post-translational modifications. Fourth, many proteins form complexes with other
proteins or RNA molecules, and only function in the presence of these other molecules.
Finally, protein degradation rate plays an important role in protein content and offers
clues to molecular pathways that may be important. In sum, the main goal of our study
was to identify proteins associated with CAD and generate new hypotheses and novel
treatment strategies.
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Like our initial study in which we utilized human coronary arteries, our second
project was the first application of proteomics to study CAD. Using this technique, the
proteins are extracted from the tissue, run in a first dimensional gel to separate the
proteins based on their isoelectric point, then transferred to a second gel, a SDS-PAGE
gel and separated based on their molecular weight. One compared the protein spots
between two groups of samples to detect a differentially expressed gene, it is cut out, and
sent to mass spectrography for identification. In our case, we found the ferritin light
chain protein was significantly up-regulated in diseased coronary arteries. Ferritin is a
major intracellular iron storage protein. It is composed of 24 subunits of the heavy and
light ferritin chains, and its subunit composition affects the rate of iron uptake and release
in different tissues. Additionally, ferritin stores iron in a soluble and nontoxic state.
Defects in the light chains ferritin have been associated with several neurodegenerative
diseases and hyperferritinemia-cataract syndrome (13).
We hypothesized that the increased expression of the ferritin light chain may
contribute to the pathogenesis of atherosclerosis by modulating the oxidation of lipids
within the vessel wall through the generation of reactive oxygen species (13). However,
this increased expression in diseased coronary may be a consequence of rather than a
cause of CAD. And it is interesting to point out that despite the mRNA of the ferritin
light chain being lower in CAD patients, the expression of the corresponding translated
protein was higher when compared to patients without coronary artery disease. As
mentioned, this important finding shows the importance of not only looking at the genetic
profile but also including the protein expression as well.
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It would have been important to identify many more protein spots on the 2D gels
that were differentially expressed between diseased and non-diseased coronary arteries,
but the cost of Mass Spectrometry and protein sequencing is very high. Nevertheless, our
study did document the global protein expression in human coronary arteries.
To continue to study the underlying genetic mechanisms that lead to CAD, we
returned to expression profiling but from yet another perspective. Rather than compare
coronary arteries with and without disease, we compared non-diseased coronary arteries
to the internal mammary artery (IMA). The rational for this investigation was due to the
fact that the IMA is resistant to atherosclerosis, the main explanation for which remains
unknown. This is quite a contrast to the atherosclerotic-prone coronary artery.
We hypothesized that not only will the genetic profile of the IMA identify
underlying molecular mechanisms that account for its resistance to atherosclerosis, but
also reveal the processes that become dysregulated in the coronary artery. Of note, the
IMA is the preferred vessel to be used in coronary artery by-pass grafting because of its
low incidence of disease. Using expression profiling, we found 29 genes differentially
expressed between non-diseased coronary arteries and the IMA. This was once again the
first large-scale expression profile done to compare these arteries using human samples.
We found a subset of genes that reflect relevant underlying physiological
processes that resist inflammation and can offer a credible hypothesis as to why the IMA
resists disease as well as novel genes to study.

The inflammatory process of

atherosclerosis is initiated when cholesterol-containing oxidized LDL accumulate in the
intima and induce the expression of cell adhesion molecules (CAM) on the surface of the
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endothelium.

These CAM permit the attachment of monocyte and subsequently

transmigration into the media of the artery. This is the first strategic location that initiates
the events generating CAD. It is also known as endothelial dysfunction.
In the IMA, there was a significant difference in three genes specifically
expressed in the endothelial cells: PECAM-1, TESS-2, and RGS-5. A brief discussion of
the clinical, physiological relevance of these genes demonstrates why the IMA may not
get disease while the coronary artery readily does. PECAM-1 was down-regulated by 3fold in the IMA. This gene mediates the attachment of monocytes to the endothelium.
Several groups have hypothesized that leukocytes utilize PECAM-1 during the process of
transmigration into the artery (16).When PECAM-1 is blocked, the consequences are
reduced myocardial infarct size due to decreased neutrophil accumulation in the
myocardium (16). RGS-5 was up-regulated 5.9-fold in the IMA. This gene is a negative
modulator of the AT1 receptor (17). Based on experimental and clinical studies, RGS-5
enhances

endothelium-dependent

relaxation

in

atherosclerosis

and

promotes

vasodilatation (17). With the up-regulation of RGS-5, the IMA has an inherent
mechanism to promote vasodilation and resist endothelial dysfunction. RGS-5 is also a
marker for VSMC during angiogenesis, stabilizes vessels, promotes endothelial cell
survival, and inhibits EC proliferation--processes which are dysfunctional in
atherosclerosis. It is also down-regulated in atherosclerotic caps (18). And finally, the
novel gene TESS-2 was up-regulated 4.3 fold in the IMA. TESS-2 plays a role in cell-cell
junctions (19,20). Initially discovered in the testes, it forms a tight-barrier and maintains
structural integrity of endothelial cells. Steady-state TESS-2 mRNA correlates with an
extensive renewal of cell-cell junctions during development (21). With TESS-2 up-
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regulated in ECs, the IMA has yet another defense mechanism to resist inflammation by
retarding the transmigration of monocytes.
A second strategic location that is altered in the generation of CAD is the smooth
muscle cells (SMCs). It is well established that the cytokines that are released by the
monocytes that have transmigrated into the media of the artery through the endothelial
cells layer induce the SMCs to migrate and proliferate especially into area of plaque (22).
The IMA had four up-regulated genes expressed in SMCs that have already been
associated as markers for athero-resistance. Four genes encoding ATF-3, TR3 orphan
receptor, HSP-70 and Nurr77 are expressed in SMCs and may contribute a resistance to
atherosclerotic. These genes prevent excessive proliferation of VSMCs.

The TR3

orphan receptor has been shown to reduce atherosclerotic vascular lesion formation (23).
The proposed mechanism of action of the TR3 orphan receptor is that it inhibits the cell
cycle by up-regulating the synthesis of the cyclin-dependent kinase inhibitor p27 (Kip1)
in VSMCs (23). ATF-3 functions as a stress-inducible transcriptional repressor and has
been described to meet the criteria of an anti-atherosclerotic gene (24). Its expression is
restricted to areas subjected to laminar flow (24). TINUR prevents apoptosis in VSMCs
(25).

And, while also expressed in inflammatory cells, it has been shown to reduce

human macrophage lipid loading and inflammatory responses (25). Similarly, HSP-70
was up-regulated greater than seven-fold, which reflects an inherent mechanism of action
in the IMA to prevent ischemic injury (26). Even though both arteries share the same
hemodynamic pressures and exposure to the risk factors for atherosclerosis (i.e.
hyperlipidemia, hyperglycemia, etc), our study clearly demonstrates that at the genetic
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level, we identified that the IMA has inherent genetic mechanism to resist the insults that
lead to disease in the coronary artery.
Finally, one more strategic location plays a role in the generation of
atherosclerosis are the inflammatory cells (such as monocytes). Coronary artery disease
is considered an inflammatory process initiated by the infiltration of monocytes into the
artery (22).

We found that the IMA had three significantly down-regulated genes

compared to the coronary artery that are expressed on inflammatory cells. Whether the
certain subpopulations of monocytes are native to an artery (known as tissue histiocytes)
or transmigrate from the blood stream has yet to identified. In any event, the lack of
inflammatory cells in the IMA demonstrates a decreased inflammatory response-to-injury
compared to the coronary artery.
The three genes:

CD163 antigen, Factor XIIIA, and PLA2, are specifically

expressed in macrophages. CD163 antigen is a 130 kDa transmembrane glycoprotein
restricted to human monocytes and macrophages and has been found in “chronic”
inflammatory diseases (27). It has been reported that anti-CD163 antibodies induce the
secretion of pro-inflammatory cytokines in macrophages and promote monocyte
infiltration into tissues by a nonclassical adhesion mechanism (27). Phospholipase A2
(Group 2A) is responsible for “amplifying” the inflammatory component of many disease
processes including atherosclerosis (28). Factor XIIIA is involved in blood coagulation
in which it cross-links fibrin molecules in a clot, stabilizing it, and producing “resistance
to fibrinolysis” (29).
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In spite of the complexity of the arterial tissues used for expression profiling
which consists of several cell types (ECs, SCMs, or inflammatory cells), we were able to
identify a subset of the genes relevant to a resistance of atherosclerosis and identify their
site of expression and quantify protein translation in the IMA compared to the coronary
artery. We had confirmed our microarray results with RT-PCR, immunocytochemistry,
and WB analysis. Furthermore, we used cell lines of ECs and VSMCs harvested from
both the IMA and LAD to study the gene expression. It is not surprising that we were
able to incorporate multiple independent experiments which studied individuals genes
associated with a resistance to atherosclerosis and found them to be native to the IMA.
Our approach of using intact, human coronary arteries has both its advantages and
disadvantages. The advantages are that one documents gene (and protein) expression in
the context of how it may be regulated physiologically in contrast to an in vitro study. At
the same time, there are many factors that may influence the expression of that gene (and
protein) that may not be accounted for in vitro as well. Yet, this approach also poses
some limitations. One cannot dissect out one isolated gene and just study its expression.
The advantage of an in vitro approach is that one can selectively alter the environmental
condition (i.e. add drugs, stressors, etc) to assess its individual impact on the system such
as atherosclerosis.
It is also important to point out that we documented only one aspect of the IMA,
namely, its genetic profile. This information complements two other areas that may
explain the molecular basis for this artery’s lack of disease. For example, the IMA may
not get atherosclerosis because: 1) based on its anatomy, it is a conduit with steady
laminar blood flow which down-regulates the expression of cell adhesion molecules-165

processes associated with endothelial dysfunction in contrast to the proximal LAD known
to have turbulent flow (30), 2) based on its histology, it contains a unique internal elastic
lamina (IEL) that is continuous, lacks perceivable gaps and serves as a barrier to the
passage of inflammatory cells into the sub-intima and media of the artery, which is based
on several electron microscopic studies of this artery (31), and ultimately 3) the
expression of genes at strategic locations, namely the EC and SMCs which reflect
specific underlying molecular mechanisms that resist inflammation.

Our focus

obviously was on the genetic profile.
With further studies on the IMA to define the nature of its tendency not to
develop atherosclerosis, we began to focus on the ECs. After all, the first strategic
location that is affected in an artery that triggers the cascade of events that lead to disease
is the EC. It is here that all the risk factors associated with CAD bombard these cells and
alter their gene expression. We hypothesized that there are unique genetic properties of
the ECs of the IMA that may account for the lack of disease.
Our initial studies supported this hypothesis. When we did an immunstain on
cross sections of both the coronary artery and IMA with CD64, a marker unique to
monocytes, we found a preponderance of CD64-labeled monocytes not only bound to the
ECs of the coronary artery but, by contrast, a near absence of this marker in the IMA.
Additionally, we could see that the CD64-specific monocytes also transmigrated into the
media of the coronary artery. As a result, one can conclude that there are unique
differences in the ECs of these two arteries that account for the lack of inflammatory cells
not only attaching to the ECs but permitting their movement into the media of the artery.
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Similarly, when we harvested these two groups of ECs and did a monocyte
adhesion assay, we found that the ECs derived from the coronary artery had a robust
expression not only of cell adhesion molecules, but bound significantly more monocytes.
Based on this important observation, we did expression profiling of EC cell lines
harvested from these two arteries to define their genetic differences.
We found 95 genes that were differentially between the ECs harvested from both
the coronary artery and the IMA. However, a subset of these genes demonstrate the
unique properties of the ECs of the IMA to resist atherosclerosis. For instance, we found
the ECs in the IMA have genes that are up-regulated and associated with a resistance to
thrombus formation. These included: tissue plasminogen activator (32), trypsin inhibitor
(33), activated leukocyte inhibitor (which may contribute to the significant down
regulation of the CAMs in the IMA ECs) (34), tissue factor inhibitor (35), heparin
cofactor II (36), as well as provide protection against oxidative stress such as heme
oxygenase-1 (37), and TNF-alpha-induced protein 1 (38).

It is interesting to point out

that the IMA expresses many genes previously associated with a resistance to
atherosclerosis has them naturally expressed. Thus, microarray analysis of the IMA
compared to the coronary artery is an effective approach to identify novel protective or
susceptibility genes involved in atherosclerosis.
At this point in time, we generated extensive gene lists expressed in the IMA and
coronary arteries, and we decided to select a few novel genes to study and determine how
they may play a role in atherosclerosis. We chose two novel genes: TES and the A2B
receptor. Both of these genes may be associated with a resistance to atherosclerosis.
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The human TESTIN (TES) gene was noted to be a putative tumor suppressor
gene in the fragile chromosomal region FRA7G at 7q31.1/2 (39). It has been reported to
be down-regulated in cancer cell lines primarily by promoter hypermethylation (40).
TES does not appear to be an enzyme, rather, it is a protein that mediates cellular
functions via three LIM domains that mediate protein-protein interactions.
TES may play a role primarily in altering cell motility. Specifically, TES may
interrupt the binding of proteins to the LIM3 domain of Ena/VASP proteins which act as
nucleators of actin filament assembly, which generate cytoplasmic protrusions needed for
cell migration (41). With TES blocking the access of the LIM3 domain (specifically the
FPPP binding site), the assembly of the focal adhesion complex is disrupted and cells
cannot efficiently migrate. Furthermore, the clinical implications of this alteration mean
that if TES is over-expressed cancer cells, they are less likely to metastasize. However,
TES is known to be down-regulated in specific malignancies. A research goal would be
to prevent the down-regulation of TES to prevent cancer from metastasizing. Yet, our
research has now linked TES with atherosclerosis, and we shall contribute and
understanding of the molecular mechanisms of this gene in this area.
At the same time, although the A2B receptor’s primary ligand is adenosine which
results in termination of superventricular tachycardias and causes vasodilation (42). The
biological mechanism(s) underlying the functional properties of the A2B receptor are not
known. However, several studies have made observations.

Recent evidence obtained

using A2B knockout (KO) mice have shown that these mice had a phenotype associated
with atherosclerosis (43). The A2B-KO mice displayed a significant increase in proinflammatory cytokines under baseline conditions, and following a challenge with
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lipopolysaccharide. At the same time, the A2B-KO mice had up-regulated levels of the
adhesion molecules E-selectin, P-selectin, and ICAM-1 in the vasculature with increased
leukocyte adhesion (43). Similarly, a femoral artery injury model with A2b-KO mice vs
the wild type showed that the A2b receptor prevented vascular lesion formation in the
artery that resembles human restenosis after angioplasty (43) It was reported that BAY
60-6583, a highly selective A2B receptor agonist, limited infarct size in rabbit hearts (44).
In vivo studies have also shown that vascular permeability and pulmonary inflammation
are significantly increased in A2B KO mice subjected to hypoxia (43). These studies
support the A2B receptor as an atherosclerotic-resistance gene, but its function is
unknown.
Our approach has involved both over expressing these genes in both EC and
SMCs as well as silencing them using small interfering RNA (siRNA) technology. We
determined a function of these genes using basic, in vitro assays that are applicable to the
development of atherosclerosis, namely: a monocyte adhesion assay, cell migration
assay, and measured the transmigration of monocyte through an endothelial cell barrier
(as done in a Boyden chamber). Because these techniques are clinically relevant, it is
important to briefly re-review the rational for these experiments.
Atherosclerosis is initiated when agents such as ox-LDL come into contact with
the ECs which line the inner surface of blood vessels, and it induces the expression of
cell adhesion molecules and integrins. These molecules captures circulating monocytes
to role, attach, and then transmigrate into the media of the artery where they differentiate
into mature macrophages. Consequently, they begin to secrete cytokines which not only
stimulate and recruit the smooth muscle cells to migrate and proliferate, but induce
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further changes in the ECs to perpetuate the cycle. Each step of the process can be
studied in vitro, and this is how we applied them to our genes of interest.
Initially, we did a monocyte adhesion assay.

It was performed with ECs over-

expressing or silencing either TES or the Adenosine A2B receptor genes. The ECs were
plated in a six-well tissue culture well, exposed to ox-LDL added to the media which
induces the expression of cell adhesion molecules (CAM) to which monocytes can attach,
and then adding caseinAM-labeled monocytes to quantitate the monocytes that attached.
We found that the over-expression of both TES and the Adenosine A2B receptor
both blunted the attachment of monocytes to the ox-LDL stimulated ECs as compared to
the control group which included the empty plasmid vector. Additionally, the application
of siRNA to these genes (and the scrambler) also disrupted the native expression of these
genes and increased the binding of monocytes. Based on these in vitro results, it is
plausible to make the hypothesis that these genes may behave similarly in situ and have
this anti-atherosclerotic phenotype.
These genes also had anti-atherosclerotic properties in both ECs and VSMCs
when we assayed for cell migration. Although the role of migrating ECs is not as
pertinent to atherosclerosis as VSMCs, these genes blunted the migration of the cells over
a 24-48 hour window. The cells which had the over-expression of these genes migrated
significantly less compared to the empty vector. Interestingly, the interference of these
genes with siRNA technology increased cell migration. As previously mentioned, it is
quite plausible to make the hypothesis that the genes are anti-atherosclerotic.
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This is further supported by the fact that when these genes were over-expressed in
ECs and plated in a Boyden chamber to measure the number of monocytes that would
transmigrate across the barrier into the bottom well, both TES and the Adenosine A2B
receptor both decreased the number of cells. This further supports a role for preventing
the evolution of atherosclerosis based on the evidence of these simple, straightforward in
vitro assays.
All of our current research to identify novel genes associated with CAD may
culminate with a long-term investment in the gene TES. Future studies will be needed to
investigate how this genes work with the continued use of genetics. We propose to: 1)
utilize a knockout mouse, 2) continue basic genetic experiments, 3) perform mutational
analysis, 4) identify more protein-protein interactions, and 5) not how TES may affect
cell trafficking.
A Testin knock-out mouse has already been created (45). To test whether Testin
was a tumor suppressor in vivo, the investigators assessed its role in a well established
gastric carcinogenic model. To summarize, in mice a zinc deficient diet enhances cellular
proliferation in parts of the stomach and makes them susceptible to Nnitrosomethylbenzylamine (NMBA) induced carcinogenesis. In the Testin KO group, the
administration of this protocol results in significantly more gastric tumors, which
supports Testin as a tumor suppressor in vivo.
Our research has now applied this gene to the generation of arterial disease,
namely, atherosclerosis. We have shown that TES blunted monocyte adhesion, decreased
cell motility and migration as well as decreased the transmigration of monocyte across an
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EC layer. We would utilize the KO model and demonstrate/hypothesize that TES is
important to maintain the vascular permeability of arteries. By administering methylene
blue to the KO animals and subsequently sacrificing them, we would measure the leak of
this dye into the various organs of the mouse model. A very high retrieval of the blue
dye from the various organs of the KO model compared to wild type would demonstrate
that TES was an important component to maintain the permeability of the artery against
molecules such as monocytes. In sum, we propose that TES is necessary to maintain the
integrity of the artery.
We will continue basic genetic experiments to define the molecular mechanisms
of TES specifically by defining the critical domains. To review, TES consists of a
cysteine rich domain (amino acid residues 1 - 90 – with no known homologies), two PET
domains (90 – 200 and linker 201 – 233), and three LIM domains (234 – 300, 300 - 365
and, 366 - 421). We propose to create a series of constructs deleting three amino acid
residues at a time from the C-terminal end of the gene to the N-terminal. Consequently,
we would assess the impact of these constructs of the atherosclerotic assays previously
described to identity which domain is critical for the function of TES.
TES has been found to be downregulated in disease states such as cancer. This is
the result of the hypermethylation of its promoter (45).

We propose to perform

mutational analysis by creating a series of point mutation in the TES promoter and assess
their impact on the expression of TES. This would demonstrate the impact and control
the promoter may have on disease processes such as cancer.
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Basic genetic techniques would also be important to incorporate into the clinical
significant of TES. Using single stranded conformational polymorphism (SSCP) on
patients with and without coronary artery disease would lead to the identification of novel
SNP associated with the disease. Consequently, this will create these SNPs in plasmids
and attempt to pharmacologically correct the expression of TES (if down-regulated) to
improve the disease process.
Since TES has been shown to be involved with several proteins, we could
demonstrate if several of these proteins (i.e. paxillin, zyxin) are affected which influence
cell migration. Furthermore, more yeast-two hybrid experiments would be indicated to
identify other structural proteins that TES may alter or interact with and affect cellular
function.
In the future and in conclusion, I hope to continue to make progress and expand
the knowledge in gene expression in the field of cardiovascular disease.

Taking a

retrospective look at the extensive lists of genes that I have generated, I have many
opportunities to pursue and define novel mechanisms that may lead to CAD. The field of
genetics is the ultimate field of primary care prevention in internal medicine and offers
one the opportunity to screen patients in advance of the development of CAD to help
reduce its ever growing morbidity and mortality.
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